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Maintaining water homeostasis by controlling both the blood osmolality and blood volume is 
essential for most physiological processes in the human body. Every day, water is lost 
through breathing, sweating, and in the urine and feces. Water is obtained through 
metabolism and food and water intake (1). While several of these processes occur 
autonomic, body water homeostasis is tightly controlled by regulating both water intake and 
urinary water excretion.




___________________________________________ i a n tid iu res is
co rrec tio n
F igure 1. B ody O sm oregu la tio n . Osmoreceptors in the brain trigger physiological responses such as 
thirst, thus regulating w ater intake, and release of A VP  from the pituitary, thereby reducing w ater 
excretion in the kidney.
A 1-2% rise in plasma osmolality or extracellular sodium concentration is detected by 
osmoreceptors located in the subfornical organ (SFO) and the organum vasculosum lamina 
terminalis (OVLT), two circumventricular organs of the hypothalamus (2; 3). In states of 
hypernatremia, these receptors are activated, which results in the sensation of thirst and 
subsequent water intake. Furthermore, neurons from the OVLT and SFO connect to the 
arginine vasopressin (AVP) producing magnocellular neurons of the supraoptic nucleus of 
the hypothalamus. Magnocellular neurons containing AVP project axons to the posterior 
pituitary, where they release AVP into the bloodstream upon activation (4) (see Fig. 1). 
Besides osmolality, blood volume is tightly regulated as well, mainly by the renin-angiotensin- 
aldosterone system. In this process, regulation of renal sodium excretion plays an important 
role. However, body volume is also regulated by water intake and excretion. Thirst and AVP
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secretion are influenced by blood volume and blood pressure changes, sensed by high and 
low pressure baroreceptors present in the aorta and the left atrium of the heart, and are also 
regulated indirectly by volume-mediated regulation of angiotensin II (2; 3; 5) (see Fig. 2). 
AVP secretion is far more sensitive to small changes in plasma osmolality than to changes in 
blood volume, as reductions in plasma volume of 10-15% are required before AVP is 
released. However, volume-induced regulation of AVP secretion is exponential, and severe 
reductions in blood volume will result in very high AVP levels (3; 5).
Figure 2. A V P  in vo lu m e regu la tion . Baroreceptors in the heart and blood vessels trigger thirst, thus 
regulating w ater intake, and the release of A V P  from the pituitary, thereby reducing w ater excretion in 
the kidney.____________________________________________________________________________________________
AVP raises the blood pressure by inducing moderate vasoconstriction, and it enhances blood 
coagulation. Besides this, AVP also increases the release of adrenocorticotropic hormone 
and influences learning, memory and social behavior (6; 7).
The most important role of AVP however, is to regulate the body's retention of water; it 
causes the kidneys to conserve water, thus concentrating the urine and reducing urine 
volume. AVP regulates the urinary concentrating process by increasing water permeability, 
urea permeability, and sodium transport (3). In the kidney, 180 liter of blood plasma is filtered 
by the human glomeruli each day. Less than 1% of this huge volume is excreted in the urine. 
Approximately 67% of the filtered water is reabsorped in the proximal tubule and 15% in the 
descending limb of Henle's loop, which both are constitutive processes. Depending on the 
body’s needs, the remaining fluid can be reabsorbed in the connecting tubule and collecting 
duct, defining the final urine concentration. This process is tightly regulated, which allows the 
body to adapt to periods of water load or water restriction. The adjustment of water 
reabsorption mainly depends on the release of AVP (8).
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Physiological regulation of AQP2
Regulation by vasopressin
AVP-regulated maintenance of the water balance in the renal nephron occurs mainly via 
modulating cell surface expression of the water channel aquaporin-2 (AQP2). AVP binds to 
the vasopressin type-2 receptor, present in the basolateral membrane of renal collecting duct 
principal cells and connecting tubule cells (9). This induces a signaling cascade, involving Gs 
protein mediated activation of adenylate cyclase, a rise in intracellular cAMP, activation of 
protein kinase A (PKA), and subsequent phosphorylation of AQP2 at Ser256. This results in 
the redistribution of AQP2 water channels from intracellular vesicles to the apical membrane, 
greatly increasing the osmotic water permeability, leading to a concentrated urine (10-13) 
(see Fig. 3). A study in oocytes showed that phosphorylation of at least three of four 
monomers of an AQP2 tetramer is needed to redistribute AQP2 tetramers from storage 
vesicles to the apical membrane (14). Driven by the transcellular osmotic gradient of sodium 
and urea, water will enter principal cells through AQP2 and leave the cells via AQP3 and
Figure 3. R egu la tion  o f A Q P 2-m ed ia ted  w a te r reab so rp tio n . A VP  binds to the vasopressin type-2  
receptor, present on the basolateral m em brane of renal collecting duct principal cells and connecting 
tubule cells. This induces a signaling cascade, involving Gs protein mediated activation of adenylate 
cyclase, a rise in intracellular cAMP, activation of protein kinase A (PKA), and subsequent 
phosphorylation of A Q P 2 at Ser256. This results in the redistribution of A Q P 2 from intracellular 
vesicles to the apical mem brane. Driven by the transcellular osmotic gradient, w ater then will enter 
principal cells through A Q P 2 and enters the blood via A Q P 3 and A Q P 4 w ater channels, which are 
constitutively expressed in the basolateral mem brane, resulting in concentrated urine. On the long 
term, vasopressin also increases A Q P 2 expression via phosphorylation of the cAMP responsive 
elem ent binding protein (C REB ), which stimulates transcription from the A Q P 2 promoter.______________
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AQP4 water channels, which are constitutively expressed in the basolateral membrane, 
resulting in concentrated urine (15; 16). Once the water balance is restored, AVP levels drop 
and AQP2 is internalized via ubiquitination at Lys270 (see Fig. 4) (17).
In addition to its effect on AQP2 localization, cAMP also increases AQP2 expression via 
phosphorylation of the cAMP responsive element binding protein (CREB), which stimulates 
transcription from the AQP2 promoter (18-20). The increase in transcription is chronic, 
requiring hours to take effect (21; 22).
Recently, it has been shown by phosphoproteomic analysis of isolated rat renal inner 
medullary collecting duct cells, that besides the phosphorylation at Ser256, AQP2 can also 
be phosphorylated at Ser261, Ser264 and Ser269 (Thr269 in human AQP2, see Fig. 4) (23). 
While Ser264 and Ser269 phosphorylation are, like Ser256, increased upon administration of 
the AVP analogue dDAVP to AVP-deficient Brattleboro rats, phosphorylation of Ser261 is 
decreased (24-26). AQP2 phosphorylated at either site shows distinct subcellular 
localizations. Phosphorylated Ser261-AQP2 is mainly found in intracellular vesicles and 
seems to be absent from the plasma membrane (24). Ser264-AQP2 resides in intracellular 
vesicles and the plasma membrane, and upon treatment with dDAVP there is a change in 
distribution from predominantly intracellular vesicles to the plasma membranes (25). Finally, 
phosphorylated Ser269-AQP2 is solely found in the apical plasma membrane and not in 
intracellular vesicles. Madin-Darby canine kidney cells expressing an Ser269Asp 
“phosphomimic” AQP2 mutant showed constitutive localization at the plasma membrane 
suggesting that Ser269 phosphorylation enhances apical plasma membrane retention of 
AQP2 (26). However, the exact function of these phosphorylation sites remains to be 
established.
Tonicity
AQP2 expression is not only regulated by AVP but also by other factors. For example 
osmolality not only affects plasma AVP, but also appears to have direct effects on AQP2 
expression and urine concentrating ability. In the syndrome of inappropriate antidiuretic 
hormone secretion (SIADH), for example, levels of AVP are inappropriately high relative to 
plasma osmolality, resulting in free-water retention and hypotonicity. Under these 
circumstances, however, the free-water excretion is considerably higher than would be 
expected from the AVP concentrations (27). This phenomenon, called vasopressin escape, 
indicates that there are mechanisms counteracting AVP action. In a rat animal model, it has 
been shown that the onset of this escape coincides with a decrease in the AQP2 expression 
in the renal collecting duct (28). Hypotonicity and/or volume expansion have been proposed 
to mediate this AVP-independent direct regulation of AQP2 expression (29).
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Figure 4. S chem atic  represen tation  o f th e  hum an A Q P 2 p ro te in . A Q P 2 is a 271 amino acid protein 
that is predicted to have six transm em brane domains with its N and C-terminus intracellular. The  
ubiquitination site (Ub) and phosphorylation sites (P) in the C-terminus are indicated.
Alternatively, an AVP-independent increase of AQP2 expression has been suggested to 
occur with hypertonicity. Valtin and Edwards reported that water deprivation of AVP-deficient 
Brattleboro rats leads to hypertonicity, increased papillary interstitial osmolality, and 
concentration of the urine (30). Similarly, Li et al found that hypertonicity due to 
hyperglycemia or increased NaCl levels increases AQP2 expression in Brattleboro rats (31). 
In mouse collecting duct principal cells (mpkCCDc14), Hasler et al. showed that hypertonicity 
decreases the abundance of AQP2 on the short term, but increases its abundance and 
mRNA levels on the long term (32). Here, hypertonicity did not affect the stability of AQP2 
mRNA or protein, indicating that hypertonicity increases AQP2 abundance by increasing its 
transcription.
A protein suggested to be involved in the hypertonicity response is the tonicity-responsive 
enhancer binding protein (TonEBP). TonEBP is upregulated with hypertonicity in cultured 
cells and in the kidney medulla (33; 34). In renal epithelial cells, acute hypertonic challenge 
triggers a rapid increase in expression of genes involved in the cellular accumulation of 
osmolytes, such as sodium/myo-inosytol co-transporter and the sodium/chloride/betaine co­
transporter, leading to cell survival in hypertonic conditions (35). Expression of these genes 
is increased by TonEBP (35).
However, TonEBP might also have effects on urinary concentration as TonEBP knockdown 
or inhibition, but also mutation of the tonicity responsive element (TonE) in the AQP2
15
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promoter, reduced AQP2 expression in mpkCCD cells (36; 37). Moreover, in TonEBP-/- mice 
and mice transgenic for dominant-negative TonEBP, AQP2 expression was decreased (38; 
39). However the severe atrophy of the renal medulla in these mice complicates the 
interpretation of the direct involvement of TonEBP in AQP2 regulation. Kasono et al. 
observed a hypertonicity-induced increase in AQP2 transcription in MDCK cells only when 
the AQP2 promoter was -6,1 kb or longer and therefore did not involve TonE, which localizes 
at 489 bases upstream of the AQP2 transcription start site (29), suggesting that TonE and 
TonEBP are not involved in AQP2 regulation.
In addition to TonEBP, activation of the nuclear factor of activated T cells c (NFATc) pathway 
has been suggested to be involved in hypertonicity. Li et al. reported that NFATc translocates 
to the nucleus upon hypertonicity and that NFATc binding sites downstream of TonE are also 
important for hypertonicity-induced AQP2 expression in mpkCCD cells (37).
Prostaglandins
Besides AVP, several other hormones and chemical messengers regulate the water balance 
by antagonizing the AVP-induced water transport, like extracellular purines and dopamine 
(40) (see Fig. 5). Prostaglandins are also involved in regulation renal water transport. In 
particular, prostaglandin E2 (PGE2) has been shown to decrease AVP-stimulated water 
reabsorption in perfused collecting ducts (41-43). Of the four E-prostanoid receptor subtypes, 
both EP1 receptor activity, inducing calcium mobilization, and EP3 receptor activity, inhibiting 
cAMP generation via Gi, can inhibit AVP-stimulated water reabsorption (42; 44-46). One 
mechanism of PGE2 counteracting AVP is by retrieving AQP2 from the plasma membrane, 
as shown in MDCK cells and inner medulla suspensions (47; 48). Furthermore, PGE2 
modulates the cytoskeleton. It has been shown in primary rat inner medullary collecting duct 
cells that PGE2 binding to its EP3 receptor activates Rho, thereby inhibiting water 
permeability by preventing depolymerization of the actin cytoskeleton, necessary for AQP2 
translocation (49).
Paradoxically, although PGE2 decreases water reabsorption in the presence of AVP, it 
increases the osmotic water permeability in collecting ducts in the absence of AVP (42; 43). 
The stimulatory effect of PGE2 on basal water permeability is most likely mediated via the 
EP4 receptor, as this receptor couples to Gs, thereby activating adenylate cyclase and 
increasing cAMP levels.
Besides PGE2, also PGF2a affects water homeostasis, as it has been shown to inhibit AVP- 
stimulated water permeability in the collecting duct (50; 51). Activation of FP receptor leads 
to calcium mobilization in most cell types, but in the collecting duct, FP receptor activation 




Figure 5. H orm onal inh ib ition  o f A Q P 2-m ed ia ted  w a te r  reabsorp tion . Several hormones can 
antagonize AVP-induced w ater transport. Indicated are adenylate cyclases (AC ), aquaporin-2 
(AQP2), vasopressin (AVP), cyclic adenosine monophosphate (cAMP), Diacylglycerol (DAG), 
dopamine receptor (DR), prostaglandin E receptor 1 (EP1), prostaglandin E receptor 3 (EP3), 
prostaglandin F receptor (FP), P2 purinergic receptor (P2), prostaglandin E2 (PGE2), prostaglandin F2a 
(PGF20), phospholipase C (PLC) , vasopressin V2 receptor (V2R).
Dopamine
Dopamine has been shown to decrease AVP-stimulated water permeability and cAMP 
production in isolated cortical and inner medulla collecting ducts (52-54). Dopamine is 
synthesized in renal proximal tubular cells and possibly in the inner medulla collecting duct. 
Also renal dopaminergic nerves may contribute to the amount of renal dopamine (55). In the 
cortical collecting duct, the diuretic effect of dopamine is mediated by activation of D4 
receptors, coupling to Gi (53; 56). In the inner medullary collecting duct, the inhibitory effect 
of dopamine is suggested to be mediated through a2-adrenergic receptors, which can also be 
activated by high concentrations of dopamine (52). Like PGE2, dopamine also causes AQP2 
internalization from the plasma membrane into intracellular storage vesicles in MDCK cells 
(48).
Extracellular purines
Extracellular purines, ATP and UTP, have been shown to decrease AVP-induced water
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permeability in isolated inner medulla collecting tubules (57; 58). Extracellular purines appear 
to attenuate the AVP-triggered increase of intracellular cAMP, which is thought to be 
conferred by increasing intracellular Ca2+ levels and the activation of a counteracting protein 
kinase C (58). There are also indications that ATP may affect AQP2-mediated water 
permeability indirectly by stimulating the release of PGE2 (59).
Extracellular purines can mediate their action via the ionotropic P2X receptors as well as the 
metabotropic, G-protein-coupled P2Y receptors. Various P2X and P2Y receptors have been 
identified in the collecting duct (60; 61).
The involvement of the P2Y2 receptor in water reabsorption is suggested by a recent study 
on P2Y2 receptor knockout mice showing that, although net urinary reabsorption was not 
different compared to wild-type mice, these knockout mice showed increased renal medullary 
expression of AQP2, as well as elevated urinary cAMP excretion (62). A recent study in 
oocytes showed that, besides P2Y2, activation of P2X2 and P2Y4 receptors by ATP 
decreases AQP2 plasma membrane expression as well (63). Whether other P2 receptors 
contribute to the purinergic effect on AVP-mediated water reabsorption is unclear.
Water homeostasis-associated pathologies
Increased AQP2
Disturbances of water balance occur frequently, and are characterized by hyponatremia, 
hypernatremia or polyuria, and can be mediated by too high or too low levels of AQP2. 
Hyponatremia with high AQP2 abundance can be caused by osmoregulation disorders, but is 
most frequently caused by diseases with low effective circulating volume. Since in these 
conditions, maintaining volume balance overrules osmoregulation, development of 
hyponatremia is the mere consequence of the body’s goal to maintain circulating volume. 
Congestive heart failure (CHF) is characterized by high levels of AVP which contribute to 
hyponatremia and increased extracellular volume (64). In CHF rat models, increased AQP2 
levels and a marked redistribution of AQP2 to the apical plasma membrane were found (65; 
66). Both AQP2 protein and AQP2 mRNA levels were increased (66).
Hepatic cirrhosis is another chronic condition associated with water retention, hyponatremia 
and increased AVP levels (64). However, unlike CHF, the changes in expression of AQP2 
protein levels vary considerably between different experimental models of hepatic cirrhosis. 
In several rat models of liver cirrhosis, increased AQP2 protein and mRNA levels were found 
(67; 68). In another study, however, total AQP2 levels were not changed, but an increase in 
plasma membrane expression of AQP2 was observed (69). Other rat models of liver cirrhosis
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displayed decreased AQP2 levels and impaired water reabsorption (70; 71). An explanation 
for the differences found between these rat models is at present lacking.
There are several disorders of disturbed osmoregulation. In the syndrome of inappropriate 
secretion of antidiuretic hormone (SIADH), AVP levels are abnormally increased, leading to 
excessive renal water reabsorption, which might result in life-threatening hyponatremia (72). 
It was shown in a rat model of SIADH that AQP2 levels are markedly increased and that 
AQP2 plays an important role in water retention and development of hyponatremia in SIADH 
(68). SIADH patients are normovolemic or slightly hypervolemic. The most common causes 
of SIADH are neoplasia, neurological diseases, lung diseases and a wide variety of drugs 
(73). Most commonly, SIADH patients show excessive release of AVP which is totally 
unrelated to plasma osmolality, caused by for example ectopic AVP production by 
neoplasms, or patients continue to regulate water excretion but do so around a lower plasma 
osmolality setpoint compared to normal. The underlying mechanism of this is unclear (73).
Another cause of normovolemic hyponatremia is the Nephrogenic Syndrome of Inappropriate 
Antidiuresis (NSIAD). The clinical presentation of NSIAD resembles those of SIADH and 
consist of hyponatraemia and the lack of urinary dilution. However, in contrast to SIADH, the 
AVP levels in plasma are undetectable or very low (74). NSIAD is a rare disorder in water 
balance caused by an activating mutation in the AVP receptor type 2 (V2R), causing the 
constitutive activation of the receptor. The basal ability of the mutant V2R to induce cAMP, 
as measured by cAMP-inducible luciferase reporter in COS-7 cells, was shown to be 
increased compared to the wild-type V2R (75). This gain of function due to constitutive 
activation of V2R in NSIAD patients explains the inappropriate antidiuresis.
Decreased AQP2
In contrast to the conditions mentioned above, Diabetes Insipidus (DI) is characterized by an 
impaired renal water reabsorption, leading to polyuria and, consequently, polydipsia. DI can 
present with hypernatremia, but patients most often have a normal plasma osmolality, 
provided the thirst mechanism is normal and there is adequate access to fluid. In central DI, 
normal AVP production is impaired. Central DI can be caused by mutations in the AVP gene, 
but is usually occurring as a consequence of head trauma or diseases in the hypothalamus 
or pituitary gland (76). In a model of central DI, the AVP-deficient Brattleboro rat, it was 
shown that these rats have decreased expression levels of AVP-regulated AQP2, and the 
AQP2 deficit was reversed by chronic AVP infusion, suggesting that patients lacking AVP are 
likely to have decreased AQP2 expression (77). Administration of the synthetic AVP homolog 
dDAVP is usually able to drastically decrease urine output in central DI patients.
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A second form of DI can occur during pregnancy, due to an abnormal increase in 
vasopressinase, an AVP-degrading enzyme produced by the placenta. Because dDAVP is 
resistant to degradation by vasopressinase, it is an effective treatment for this form of DI 
(78).
The last form of DI is called nephrogenic DI (NDI), and is caused by the inability of the kidney 
to respond to AVP stimulation. NDI can be congenital or acquired. Congenital NDI can be 
divided into X-linked, autosomal recessive and autosomal dominant NDI.
The X-linked form of congenital NDI is caused by loss-of-function mutations in the AVPR2 
gene, encoding the V2R (79). More than 90% of all congenital NDI patients suffer from X- 
linked NDI. Mutations in the AVPR2 gene interfere with receptor signaling, thus making the 
principal cells of the collecting duct insensitive to AVP. This results in a severe urine 
concentration defect. The molecular mechanism underlying this insensitivity differs among 
mutants. The most common mechanism is misfolding of the protein and retention in the 
endoplasmic reticulum. Other mechanisms include defective processing or unstable mRNA, 
diminished binding of the Gs protein, reduced affinity for AVP, and misrouting of the V2R to 
different organelles in the cell (80).
Approximately 10% of the patients diagnosed with NDI have mutations in the AQP2 gene. In 
more than 90% of patients there is evidence of autosomal recessive inheritance. Nearly all 
mutations cause misfolding of the protein, which is consequently trapped in the ER, followed 
by rapid proteasomal degradation (80). The healthy parents of patients with recessive NDI 
express both mutant and wild-type AQP2 proteins. However, since these AQP2 mutants are 
not able to form heterotetramers with wild-type AQP2, this leaves only the formation of the 
functional wild-type AQP2 homotetramers, likely explaining the healthy phenotype of the 
parents (81).
The least occurring form of hereditary NDI, autosomal dominant NDI, is caused by mutations 
in the C-terminal tail of AQP2. These AQP2 mutants form heterotetramers with wild-type 
AQP2 and are, due to the mutation, missorted to other cellular organelles (80). Since wild­
type AQP2 is retained in mixed tetramers and also missorted, water reabsorption is severely 
affected, explaining the dominant mode of inheritance of NDI in these patients.
In contrast to the rare inherited forms of NDI, acquired forms of NDI are much more common. 
It has been demonstrated that hypokalemia and hypercalcemia, two common electrolyte 
disorders, cause NDI.
In rat models of hypokalemia it was shown that this condition is associated with a decreased 
AQP2 expression (82). Besides AQP2, hypokalemia also decreases the expression of renal
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urea and sodium transporters, which may contribute to the urinary concentrating defect (83; 
84).
Hypercalcemia does decrease AQP2 abundance in rats as well, but does not affect AQP2 
mRNA levels. This suggests that there is no effect on AQP2 transcription, but that 
hypercalcemia increases AQP2 degradation or decreases AQP2 translation. Hypercalcemia 
also decreased the fraction of AQP2 at the apical membrane, suggesting an effect on AQP2 
targeting (85). Hypercalcemia also reduces the expression of the water channels AQP1 and 
AQP3, and decreases the expression of renal sodium transporters, likely contributing to the 
decreased urine concentrating ability (86; 87).
A relatively common condition associated with long-term impairment of urinary concentrating 
ability is obstruction of the urinary tract. Urinary tract obstruction is a serious clinical 
condition, which in children is usually due to congenital abnormalities, whereas in adults it is 
mostly caused by stones, enlargement of the prostate, and urinary tract neoplasms. 
Experimental bilateral obstruction of the ureters was found to be associated with markedly 
reduced expression of AQP1, AQP2 and AQP3 (88; 89) In addition, bilateral ureteral 
obstruction is associated with marked down-regulation of sodium transporters and urea 
transporters (90; 91). Following release of the obstruction, there is a marked polyuria during 
which period AQP2 and AQP3 levels remain down-regulated, but are restored to normal in 
time, providing an explanation at the molecular level for the observed postobstructive 
polyuria (89).
Recently, bilateral obstruction has been demonstrated to be associated with increased 
cyclooxygenase-2 (COX-2) expression and prostaglandin release from interstitial cells. 
Treatment of rats with COX-2 inhibitors prevented down-regulation of AQP2 (92; 93).
Lithium-treatment
The most common form of NDI is lithium-induced NDI. Lithium is regularly used to treat 
psychiatric diseases, such as bipolar disorders, schizoaffective disorders and depression. 
Lithium is a frequently prescribed drug and used by 1 in 1000 of the population (94; 95). 
Unfortunately, approximately 20% of patients develop NDI (96-98). Lithium-NDI patients are 
at risk for dehydration-induced lithium toxicity, and prolonged lithium treatment might lead to 
end stage renal disease (94). However, since the symptoms of the underlying psychiatric 
disorder have a high impact on the quality of life, cessation of lithium therapy is not an option 
for many patients.
Studies in rats showed that lithium-NDI develops in two stages. At the short term (10 days), 
lithium-NDI coincides with AQP2 and AQP3 down-regulation and natriuresis, without gross 
changes in renal morphology (99-101). The lithium-induced natriuresis is suggested to be
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due to the reduced expression, in some renal segments, of the salt-transporting proteins 
NCC, the p- and Y-subunits of ENaC, and the Na-K-ATPase (99; 102; 103).
Chronic lithium treatment (4 weeks) also leads to a severe decrease in the fraction of 
principal cells. This is ‘compensated’ by an increase in the fraction of intercalated cells, which 
are involved in acid/base balance regulation (104; 105).
At present, it is unclear how lithium causes NDI. Some data, however, suggest that lithium 
may exert its effects by entering principal cells through the epithelial sodium channel, ENaC. 
ENaC has a higher permeability for lithium than for sodium (106), the ENaC-blocker 
triamterene increases lithium excretion (107) and it has been shown in a limited number of 
lithium-NDI patients that blocking ENaC with amiloride significantly reduces urine volume and 
increases urine osmolality (108-110).
Recently it was shown in mpkCCD cells, which endogenously express AQP2, that lithium 
does not affect AVP-induced cAMP generation, PKA-dependent phosphorylation of AQP2, or 
the phosphorylation of the AQP2 transcription factor CREB. Also in vivo, in AVP-deficient 
Brattleboro rats with clamped blood dDAVP levels, there was no difference in dDAVP- 
generated cAMP generation after lithium treatment (111).
Lithium has been shown to decrease renal medullary glycogen synthase kinase (Gsk)-3p 
activity, and this was temporally related to increased COX-2 expression in the kidney, 
consistent with a tonic in vivo suppression of COX-2 expression by Gsk-3 activity (112; 113). 
Consistent with the role of COX-2 in prostaglandin production, lithium increased excretion of 
PGE2 in the urine of rats and mice (112; 114). As PGE2 reduces AVP-stimulated water 
reabsorption in the collecting duct (41; 42), this could suggest an important role for PGE2 in 
the development of lithium-induced NDI. This is also suggested by studies showing that 
blocking prostaglandin production by indomethacin reduces the urine volume of lithium- 
treated rats (115) as well as of patients with lithium-induced NDI (116; 117).
Pharmacological regulation of AQP2-related pathologies
Demeclocycline
Demeclocycline is a bacteriostatic antibiotic of the tetracycline group, which has been shown 
to cause water diuresis and NDI (118; 119). Because of the effect on water diuresis, 
demeclocycline is currently used to treat sustained hyponatremia in patients with SIADH 
(120). Demeclocycline has been shown to restore the sodium plasma concentration in 
SIADH patients to normal levels, permitting unrestricted water intake in these patients (121). 
Wilson et al. showed that the aquaretic effect of demeclocycline is exerted by selective 
inhibition of the water reabsorption in the distal part of the nephron (122). Others have shown
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that demeclocycine inhibits the AVP-induced osmotic water flow in the toad urinary bladder 
(118; 123; 124), a model system of the mammalian collecting duct.
V2R antagonists
Recently, several V2-receptor antagonists have been developed. In rat models of SIADH and 
liver cirrhosis, administration of the V2R antagonist OPC-31260 increased the urinary flow 
rate, lowered the urinary osmolality and attenuated the hyponatremia (125; 126). Besides 
that, OPC-31260 has been shown to produce water diuresis and improve hyponatremia in 
SIADH patients as well (127). Three other V2R antagonists, Tolvaptan, Lixivaptan and 
Conivaptan, were tested in patients with hyponatremia due to a variety of causes including 
CHF, liver cirrhosis and SIADH and were found to increase diuresis and correct 
hyponatremia (128-130). The V2R antagonist SR-121463B increased the urinary volume, 
decreased urinary osmolality and corrected the hyponatremia in patients with SIADH, 
suggesting that also SR-121463B is a successful treatment of hyponatremia (131). 
Altogether, this suggests that the V2R antagonists are promising drugs for the treatment of 
hyponatremia.
Diuretics
At the moment, thiazide diuretics are used to reduce excessive urine output in NDI patients. 
In 1960, the first study was published that showed that hydrochlorothiazide could decrease 
urine volume and increase urine osmolality in patients with congenital NDI (132). Since then, 
thiazides have become an important component in the treatment of patients with congenital 
diabetes insipidus. Also in lithium-induced nephrogenic diabetes insipidus, thiazide diuretics 
have been used successfully (119).
The precise mechanisms by which thiazide diuretics elicit their paradoxical anti-diuretic effect 
are largely elusive. The distal convoluted tubule, where the thiazide-sensitive NaCl- 
cotransporter is located, is water impermeable; therefore, the water-preserving effect of 
thiazides is unlikely related to a direct effect on this tubule. Thiazides antidiuretic action might 
by secondary to an increased renal sodium excretion, causing a decreased extracellular 
volume leading to an activation of the renin-angiotensin-aldosterone system, a decrease in 
glomerular filtration rate and an increased proximal sodium and water reabsorption. As a 
result, less water is delivered to the distal tubules, and less is excreted in the urine. Recently 
it has also been shown that thiazide directly enhances water permeability of isolated 
collecting ducts (133), and that thiazide treatment increases the expression of AQP2 in 
lithium-induced NDI (134), suggesting a direct effect of thiazide on the collecting duct.
The combined administration of hydrochlorothiazide with a prostaglandin synthesis inhibitor 
such as indomethacin was shown to be more effective in reducing urine volume than the
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thiazide-diuretic alone (135-137). Similarly, combining administration of hydrochlorothiazide 
with the ENaC-blocker amiloride was shown to be more effective than the thiazide-diuretic 
alone as well (138-140). Besides this, the addition of amiloride also prevents hypokalemia 
and metabolic alkalosis, common side-effects of thiazide therapy (138; 139).
Aim of the thesis
Regulation of AQP2 is critical to osmoregulation and the maintenance of body water 
homeostasis. However, the exact molecular mechanisms which regulate AQP2 in different 
conditions are still unknown. This thesis aims to improve the understanding of the 
physiological and pharmacological modulation of renal water reabsorption and AQP2 
expression.
In the first chapters, the physiological regulation of AQP2 was investigated. In chapter 2, the 
pathways involved in the inhibition of AQP2 mediated water transport by ATP and dopamine 
were studied in a cell model as well as in kidney.
Prostaglandins counter-act AVP-induced water reabsorption, but can also stimulate water 
reabsorption in the absence of AVP. To further investigate this, the effects of prostaglandins 
on AQP2 expression, as well as the effect of AVP on prostaglandin production and receptor 
expression were investigated, as described in chapter 3.
Osmolality not only affects plasma AVP, but also has a direct effect on AQP2 expression and 
urine concentrating ability. These effects were further investigated in chapter 4, using a 
collecting duct cell model.
In chapter 5, the long term AQP2 regulation after sustained AVP stimulation, in contrast to 
the effects after immediate stimulation, was investigated.
AQP2 expression can also be modulated by several medications. One of these, 
demeclocycline, is currently used to treat sustained hyponatremia in patients with SIADH. 
The mechanism by which demeclocycline decreases renal water reabsorption is unknown, 
and is investigated in chapter 6.
Lithium-induced NDI, the most common form of NDI, is associated with a decreased AQP2 
expression. The exact mechanism by which lithium causes this AQP2 downregulation is 
investigated in chapter 7. At present it is unclear whether lithium-induced NDI can be 
attenuated. In chapter 8 the effect of the ENaC blocker amiloride on lithium-induced NDI is 
described, using a cell model as well as lithium-NDI rats.
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Abstract
Water homeostasis is regulated by a wide variety of hormones. When in need for water 
conservation, vasopressin, released from the brain, binds renal principal cells and initiates a 
signalling cascade resulting in the insertion of AQP2 water channels in the apical membrane 
and water reabsorption. Conversely, hormones, including extracellular purines and dopamine 
antagonize AVP-induced water permeability, but their action mechanism is largely unknown, 
which was investigated here.
Addition of these hormones to mpkCCD cells decreased total and plasma membrane 
abundance of AVP-induced AQP2, partly by increasing its internalization to vesicles and 
lysosomal degradation. This internalization was ubiquitin-dependent, because the hormones 
increased AQP2 ubiquitination, and the plasma membrane localization of AQP2-K270R, 
which cannot be mono-ubiquitinated, was unaffected by these hormones. Both hormones 
also increased AQP2 phosphorylation at S261, which followed ubiquitination, but was not 
essential for hormone-induced AQP2 degradation. A similar process occurs in vivo, as 
incubation of dDAVP-treated kidney slices with both hormones also resulted in the 
internalization and S261 phosphorylation of AQP2. Both hormones also reduced cAMP and 
AQP2 mRNA levels, suggesting an additional effect on AQP2 gene transcription. 
Interestingly, phorbol esters only reduced AQP2 through the first pathway.
Together, our results indicate that ATP and dopamine counteract AVP-induced water 
permeability by increasing AQP2 degradation in lysosomes, preceded by ubiquitin- 
dependent internalization, and by decreasing AQP2 gene transcription by reducing the AVP- 
induced cAMP levels.
Introduction
Vasopressin (AVP)-regulated maintenance of the water balance in the renal collecting duct 
occurs via alternating cell surface expression of the water channel aquaporin-2 (AQP2), and 
depends on the body’s need for water conservation. In states of hypernatremia and 
hypovolemia, AVP is released into the bloodstream, interacts with its renal type 2 receptors 
and initiates a signal transduction cascade (1). This includes activation of adenylate cyclase, 
a rise in intracellular cAMP and calcium levels, activation of protein kinase A (PKA) and its 
recruitment to AQP2 containing vesicles, and subsequent phosphorylation of AQP2 at serine 
256 (S256) (2-4). This phosphorylation is essential for the re-distribution of tetrameric AQP2 
from intracellular storage vesicles to the apical plasma membrane (5). In addition, cAMP also 
increases AQP2 expression via phosphorylation of the cAMP responsive element binding
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protein (CREB), which activates the AQP2 promoter (6; 7). Due to the increased plasma 
membrane expression of AQP2, water is able to pass the apical membrane passively along 
an osmotic gradient and enters the blood via AQP3 and AQP4 water channels, which are 
constitutively expressed in the basolateral membrane. Once the water balance is restored, 
AVP levels drop and AQP2 is internalized via ubiquitination at Lys270 (8).
Besides AVP, several other hormones regulate the water balance by antagonizing the AVP- 
induced water transport (9), but the underlying mechanism is poorly understood. Extracellular 
purines, ATP and UTP, decrease AVP-induced water permeability, which is at least partially 
mediated via the P2Y2 receptor, located in the basolateral membrane of principal cells (10­
13), but may also involve P2X2 and P2Y4 receptors (14). Moreover, dopamine, carbachol, 
an acetylcholine analogue, and endothelin-1 inhibit the AVP-induced water permeability (15­
20).
Intracellularly, the action of these hormones shows overlap, but also differs. ATP/UTP and 
dopamine appear to attenuate the AVP-triggered increase of intracellular cAMP, which is 
thought to be conferred by activation of a counteracting protein kinase C (PKC, ATP/UTP; 
(11)), or coupling of the hormone receptor to the inhibitory G (Gi) protein (dopamine; (15). In 
contrast, carbachol reduced the AVP-induced water transport via a PKC-dependent pathway, 
but did not impair the AVP-induced cAMP production (20; 21).
At present, however, it is unknown whether the reduced AVP-induced water permeability 
induced by these hormones involves AQP2 degradation and, if so, whether this occurs via 
AQP2 ubiquitination, internalization and degradation, as we recently reported to occur with 
forskolin removal or addition of phorbol ester 12-tetradecanoylphorbol-13-acetate (TPA), a 
drug that can activate PKC (8; 22). Moreover, it is unknown whether any of these hormones 
employs phosphorylation of AQP2 at any other site than S256, as it has recently been shown 
that AQP2 can also be phosphorylated at S261, S264 and S269, and that pS261-AQP2 is 
mainly found in intracellular vesicles (23; 24).
Therefore, to obtain more insight into the mechanism by which hormones counteract the 
action of AVP on AQP2, we here analyzed in detail the effect and underlying mechanism of 
ATP and dopamine on the AVP-induced AQP2 abundance.
Materials and Methods
Chemicals and reagents
[deamino-Cys1, D-arg8]-vasopressin (dDAVP), ATP, UTP, dopamine, forskolin, cycloheximide 
and chloroquine were purchased from Sigma (St. Louis, MO, USA). dDAVP was
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administered to the basolateral side only. All other compounds were administered to both the 
apical and basolateral side.
Ex vivo immunofluorescence
Female Sprague Dawley rats were anesthetized with ether and sacrificed by decapitation. 
Kidneys were quickly removed and sections of approximately 0.5 mm were made and 
divided in four groups. The sections were equilibrated for 10 min in a buffer containing 118 
mM NaCl, 16 mM HEPES, 17 mM Na-HEPES, 14 mM glucose, 3.2 mM KCl, 2.5 mM CaCl2,
1.8 mM MgSO4, and 1.8 mM KH2PO4 (pH 7.4). AQP2 trafficking was stimulated in the same 
buffer and at 37°C with 1 nM dDAVP for 15 minutes followed by a 30 minutes incubation with 
dDAVP alone or in combination with either 0.1 mM dopamine or ATP, or 100 nM TPA. Next, 
the kidney sections were overnight fixed in 4% paraformaldehyde at 4°C, infiltrated with 30% 
sucrose in PBS for 24 hours, embedded in Cryomatrix (DDK Srl Milano, Italy) at dry ice and 
cut with a cryostat to obtain 5 ,^m sections.
To stain for AQP2, the kidney sections were washed three times with PBS, blocked with 1% 
PBS-BSA for 1 hour, incubated with our affinity-purified rabbit 1: 1000-diluted antibodies 
raised against the 20 amino acids N-terminal of the poly-phosphorylated region of human 
AQP2 (CLKGLEPDTDWEEREVRRRQ; pre-C tail) for 2 hours, and washed three times with 
PBS. After washing, the sections were incubated with 1:1000 diluted goat anti-rabbit 
antibodies coupled to Alexa-488 (Invitrogen, Milano, Italy), rinsed three times with PBS and 
mounted in mounting medium containing 50% glycerol in 0.2 M Tris-HCl, pH 8.0 in the 
presence of 2.5% n-propyl gallate. Images were obtained with a Leica TCS SP2 (Leica 
Microsystems, Heerbrugg, Switzerland).
Cell culture
MpkCCD cells (clone 14)(25) were grown in a modified defined medium (DMEM:Ham’s F12 
1:1 vol/vol; 60 nM sodium selenate, 5 ^.g/ml transferrin, 2 mM glutamine, 50 nM 
dexamethasone, 1 nM triiodothyronine, 10 ng/ml epidermal growth factor, 5 ^.g/ml insulin, 20 
mM D-glucose, 2% foetal calf serum, and 20 mM HEPES (pH 7.4)).
Cells were seeded at a density of 1.5x105 cells/cm2 on semi-permeable filters (Transwell, 0.4 
.^m pore size, Corning Costar, Cambridge, MA, USA). 1.13 cm2 filters were used for 
immunocytochemistry or immunoblotting, and 4.7 cm2 filters for biotinylation experiments. 
The cells remained in culture for 8 days before being analyzed. Cells were incubated with 1 
nM dDAVP for the last 4 days, to maximally induce AQP2 expression (26). Biotinylation was 
performed as described (27). The concentrations of the AVP-counteracting hormones ATP 
and dopamine were 100 ^M and the concentration of TPA used was 100 nM. Each 
experiment was done in triplicate and was repeated at least 3 times.
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For the generation of cell lines stably expressing exogenous wtAQP2 of AQP2-K270R, the 
expression constructs pcB6-dBamHI-AQP2 and pcB6-dBamHI-AQP2-K270R (8), which 
encode these respective channels, were transfected into mpkCCD cells using the calcium 
phosphate method as previously described for MDCK cells (27). MDCK-wtAQP2 have been 
described (27).
Immunocytochemistry
Immunocytochemistry and confocal laser scanning microscopy (CLSM) of cells grown on 
semi-permeable filters were performed as described (27). For AQP2 detection, the filters 
were incubated with affinity-purified rabbit anti-AQP2 antibodies (1:100; (28)) and goat anti 
rabbit antibodies coupled to Alexa 488 (Molecular Probes, Eugene, OR, USA; 1:100).
Immunoblotting
Immunoblotting was performed as described (27). As antibodies, affinity-purified rabbit 7 anti- 
AQP2 antibodies (1:3000; (28)), guinea pig anti-AQP2 (1:4000) antibodies, rabbit anti-AQP2- 
pS261 antibodies (1:2000; kindly provided by Dr. M. A. Knepper, Bethesda, USA), mouse 
anti-ubiquitin (P4D1; Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:1000) or mouse 
anti-p-actin (Sigma, St. Louis, MO, USA; 1:25000) were used. As secondary antibodies, goat 
anti-rabbit, goat anti-guinea pig, or sheep anti-mouse antibodies coupled to horseradish 
peroxidase (HRP; Sigma, St. Louis, MO, USA; 1:10000) were employed.
For immunoblotting of kidney sections, this tissue was lysed in a buffer containing 1% Triton 
X-100, 150 mM NaCl, 10 mM NaF, 1mM sodium orthovanadate, 25 mM Hepes (pH 7.4) and 
subjected to immunoblotting studies. Total AQP2 was detected with 1:1000 dilution of our 
affinity-purified preCtail antibodies. AQP2-pS261 antibodies (1:1000) were purchased from 
DBA (Segrate, Milano, Italy). As secondary antibodies, goat anti-rabbit HRP-coupled 
secondary antibodies were used.
Quantitative-RT-PCR
MpkCCD cells were grown as described (26) and total RNA was isolated using TriZol 
extraction reagent (Gibco BRL, Life Technologies, Rockville, MD), according to the 
manufacturer’s instructions. To remove potentially contaminating DNA, total RNA was 
treated with DNase (Promega, Madison, WI) in DNase buffer, incubated for 1 hr at 37 °C, 
extracted with phenol/chloroform and precipitated using sodium acetate (3M, pH 5.2) and 
100% ethanol. 1.5 ^g RNA was reverse-transcribed into cDNA using MMLV Reverse 
Transcriptase with random primers (Promega, Madison, WI). SYBR Green Real-time 
quantitative PCR was performed on an iQ5 Real-Time PCR Detection System from Bio-Rad 
by utilizing the SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA), in
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combination with mouse AQP2 primers (5’-CTCCACAACAATGCAACAGC-3’ and 5’- 
GAGCAGCCGGTGAAATAGAT-3’). As an internal standard, RNA of ribosomal 18S was 
amplified in parallel using the primers 5’-GTAACCCGTTGAACCCCATT-3’ and 5’- 
CCATCCAATCGGTAGTAGCG-3’.
cAMP assay
MpkCCD cells were grown on 0.33 cm2 filters for 8 days, with dDAVP for the last 4 days. At 
the last day, cells grown with dDAVP were incubated with culture medium supplemented with
1 nM dDAVP and 250 ^M 3-Isobutyl-1-methylxanthine (IBMX; Sigma, St. Louis, MO, USA) 
for 10 min to prevent cAMP degradation by phosphodiesterases, followed by 15 min 
incubation with the AVP-counteracting hormones mentioned above in the presence of 
dDAVP and IBMX. The filters were rapidly excised from their plastic support, lysed in 150 ^l 
of 0.1 M HCl, and incubated for 15 min at room temperature to complete lysis. To remove 
debris, the scraped samples were then centrifuged at 600 g for 5 min at room temperature. 
Subsequently, 100 .^l supernatant was used to determine the cAMP levels using a direct 
cAMP enzyme immunoassay kit (Sigma, St. Louis, MO, USA).
Immunoprecipitation
20 ^l protein A agarose beads (Kem-En-Tec A/S, Copenhagen, Denmark) per sample were 
washed three times in lysis buffer (1% Triton X-100, 150mM NaCl, 25mM Hepes (pH 7.4)). 
Per sample, 1 ^l of rabbit anti-AQP2 or guinea pig anti-AQP2 antibodies was added to 1 ml 
lysis buffer with protease inhibitors (1 mM PMSF, 5 ^g/ml pepstatin, 5 ^g/ml leupeptin, and 5 
^g/ml a-protinin) and rotated for 4h at room temperature. Before use, the antibody-coupled 
beads were washed three times with lysis buffer. Cells were treated as described and lysed 
in 1 ml lysis buffer containing protease inhibitors and 20 mM W-ethylmaleimide (NEM). The 
samples were centrifuged at 12,000X G for 10 minutes and the supernatant was incubated 
for 16 hours with the antibody-coupled beads at 4°C. The beads were washed four times with 
lysisbuffer, carefully dried and resuspended in 30 ^l of 1x Laemmli buffer with 0.1 M DTT. 
Subsequently, the samples were analyzed by immunoblotting for ubiquitin, AQP2-phospho- 
S261, or total AQP2 as indicated.
Statistical analyses
Films were scanned using a GS-690 Imaging Densitometer (Bio-Rad, CA, USA) and 
analyzed using Bio-Rad software. Statistical comparisons were made using one-way 





Effect of ATP and dopamine on AQP2 abundance
To study the role of hormones counteracting AVP in vitro, we used the mouse cortical 
collecting duct (mpkCCD) cells as a model, because these cells show an AVP-induced 
expression of endogenous AQP2 (25). To determine whether AVP-counteracting hormones 
counteract AVP, mpkCCD cells were grown to confluence for 8 days, incubated for the last 4 
days with dDAVP to generate a steady-state endogenous AQP2 abundance (26), and then 
incubated for the last 8 hours with 100 ATP or dopamine in the continued presence of 
dDAVP. TPA, which is known to decrease AQP2 abundance in mpkCCD cells (8), was taken 
along as a control. Subsequent immunoblotting showed that both hormones and TPA 
decreased AQP2 abundance (Fig. 1). These data indicated that mpkCCD cells can be used 
as a model to study the mechanism by which ATP and dopamine counteract AVP. Although 
lower concentrations of ATP and dopamine also affected AQP2 abundance, the above­
mentioned concentrations of AVP-counteracting hormones gave more consistent results and 
were therefore selected for the experiments below.
Figure 1. Effect o f TPA, ATP and dopam ine on dDAVP-induced AQP2 abundance. MpkCCD cells 
were grown for 4 days, incubated with 1 nM dDAVP for an additional 4 days and treated with 100 nM 
TPA, 100 ^M ATP, or 100 ^M dopamine in the presence of dDAVP for the last 8 hours. Subsequently, 
the cells were lysed and immunoblotted for AQP2. The signals were semi-quantified using 
densitometry. Samples significantly (P<0.05) different from controls are indicated by asterisk. One out 
of three independent experiments is shown. The quantification shown here is pooled data from all 
three experiments.
Effect of ATP and dopamine on AQP2 internalization
The observed reduction in AVP-induced AQP2 abundance in the 8 hours time frame can be 
due to increased AQP2 internalization and degradation, which is a relative fast process, 
and/or reduced AQP2 transcription, which usually is a slow process. To determine whether 
these hormones employ AQP2 internalization, dDAVP-induced mpkCCD cells were left 
untreated or treated with TPA, ATP or dopamine for 2h, and subjected to apical cell surface
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biotinylation assays. Immunoblotting of the biotinylated proteins and normalization for the 
respective total amounts of AQP2 revealed a significantly-reduced AQP2 abundance in the 
apical membrane with TPA, ATP and dopamine (Fig. 2). As anticipated for the short 
incubation time, none of the treatments significantly affected the total amount of AQP2.
dDAVP
Figure 2. Effect of TPA, ATP and 
dopam ine on AQP2 internalization
MpkCCD cells were grown and 
treated as described in the legend of 
Fig. 1, except that the treatment with 
TPA, ATP and dopamine was for 2 
hours. Subsequently, cells were 
subjected to cell surface biotinylation 
and lysed. Biotinylated proteins were 
pulled-down from the remaining 
solution and immunoblotted for 
AQP2 (plasma membrane). In 
addition, total lysates were 
immunoblotted for AQP2 (Total). The 
signals were semi-quantified using 
densitometry. Samples significantly 
(P<0.05) different from controls are 
indicated by asterisk. Triplicate 
samples were analyzed and 
independent experiments were 
performed in threefold, of which a 
representative experiment is shown. 
Graphs show pooled data from three 
experiments.
Recently, we showed that TPA induces short chain ubiquitination of AQP2 in vitro and in vivo 
and that this ubiquitination precedes, and is essential for, AQP2 internalization and 
degradation upon TPA treatment in MDCK-AQP2 cells (8). As ubiquitination is more readily 
detectable in MDCK then in mpkCCD cells, we initially reverted to MDCK-AQP2 (29) cells for 
this purpose. Following forskolin incubation for 45 minutes, these MDCK-AQP2 cells were 
left untreated (control) or incubated with TPA, ATP or dopamine for 15 minutes (optimal 
period for detecting ubiquitination in these cells), lysed and subjected to AQP2 
immunoprecipitation. Subsequent immunoblotting for ubiquitin revealed the typical strong 43 
and 50 kDa and the weaker 58 kDa ubiquitinated AQP2 bands in all lanes, which were 
clearly increased for cells co-incubated with ATP and dopamine and, to a higher extent, with 
TPA, as compared to control cells (Fig. 3). Detection of immunoprecipitated equivalents with 
AQP2 antibodies (Fig. 3; lower panel) revealed that similar amounts of AQP2 were loaded.
Effect of ATP and dopamine on AQP2 ubiquitination
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To assess the involvement of ubiquitination in the ATP and dopamine-induced internalization 
of AQP2 from the plasma membrane in mpkCCD cells, these cells were stably-transfected 
with wtAQP2 or the mutant AQP2-K270R, which cannot be short-chain ubiquitinated (8). As 
shown in figure 4, incubation with forskolin alone results in apical plasma membrane 
localization of wtAQP2 and AQP2-K270R. In line with the biotinylation data above, co­
incubation with TPA, ATP or dopamine induced internalization of wtAQP2 into vesicles. In 
contrast, the apical localization of AQP2-K270R remained unaffected by any of these 
compounds, demonstrating that ubiquitination of K270 is essential for hormone-induced 
internalization of AQP2 in mpkCCD cells.
Figure 3. Effect of TPA, ATP and 
dopam ine on AQP2 ubiquitination.
Confluent monolayers of MDCK-AQP2 
cells were incubated with 5x10"5 M 
forskolin followed by co-incubation 
with 100 nM TPA, 100 |jM ATP, or 100 
j M dopamine for the last 15 minutes. 
Cells were lysed and subjected to 
immunoprecipitation using rabbit anti- 
AQP2 antibodies. Samples were 
immunoblotted and blots were 
incubated with mouse anti-ubiquitin 
(upper panel) or guinea pig anti-AQP2 
(lower panel) antibodies. Protein 
masses ( in kDa) are indicated on the 
left.
Besides phosphorylation of AQP2 at S256 by PKA, three additional phosphorylation sites 
were identified in the C-terminal tail of AQP2, S261, S264, and S269 (23; 24). Interestingly, 
whereas AVP application increased phosphorylation at S256, AQP2-pS261 mainly localized 
in vesicles and AQP2 phosphorylation at S261 was decreased upon AVP incubation (24). To 
investigate whether the AVP-counteracting hormones affect the phosphorylation state of 
AQP2 at S261 and how this relates to ubiquitination of AQP2, mpkCCD-AQP2 and AQP2- 
K270R cells were left untreated or pre-incubated with 100 nM dDAVP, followed by co­
incubation with TPA, ATP, or dopamine for 15 minutes. Consistent with in vivo data, dDAVP 
reduced the pS261 29 kDa signals for wtAQP2 (Figure 5A, top panel, left lanes). Upon co­
incubation of mpkCCD-AQP2 cells with TPA, ATP or dopamine two forms of data were 
obtained. Often, TPA, ATP and dopamine did not change the signal for AQP2-pS261 at 29 
kDa, but induced the appearance of a signal at 43 kDa (Fig. 5A, upper left panel), a band 
that also appeared in the blot representing total AQP2 (Figure 5A, bottom left panel). In other 
experiments, AQP2-pS261 of 29 kDa was also observed (not shown). For AQP2-K270R, the 
basal level of AQP2-pS261 also decreased upon incubation with dDAVP (Fig. 5A, upper right
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Figure 4. Effect of TPA, ATP and dopam ine on the subcellular localization of AQP2 and its 
ubiquitination-m utant AQP2-K270R. MpkCCD-wtAQP2 and AQP2-K270R cells were grown for 8 
days, incubated with 5x10-5 M forskolin for 45 minutes to induce apical localization of AQP2, and were 
then left untreated (control), or treated with dDAVP in the presence of 100 nM TPA, 100 j M ATP, or 
100 j M dopamine for 30 minutes. Subsequently, cells were fixed and subjected to 
immunocytochemistry for AQP2. Top view (XY) confocal images and their corresponding cross 
sections (XZ) are shown.
panel). Co-incubation with TPA, ATP and dopamine neither led to an increase of the 29 kDa 
signal, but also did not result in the appearance of the 43 kDa signal as observed for 
wtAQP2. Total levels of AQP2 protein remained unaltered during the experiment (Figure 5A, 
bottom panels). These data suggest that ubiquitination precedes pS261 in AQP2.
To examine this in more detail, we analyzed phosphorylation of S261 in wild-type (wt) AQP2 
and AQP2-K270R expressing mpkCCD cells time-dependent, after incubation with ATP and 
dopamine. As shown for ATP (Fig. 5B), wt-AQP2 starts to get phosphorylated at S261 
around 15 minutes after starting ATP treatment. At this time point, however, it is 
predominantly the ubiquitinated form of AQP2 that is phosphorylated. At 30 minutes after 
ATP stimulation, when the extent of AQP2 ubiquitination has dropped (8), the signal for 
ubiquitinated AQP2-pS261 decreases, while that of 29 kDa AQP2-pS261 increased to a level 
that is sustained at later time points. In contrast, AQP2-K270R does not get phosphorylated 
at pS261 at any timepoint measured (Fig. 5B). Similar data were obtained for dopamine (not
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Figure 5. Effect of TPA, ATP and dopam ine on S261 phosphorylation and ubiquitination of 
AQP2. A) MpkCCD wtAQP2 or AQP2-K270R cells were incubated with 100 nM dDAVP for 1 h 45 min, 
followed by co-incubation with 100 nM TPA, 100 ^M ATP, or 100 ^M dopamine for an additional 15 
min. Cells were lysed in Laemmli buffer supplemented with DTT and de-phosphorylation and de- 
ubiquitination inhibitors, and analyzed on a 12% PAAG followed by immunoblotting for pS261-AQP2 
(upper panel) and AQP2 (lower panel). B) Confluent mpkCCD cells stably expressing wtAQP2 or 
a Q p 2-K270R were incubated with dDAVP for 2 h to induce translocation of AQP2 to the plasma 
membrane (0, dDAVP) followed by incubation for different time periods (in minutes) with dDAVP and 
ATP. Cells were lysed and analyzed as described in A.C) MpkCCD cells were incubated for 4 days in 
the presence of dDAVP and, subsequently, treated with culture medium supplemented with 1 nM 
dDAVP and 100 ^M ATP or 100 ^M dopamine for the indicated time points (in minutes). Cells were 
lysed in the presence of de-phosphorylation- and de-ubiquitination blockers and AQP2 proteins were 
extracted by immunoprecipitation using guinea pig anti-AQP2 antibodies. Samples were analyzed by 
immunoblotting for ubiquitin, AQP2-pS261, or total AQP2 as indicated. Total lysates were blotted for 
total AQP2 to demonstrate equal AQP2 input levels. Protein mass (in kDa) is indicated on the left.
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shown). Also, following incubation with ATP or dopamine at a more detailed early time frame 
and immunoblotting for ubiquitin revealed an increase in ubiquitinated AQP2 after 5 minutes, 
with a peak after 10 to 15 minutes (Fig. 5C, top panels), while pS261 signals of 29 and 43 
kDa AQP2 mainly increased between 10 and 20 after hormone addition (Figure 5C, upper 
middle panel). [note that the 25 kDa band in the blot for ubiquitination is a background band, 
because it is present in mpkCCD cells not pre-treated with dDAVP (see also input, lower 
panel)]. The total levels of immunoprecipitated and total AQP2 remained essentially 
unaltered (Figure 5C, bottom two panels). Together, these data indicated that hormone- 
induced phosphorylation of S261 indeed follows ubiquitination of AQP2.
dDAVP
Supplem entary Figure S1: Effect of 
calcium on S261-phosphorylation  
and degradation of AQP2. Confluent 
mpkCCD cells stably expressing wild­
type AQP2 were incubated with 10 
nM dDAVP for 2  hours to induce 
translocation of AQP2 to the plasma 
membrane, followed by 15 minutes 
co-treatment with TPA, ATP or 
dopamine. Subsequently, cells were 
lysed in IPP100 in the presence of 
de-phosphorylation and de- 
ubiquitination inhibitors and subjected 
to immunoprecipitation using guinea 
pig anti-AQP2 antibodies. 
Subsequently, samples analyzed on a 
12% PAAG followed by 
immunoblotting using AQP2- 
phospho-S261, total AQP2, or 
ubiquitin antibodies.
In addition, we investigated the effects of intracellular calcium levels on ubiquitination and 
subsequent S261 phosphorylation of AQP2. However, as shown in Supplementary Fig. S1, 
exclusion of calcium by co-incubation with Bapta-AM did not affect ATP, dopamine, or TPA- 
induced ubiquitination or pS261 of AQP2. These data indicated that these processes are 
calcium-independent.
To test whether S261 phosphorylation is important in the hormone-induced degradation, 
mpkCCD cells stably-expressing AQP2-S261A, which cannot be phosphorylated, or AQP2- 
S261D, which mimics its constitutively-phosphorylated form, were treated with the hormones 
as above. Immunocytochemistry and immunoblotting (Supplementary Fig. S2), however, 
revealed that ATP, dopamine and TPA induced internalization and degradation of AQP2- 
S261A and AQP2-S261D, similar as observed for wtAQP2. These data reveal that 
ubiquitination, but not the phosphorylation status of S261, is critical in the process of AQP2 
internalization and its subsequent degradation.
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Supplem entary Figure S2: Horm one-induced internalization and degradation of AQ P2-S261A  
and AQP2-S261D. A) Confluent mpkCCD cells stably expressing AQP2-S261A or AQP2-S261D were 
treated with 10 nM dDAVP for 2 hours to induce translocation of AQP2 to the plasma membrane, 
followed by co-incubation with TPA, ATP or dopamine for 2  hours, after which cells were fixed and 
immunocytochemically stained using anti-AQP2 antibodies. Filters were analyzed using CLSM, of 
which representative cross-sections are shown. B) In parallel, cells were treated for 8 hours in the 
presence of cycloheximide and dDAVP alone, or supplemented with TPA, ATP, or dopamine. 
Subsequently, cells were lysed in Laemmli buffer supplemented with DTT and de-phosphorylation and 
de-ubiquitination inhibitors, followed by analysis on a 12% PAAG followed by immunoblotting using 
total AQP2 antibodies.
Effect of ATP and dopamine on AQP2 degradation
In mpkCCD cells, TPA-induced internalization of AQP2 leads to its degradation via the 
lysosomal pathway, which can be inhibited by chloroquine (8; 30). To test whether the 
hormones also affect AQP2 degradation, dDAVP pre-treated cells were co-incubated for 8 
hours with ATP, dopamine or TPA in the presence or absence of cycloheximide to block 
protein synthesis, and in the presence or absence of chloroquine. Subsequent 
immunoblotting showed a significant reduction in AQP2 abundance when cells were 
incubated with these compounds (Fig. 6). This reduction was significantly prevented by 
blocking lysosomal protein degradation with chloroquine. Together, the data above reveal 
that ATP, dopamine (and TPA) counteract AVP-induced water permeability by increasing the
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Figure 6. Effect of TPA, ATP and dopamine on lysosomal degradation of AQP2. MpkCCD cells 
were grown to confluence, treated with 1 nM dDAVP for 4 days, and then left untreated or incubated 
with 100 nM TPA, 100 ^M ATP, or 100 ^M dopamine with or without 100 ^M chloroquine, dDAVP and 
50 ^M cycloheximide for B hours. Subsequently, cells were lysed and immunoblotted for AQP2 and 
signals quantified using densitometry. Quantified data represents pooled data from triplicate samples 
of three independent experiments. Samples significantly (P<0.05) different from the dDAVP alone 
control are indicated with an asterisk.
internalization of AQP2 from the plasma membrane in an ubiquitin-dependent manner to 
induce its lysosomal degradation.
Effect of ATP and dopamine on AQP2 mRNA abundance
Besides increased AQP2 internalization and degradation as shown above, the observed 
reduction in AVP-induced AQP2 abundance can partially be due to reduced AQP2 
production. To determine whether the above-mentioned hormones affect AQP2 mRNA 
levels, cells were treated as above and subjected to quantitative RT-PCR. Using equal 
amount of starting cDNA and following normalization for 18S RNA, ATP gave a nearly 60% 
reduction in AQP2 mRNA, while dopamine showed a 30% reduction (Fig. 7). TPA did not 
reduce AQP2 mRNA levels.
Effect of ATP and dopamine on cAMP production
Binding of AVP to its V2R induces an increase in cAMP, which results via activation of CREB
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Figure 7. Effect of ATP, dopamine, 
and TPA on AQP2 m RNA amount.
MpkCCD cells were grown and 
treated as described in the legend of 
Figure 6, except that cycloheximide 
was omitted. Cells were lysed, mRNA  
was isolated, and reverse transcribed 
to cDNA using random primers. 
Equal amounts of cDNA were 
subsequently subjected to Q-PCR  
using primers for mouse AQP2 and 
18S (internal control). Following 
normalization against the 18S signal, 
the AQP2 mRNA amounts are 
expressed relative to control values.
in increased AQP2 gene transcription (6; 7). Considering the observed reduction in AQP2 
mRNA levels with ATP and dopamine (Fig. 7), we tested whether the used AVP- 
counteracting hormones reduce the steady-state cAMP levels induced by dDAVP. For this, 
mpkCCD cells were grown and pretreated with dDAVP as above, incubated with the 
phosphodiesterase inhibitor IBMX for 10 minutes, followed by incubation with ATP, dopamine 
and TPA for 15 minutes in the continued presence of dDAVP and IBMX. Subsequent 
analysis of the cAMP levels revealed that ATP and dopamine significantly decreased cAMP 
levels, which was not observed with TPA (Fig. 8).
Figure 8. Effect o f ATP, dopamine, 
and TPA on dDAVP-induced cAMP  
production. MpkCCD cells were 
grown to confluence, treated with 1 
nM dDAVP for 4 days, incubated with 
250 pM IBMX for 10 minutes, and 
then left untreated or treated with 100 
nM TPA, 100 pM ATP, or 100 pM 
dopamine for another 15 minutes in 
the presence of dDAVP and IBMX. 
Then, cells were lysed and cAMP 
levels were determined with a cAMP 
enzyme immunoassay kit.
Effect of ATP and dopamine ex vivo
To investigate whether TPA, ATP and dopamine also induce AQP2 internalization in kidney 
principal cells and whether this also coincides with increased phosphorylation of AQP2 at 
S261, rat kidneys slices were pre-incubated with 1 nM dDAVP for 15 minutes, followed by 30 
minutes with dDAVP alone or in combination dopamine, ATP, or TPA. Consistent to our 
mpkCCD cell line results, immunohistochemistry indeed showed that treatment with dDAVP
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alone yielded a localization of AQP2 in the apical membrane, whereas co-treatment with 
dopamine, ATP, or TPA revealed internalized AQP2 (Fig. 9A). Moreover, immunoblotting 
indeed revealed that, normalized for total AQP2 levels, AQP2-pS261 levels were significantly 
increased upon co-incubation with dopamine, ATP, or TPA (Fig. 9B,C).
Control Dop ATP TPA
AQP2-pS261
Total AQP2
Figure 9. Effect of ATP, dopam ine, and TPA on AQP2 localization and S261 phosphorylation ex 
vivo. Rat kidney slices were pre-incubated at 37°C with 1 nM dDAVP for 15 min, followed by 30 min 
incubation with dDAVP alone or together with 100 pM dopamine, 100 pM ATP or 100 nM TPA. Then, 
the kidney sections were (A) stained for AQP2 and subjected to confocal laser scanning microscopy, 
or (B) lysed in a 1% Triton X-100 buffer and subjected to immunoblotting for total AQP2 and AQP2- 
pS261. (C) The signals of (B) were semi-quantified using densitometry. Samples significantly (p<0.05) 
different from controls are indicated by asterisk.
Discussion
ATP and dopamine counteract AVP-action by inducing ubiquitin-dependent AQP2 
internalization and lysosomal degradation.
Several studies have demonstrated a role for extracellular purines ATP and UTP, and 
phenetylamine dopamine in the inhibition of AVP-induced water reabsorption (10; 11; 15; 16;
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31; 32). Our present study reveals that the mechanism of action by which these hormones 
counteract vasopressin consists of two parts:
The first part involves the short-term ubiquitin-dependent internalization and lysosomal 
degradation of AQP2. Using mpkCCD cells stimulated with AVP to induce total and plasma 
membrane expression of endogenous AQP2, ATP and dopamine induced internalization of 
AQP2 from the apical membrane (Fig. 2) followed by lysosomal degradation (Fig. 6). 
Importantly, using kidney slices we could show that these short term effects on AQP2 
internalization mimicked the in vivo effects of ATP and dopamine on AQP2 localization (Fig. 
9A). As we have shown for TPA-induced internalization of AQP2 (8), our data reveal that this 
internalization of AQP2 by ATP and dopamine is dependent on the ability to ubiquitinate 
AQP2 (Fig. 4). Using MDCK-AQP2 cells, we found that both hormones increase AQP2 
ubiquitination, resulting in two main bands of 43 and 50 kDa, a weaker higher band of around 
58 kDa and some smear (Fig. 3). This smear may represent glycosylated, K63-ubiquitinated 
AQP2 or possibly K29-poly-ubiquitinated AQP2. Poly-ubiquitination via K29 in ubiquitin is 
thought to be a general mechanism to degrade membrane proteins via the ER-associated 
degradation (ERAD) pathway. These different ubiquitination bands were not observed in 
precipitates of mock-transfected MDCK cells and are consistent with the addition of 2-4 
ubiquitin moieties onto AQP2 (8). Possibly because of increased expression of de- 
ubiquitinating enzymes in dDAVP-induced mpkCCD cells, ubiquitinated AQP2 is not readily 
detectable in mpkCCD cells (see also below). However, our finding that wt-AQP2, but not the 
constitutively-de-ubiquitinated AQP2-K270R (8), is internalized in mpkCCD cells with both 
hormones (Fig. 4), indicates that ubiquitination is an important regulatory mechanism in 
mpkCCD cells as well and that ubiquitination of AQP2 is needed for both hormones to 
internalize AQP2.
The second part involves the long term effects on AQP2 mRNA expression. As shown in 
figure 8 and consistent with in vivo data using perfused inner medullary collecting ducts (11;
21), ATP and dopamine also significantly reduce the steady state cAMP levels. As AQP2 
gene expression is increased when the PKA-phosphorylated cAMP-regulatory element 
binding protein (CREB) binds to the CRE present in the AQP2 promoter (6; 7), the reduced 
AQP2 mRNA levels observed with both hormones (Fig. 7) is likely a consequence of the 
reduced cAMP levels.
The reduction in cAMP with dopamine and ATP seems rather low, but it has to be taken into 
account that it is considered and even shown for AQP2 that intracellular cAMP levels are 
locally regulated, in which the kinase anchoring proteins (AKAPs) play an important role (33; 
34). AKAPs bind PKA, PKA substrates, phosphatases and PDEs, and target these proteins, 
and thus cAMP-induced signalling cascades to various subcellular compartments to their
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unique targeting domains (3; 35; 36). It will be interesting to test whether ATP and dopamine 
do decrease local pools of intracellular cAMP.
Short-chain ubiquitination of AQP2 precedes phosphorylation at S261 
While the essentiality of S256 phosphorylation for AQP2 translocation to the apical 
membrane is unchallenged, several data reveal that internalization of AQP2 does not 
necessarily require S256 de-phosphorylation, as activation of PKC by TPA (37), but also 
dopamine and prostaglandin E2 (PGE2)-induced internalization of AQP2 to intracellular 
vesicles occurred without reducing S256 phosphorylation (38; 39). Recently, we have shown 
that TPA-induced AQP2 endocytosis involves its short-chain ubiquitination at K270 (8), but it 
is unclear if any of the three newly identified additional phosphorylation sites in the C- 
terminal tail of AQP2 may be involved, being S261, S264, and S269 (23). Interestingly, 
Hoffert et al showed that S261 phosphorylation of IMCD AQP2 was decreased upon AVP 
incubation (24). Here, we demonstrated that, in line with in vivo, dDAVP decreases 
phosphorylation of AQP2 at S261 (Fig. 5). More importantly, however, our data reveal that 
also internalization of AQP2 with ATP and dopamine coincides with an increase in S261 
phosphorylation (Fig. 5B).
In mpkCCD cells stably transfected with AQP2, ATP and dopamine application initially 
results in an increased pS261 signal of a 43 kDa band, while the 29 kDa band was not or 
only weakly increased (Fig. 5A). In two different time series, it appeared that 43 kDa AQP2- 
pS261 preceded AQP2-pS261 of 29 kDa (Fig. 5B,C). This pS261-labelled 43 kDa band likely 
represents AQP2 bound by 2 ubiquitin moieties, because its mass is consistent with this (8), 
and the band is not observed in ATP or dopamine treated mpkCCD cells expressing AQP2- 
K270R (Fig. 5A, B). Although we cannot exclude the possibility that our pS261 antibodies 
have a higher affinity for ubiquitinated than non-ubiquitinated AQP2 and/or that ubiquitinated 
AQP2 is more prone to S261 phosphorylation than 29 kDa AQP2, these data indicate that 
AQP2 ubiquitination precedes pS261 phosphorylation as an early event in the 
ATP/dopamine-induced AVP-counteracting pathway of AQP2 proteins from the plasma 
membrane to lysosomes. This phosphorylation of S261, however, was not essential for 
ATP/dopamine/TPA induced internalization or degradation, because internalization and 
degradation of AQP2 proteins mimicking constitutively phosphorylated or de-phosphorylated 
S261 (Fig. S2) was similar to that of wt-AQP2. Although these data may suggest that 
ubiquitination is needed before pS261 can occur, it is more likely that ubiquitination is a 
faster process or that pS261 of AQP2 occurs at an intracellular location (i.e. after ubiquitin- 
mediated endocytosis), because AQP2 that cannot be ubiquitinated (AQP2-K270R) is 
phosphorylated at S261 in unstimulated mpkCCD cells. The role of S261 phosphorylation in 
AQP2 thus remains to be established. Moreover, it is noteworthy that the localization of
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AQP2-S261A/D in mpkCCD cells with or without application of dDAVP is similar to that found 
by others in different cells types (24; 40), but is different from the localization we observed in 
MDCK cells (unpublished data), which is likely due to expression of a different set of proteins 
in our MDCK type I cell model. It will be interesting to identify the protein(s) causing this 
difference in handling AQP2-S261A/D.
Recently, the first steps were taken to identify the kinases involved in the phosphorylation of 
AQP2 at S261. Although PKA is responsible for the phosphorylation of AQP2 at S256, 
Hoffert et al. demonstrated that PKA is unable to phosphorylate S261 (41). In vitro 
experiments where synthetic COOH-terminal AQP2 peptides were incubated with various 
purified MAP kinases, demonstrated that JNK, p38, and CDK5/9 could potentially be involved 
in the phosphorylation of AQP2 at S261 (42). Although JNK, p38, and CDK5/9 are putative 
candidates, the identity of kinases involved in the ATP and dopamine dependent S261 
phophorylation of AQP2 remains to be established.
ATP and dopamine receptors involved in AQP2 degradation
Hormones can inhibit AVP-stimulated water permeability by decreasing cAMP levels, but can 
also exert their effects without affecting cAMP production, depending on the receptor subtype 
and subsequent G protein that is activated. In case the receptor couples to Gi, cAMP 
production will be inhibited, whereas upon Gq coupling, phospholipase C is activated and 
intracellular Ca2+ levels will increase. In AVP-stimulated mpkCCD cells, ATP and dopamine 
both decreased cAMP production (Fig. 8), suggesting that ATP and dopamine activate 
receptors that couple to Gi.
Various purinergic receptors have been identified in the collecting duct. Our recent paper 
suggests the involvement of P2Y4 and P2X2 receptors, in addition to P2Y2, in AQP2- 
mediated water permeability in mpkCCD cells (14). Alternatively, the effect of ATP may be 
mediated indirectly through EP receptors. Extracellular purines have been shown to stimulate 
P2Y2 receptor-mediated release of arachidonic acid and PGE2 (45), which activate the Gi 
coupled EP receptors EP1 and EP3.
Of the dopamine receptors, D2, D3 and D4 couple to Gi. Of these, the D4 receptors may be 
most likely to mediate the effect of dopamine on AQP2, since these receptors are expressed 
in the renal collecting duct (15; 16).
Considering the fact that TPA, which is thought to activate PKCs, does counteract 
vasopressin action through the short term mechanism (AQP2 internalization, ubiquitination, 
lysomal degradation; Fig. 2, 3, and 6)), but does, in contrast to ATP and dopamine, not affect 
reduce cAMP levels (Fig. 8), may indicate that ATP and dopamine indeed use a bimodal 
mechanism (direct PKC activation through Gq and indirect reduction of cAMP through 
activation of prostaglandin receptors and Gi) to counteract vasopressin action. The identity of
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the purinergic and dopamine receptors involved and the precise mechanism by which 
activation of these receptors result in reduced cAMP and AQP2 levels remains to be 
established.
In summary, we demonstrated that ATP and dopamine counteract AVP-induced water 
permeability by two mechanism, being AQP2 internalization and lysosomal degradation in an 
ubiquitin-dependent and pS261-related manner, and through decreased cAMP levels.
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Abstract
Urine concentration involves arginine vasopressin (AVP), which induces the redistribution of 
aquaporin-2 (AQP2) water channels to the apical membrane and an increased transcription 
of AQP2 in renal principal cells. Besides AVP, prostaglandins are also involved in water 
balance regulation. Prostaglandin E2 (PGE2) and F2a (PGF2a) decrease water reabsorption in 
the presence of AVP. However, PGE2 increases water reabsorption in the absence of AVP.
In the present study, we utilized mouse cortical collecting duct (mpkCCDcl4) cells as a model 
system to delineate how prostaglandins can exert their diverse effects on AQP2. In the 
presence of dDAVP, blocking cyclooxygenase activity by indomethacin for 48 hours 
increased AQP2 levels, while both PGE2 and PGF2a application reduced AQP2. In the 
absence of dDAVP, AQP2 was increased by PGE2. dDAVP application significantly 
increased PGD2 and PGE2 production, while PGF2a was decreased. The prostaglandin 
receptors EP1, EP4, FP and TP were found to be expressed by RT-PCR. dDAVP application 
increased the expression of the EP1 and FP receptor, while EP4 expression was decreased. 
Altogether, our study shows that in mpkCCDcl4 cells, both PGE2 and PGF2a decrease 
dDAVP-stimulated AQP2 abundance, while in the absence of dDAVP, PGE2 increases AQP2 
levels. This difference in PGE2 effects might be explained by the different receptor subtype 
expression induced by dDAVP. Besides, dDAVP significantly increased both the production 
of PGD2 and PGE2, while levels of PGF2a were decreased.
Introduction
To prevent dehydration, a proper regulation of the water homeostasis is essential. In this 
process, the kidney is the main organ involved. In response to hypernatremia or 
hypovolemia, arginine vasopressin (AVP) is released from the posterior pituitary gland. 
Subsequently, binding of AVP to the basolateral vasopressin type-2 receptor in the collecting 
duct principal cells in the kidney results in redistribution of aquaporin-2 (AQP2) water 
channels from intracellular vesicles to the apical membrane, greatly increasing the osmotic 
water permeability, leading to a concentrated urine (1). In addition, AVP also increases the 
expression of AQP2 via phosphorylation of the cAMP responsive element binding protein 
(CREB), which activates the transcription from the AQP2 promoter (2-4).
Besides AVP, several other signaling molecules regulate the water balance by antagonizing 




The arachidonic acid/prostaglandin pathway involves many different enzymes and products 
(Fig. 1). Arachidonic acid, which is derived from membrane phospholipids, is converted to 
prostaglandin H2 (PGH2) by the enzymes cyclooxygenase (COX) 1 and 2. PGH2 is a 
substrate for many different synthases to produce PGD2, PGE2, PGF2a, PGI2 and TxA2. 
Besides being produced directly from PGH2, PGF2a is also synthesised via PGE2 by a 
reaction catalyzed by the enzyme prostaglandin E 9-ketoreductase (6)
The prostanoids are released from the cells either by diffusion or by an efflux transporter 
such as the multidrug resistance protein 4 (MRP4) (7). Released prostanoids can bind to 
their unique G-protein coupled receptors (DP, FP, IP and TP), or to one or more of four 
different receptors as found for PGE2 (EP1, EP2, EP3, EP4). Some of these receptors (DP, 
EP2, EP4, IP) are Gs-coupled and thus increase intracellular cAMP levels when activated, 
whereas others are coupled to Gi (EP3, FP), reducing cAMP synthesis, and/or Gq (EP1, FP, 
TP), inducing calcium mobilization (6; 8; 9).
Figure 1. Synthesis of the prostaglandins. Arachidonic acid (AA) is metabolized by COX1 or COX2 
to PGH2. PGH2 is enzymatically converted, by specific synthases (thromboxane synthase, PGE 
synthase, PGF synthase, PGD synthase, and PGI synthase) or prostaglandin E 9-ketoreductase 
(PGE-9KR), to one of five known primary prostanoids: PGI2, PGD2, PGE2, PGF2a, or TxA2. Each 
prostanoid interacts with distinct members of a subfamily of the G protein-coupled receptors. PGI2 
activates the IP receptor, PGD2 activates the DP receptor, PGF2a activates the FP receptor, and TxA2 
activates the TP receptor. PGE2 interacts with one of four distinct EP receptors.______________________
Of the different prostaglandins, in particular PGE2 has been shown to decrease AVP-
stimulated water reabsorption in perfused collecting ducts (10-12). In addition to its role in
ambient water homeostasis, PGE2 is also involved in pathological regulation of water
reabsorption. PGE2 has been suggested to play an important role in the development of
lithium-induced nephrogenic diabetes insipidus. This is based on the observation that the
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expression of COX-2 is markedly increased in the kidney of lithium treated mice, resulting in 
an increased urinary PGE2 excretion (13). Similarly, in bilateral ureteral obstruction, 
associated with AQP2 down-regulation, COX-2 protein abundance as well as the 
concentration of all five primary prostanoids are increased in the kidney inner medulla (14). 
Administration of a COX-2 inhibitor prevents down-regulation of AQP2 in inner medullary 
collecting ducts and attenuates the polyuria (15). In addition, the polyuria observed in patients 
with antenatal Bartter’s syndrome may in part be worsened by the excessive renal formation 
of PGE2 (16).
Besides PGE2, also PGF2a affects water homeostasis, as it has been shown to inhibit 
vasopressin-stimulated water permeability in the collecting duct (9; 17).
Paradoxically, although PGE2 decreases water reabsorption in the presence of AVP, it 
increases the osmotic water permeability in the absence of AVP (11; 12). The mechanism, 
however, is still unclear. In the present study, therefore, we utilized mouse cortical collecting 
duct (mpkCCDcl4) cells as a model system for the renal principal cell to delineate how 




Mouse mpkCCDcl4 cells were essentially maintained as described previously (18). Cells were 
seeded at a density of 1.5x105 cells/cm2 on semi-permeable filters (Transwell®, 0.4 ^m pore 
size, Corning Costar, Cambridge, MA) and cultured for 8 days. Unless stated otherwise, the 
cells were exposed to 1 nM dDAVP at the basolateral side during the last 96 hrs, to 
maximally induce AQP2 expression (19). Cells were incubated with 10 pM indomethacin, 1 
pM PGE2 (both Sigma, St. Louis, MO, USA) or PGF2a (Calbiochem, San Diego, CA) during 
the last 48 hours.
Immunoblotting
MpkCCDcl4 cells grown on 1.13 cm2 filters were lysed in 200 .^l Laemmli. SDS-PAGE, blotting 
and blocking of the PVDF membranes were done as described previously (20). Membranes 
were incubated for 16 hrs with 1:3000-diluted affinity-purified rabbit R7 anti-AQP2 antibodies 
(21) in Tris-Buffered Saline Tween-20 (TBS-T) supplemented with 1% w/v non-fat dried milk. 
Blots were incubated for 1 hr with 1:5000-diluted goat anti-rabbit IgG’s (Sigma, St. Louis, 
MO) as secondary antibody coupled to horseradish peroxidase. Proteins were visualized 




MpkCCDcl4  cells were grown on semi-permeable filters for 8 days as described above, and 
total RNA was isolated using TriZol extraction reagent (Gibco, Life Technologies, Rockville, 
MD), according to the manufacturer’s instructions. To remove genomic DNA, total RNA was 
treated with DNase (Promega, Madison, WI) for 1 hr at 37°C, extracted with 
phenol/chloroform and precipitated. RNA was reverse-transcribed into cDNA using MMLV 
Reverse Transcriptase and random primers (Promega, Madison, WI). During cDNA 
production, a control reaction without the reverse transcriptase enzyme was conducted to 
exclude genomic DNA amplification. Primers for prostaglandin receptors were designed to 
bind to two different exons (see Table 1). Amplification was performed using the cDNA 
equivalent of 5 ng RNA for 40 cycles (95°C 45 sec, 50°C 1 min, 72°C 1.5 min). p-actin was 
used as a positive control for cDNA amplification. For all prostaglandin receptor primers, 
cDNA from tissue reported to express the particular receptor was taken along as a positive 
control. The proper identity of products was confirmed using restriction analysis.
SYBR Green Real-time quantitative PCR was performed on an iQ5 Real-Time PCR 
Detection System from Bio-Rad by utilizing the SYBR Green PCR Master Mix (Applied 
Biosystems Foster City, CA) and primers for the prostaglandin receptors. Signals for the 
ribosomal 18S (GTAACCCGTTGAACCCCATT and CCATCCAATCGGTAGTAGCG), which 
was amplified in parallel, were used to normalize for differences in the amount of starting 
cDNA.
Table 1: Overview of prim er sets
Protein Forward primer (5 '-3 ') Reverse primer (5 '-3 ') Product size (bp)
DP AGGAGCT GGACCACTTTGTG TCACAGACAGGAAACGCAAG 159
EP1 GCACGGAGCCGAGGAGC GCAGGGGCTCATATCAGTGG 107
EP2 TCGCCATATGCTCCTTGC TCCTCTGACACTTTCCACAAA 449
EP3 GCAGAATCACCACGGAGACG GCGAAGCCAGGCGAACTG 190
EP4 TACGCCGCCTTCTCTTACAT TTCACCACGTTTGGCTGATA 380
FP CGTCACGGGAGTCACACTCT TTCACAGGTCACTGGGGAAT 190
IP CATGACCGTCATCATGGCCGTG GTT GAAGGCGTT GAAGCGGAAGG 120
TP GTGGGCATCATGGTGGTGG CACACGCAG GT AGAT GAG CAG C 168
ß actin GTATGCCTCTGGTCGTACCAC ACGATTTCCCTCTCAGCTGTG 201
Prostanoid analysis
Samples were prepared as described (22) with minor modifications. Briefly, cell culture 
supernatants were spiked with ~1 ng of deuterated internal standards, and the methoximes 
were obtained through reaction with an O-methylhydroxylamine hydrochloride-acetate buffer. 
After acidification to pH 3.5, prostanoid derivatives were extracted, and the
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pentafluorobenzylesters were formed. Samples were purified by thin layer chromatography, 
and a broad zone with RF 0.03-0.4 was eluted. After withdrawal of the organic layer, 
trimethylsilyl ethers were prepared by reaction with bis(trimethylsilyl)-trifluoroacetamide and 
thereafter subjected to GC/MS/MS analysis on a Finnigan MAT TSQ700 GC/MS/MS 
(Thermo Electron Corp., Dreieich, Germany) equipped with a Varian 3400 gas 
chromatograph (Palo Alto, CA) and a CTC A200S autosampler (CTC Analytics, Zwingen, 
Switzerland).
Statistics
Students unpaired t-test was used when two groups with Gaussian distribution were 
compared. A p value of less than 0.05 is considered significant. Data are presented as mean 
and bars are standard error of the mean (SEM).
Results
Effect of prostaglandins on AQP2 expression
As introduced, PGE2 has been reported to increase water reabsorption in the absence of 
AVP, but to decrease it in the presence of AVP (10-12). Moreover, PGF2a has also been 
shown to inhibit water absorption in the collecting duct (9; 17). To analyze the effect of PGE2 
on AQP2 expression in mpkCCDcl4 cells, cells were incubated with 1 pM PGE2 for 48 hrs in 
the presence or absence of dDAVP for 4 days. Consistent with in vivo, PGE2 increased the 
AQP2 abundance in the absence of dDAVP, but decreased it in the presence of the AVP- 
analogue (Fig. 2). In addition, in the presence of dDAVP, PGF2a decreased AQP2 
abundance (Fig. 2), although this effect seemed smaller than what was observed with PGE2. 
To test whether the COX inhibitor indomethacin affects dDAVP-induced AQP2 expression, 
cells were grown as described above, the last 4 days in the presence of dDAVP, and the last 
48 hrs in the presence of 10 ^M indomethacin. Subsequent immunoblotting showed 
increased AQP2 abundance with indomethacin (Fig. 2).
These data revealed that the effects of PGE2 and PGF2a on water permeability as found in 
vivo are mimicked in our mpkCCDcl4 cells by effects on AQP2 abundance, and that dDAVP- 
treated mpkCCDcl4 cells produce prostanoids which decrease AQP2 abundance.
Effect of dDA VP on prostanoid production in mpkCCD cells
To determine whether the presence of dDAVP affects the release of PGE2 or other 
prostanoids in mpkCCDcl4 cells, cells were grown as above, with or without dDAVP for the 
last 4 days, after which the medium was collected and analysed for the presence of 













m m  -^ m ''
dDAVP dDAVP+lndo
subtracted. The major prostanoids 
released from control cells were PGE2 
and PGF2 a, while levels of PGD2 , 6-keto- 
—  a q p 2 PGF1a (a stable metabolite of PGI2) and 
TxB2 (a stable metabolite of TxA2) were 
lower and close to the detection limit 
(Fig. 3). dDAVP incubation significantly 
increased the production of PGD2 and 
PGE2, while PGF2a levels were 
decreased. No effect of dDAVP was 








fragments for the different receptors is 
in table 1. From reverse
Effect of dDA VP on prostanoid receptor
expression in mpkCCD cells
The effect of prostaglandins on AQP2
expression has to be conferred by their
respective G-protein coupled receptors.
_________________________________________  By RT-PCR, we determined the
Figure 2  f t  ° f  pr<>sta3landins on AQp2 expression of the individual prostaglandin 
expression. mpkCCDci4 cells were grown for 8 days, r  i- a
either with our without 1 nM dDAVP stimulation for the receptors in the mpkCCD cell system. 
last 4 days and with or without 1 pM PGE2, 1 pM
PGF2a or 10 pM indomethacin during the last 48 The lengths of the expected PCR 
hours. Cells were lysed and subjected to 
immunoblotting for AQP2. Molecular masses (in kDa) 
are indicated on the left. Non-glycosylated (AQP2) and given 
complex-glycosylated (g-AQP2) forms of AQP2 are 
detected. transcribed RNA derived from dDAVP-
treated cells, cDNA products of the
expected size were obtained for EP1, EP4, FP and TP receptors (Fig. 4A). While EP2, EP3
or DP receptors were found to be expressed in control tissues, no expression was found in
mpkCCDcl4 cells, suggesting that these receptors are not present in this cell system. The
expression of the IP receptor was inconsistent. The same receptors were found to be
expressed in mpkCCD cells treated without dDAVP (not shown).
To test if the expression levels of the prostanoid receptors were influenced by dDAVP, we 
determined their relative expression by Q-PCR. dDAVP stimulation resulted in an increased 
expression of the EP1 and FP receptor subtypes, while expression of the EP4 receptor was 
significantly decreased. No difference was detected in the expression of the TP receptor (Fig. 
4B).
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Figure 3. Effect of dDAVP on prostaglandin production in mpkCCD cells. MpkCCDcl4 cells were 
grown for 8 days and incubated with or without 1 nM dDAVP for the last 4 days. Medium from both 
sides, incubated with the cells for 24 hrs, was collected and prostaglandin concentrations were 
determined. Bars are mean values of four independent filters per condition (+/- SEM). Significant 
differences from control (p<0.05) are indicated by an asterisk.______________________________________
Discussion
mpkCCD cells as a model system for prostanoid regulation of AQP2 expression 
In the present study, we examined the effect of prostaglandins on the expression of 
endogenous AQP2 in mpkCCDcl4 cells. Prostaglandin E2 is known to reduce AVP-stimulated 
water reabsorption in the collecting duct (10; 11). Similarly, in our cell system PGE2  reduced 
AQP2 expression after dDAVP stimulation. In addition, PGE2 stimulated AQP2 abundance in 
the mpkCCDcl4 cells in the absence of dDAVP, which is in agreement with in vivo 
observations showing an increase in collecting duct water permeability (12).
In dDAVP-treated mpkCCDcl4 cells, AQP2 levels were decreased after application of PGF2a, 
which might explain the inhibition of water reabsorption in the collecting duct observed after 
PGF2a treatment (9; 17). Furthermore, blocking COX activity by indomethacin increased 
AQP2 abundance, showing that COX activity influences AQP2 levels and that in cells without 
indomethacin, dDAVP-stimulated AQP2 abundance is decreased by the action of 
endogenously produced prostaglandins.
The major prostaglandins produced in our cell system were PGE2 and PGF2a, while 
production of PGD2 , 6-keto-PGFia (a metabolite of PGI2) and TxB2 (a metabolite of TxA2 ) was 
low. Of the prostaglandin receptors, EP1, EP4, FP and TP receptors were found in 
mpkCCDcl4 cells. No expression was found of DP, EP2 and EP3 receptors.
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Figure 4. Prostaglandin receptor expression. A) MpkCCDcl4 cells were grown for 8 days. Cells were 
lysed, total RNA was isolated and RNA was reverse-transcribed into cDNA. By RT-PCR the 
expression of the prostaglandin receptors was analyzed. p-actin was used as a positive control for 
cDNA amplification. Amplification products are visualized by agarose gel electrophoresis. +/- = with or 
without Reverse Transcriptase during the cDNA production. For receptors not detected in mpkCCD 
cells, a RT-PCR done in control tissue (B= brain, U=uterus) is shown. Arrows point at product of 
expected size. Sizes in bp are indicated on the left. B) MpkCCDcl4 cells were grown for 8 days and 
treated with or without 1 nM dDAVP for the last 4 days. Cells were lysed, total RNA was isolated, RNA 
was reverse-transcribed into cDNA and relative expression of the prostaglandin receptors was 
analyzed by performing Q-PCR. Signals obtained from the house-keeping 18S were used to normalize 
for difference in the amount of starting cDNA. Mean values of four independent filters per condition are 
relative to control (+/- SEM). Significant differences (p<0.05) from control are indicated by an asterisk.
dDAVP-induced changes in EP1 and EP4 receptor subtype expression likely mediate the 
difference in AQP2 abundance in response to PGE2 in mpkCCD cells 
dDAVP stimulation significantly increased both the production of PGD2 and PGE2, while 
levels of PGF2a were decreased. No effect was seen on 6-keto-PGF1a or TxB2. In agreement 
with these findings, it has been shown that vasopressin stimulates PGE2 synthesis in isolated 
collecting ducts (23; 24).
Incubation of mpkCCDcl4 cells with dDAVP resulted in an increased expression of the calcium 
mobilizing EP1 receptor, but decreased the expression of the EP4 receptor, coupling to Gs-
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stimulated cAMP generation. As the inhibitory effects of PGE2 on AVP-induced water 
reabsorption most likely occur through activation of EP1 and/or EP3 receptors (12; 25; 26), 
whereas the stimulatory effects of PGE2 on basal water transport could be mediated via the 
EP4 receptor, this suggests that the differences in PGE2-mediated actions on water 
permeability can most likely be attributed to the presence of different relative expression of 
the E-prostanoid receptor subtypes.
It is interesting to note that, while dDAVP increases PGE2 production and release, the mRNA 
expression of EP4 receptor is reduced, whereas that of the EP1 receptor is increased. As 
both are bound and activated by PGE2 , these data suggest that it is not the agonist per se 
that determines the expression level of the receptors. Instead, our data rather indicate that 
the signaling cascade that is mainly activated exerts a negative feedback regulation on 
receptors stimulating the same pathway and a positive feedback on receptors activating an 
opposite pathway: dDAVP increases the cAMP-AQP2 pathway, which is also stimulated by 
EP4, whereas EPl, activates a pathway that leads to decreased AQP2 expression and water 
permeability.
Similarly to this mechanism, dDAVP increases the mRNA levels of the purinergic receptor 
subunit P2Y2 in mpkCCD cells, and targets the subunits P2Y2 and P2X2 to the plasma 
membrane, where activation of these receptors leads to AQP2 internalisation and a decrease 
in water permeability (27). The same mechanism can be seen in the opposite response, 
where endothelin, counteracting vasopressin mediated water permeability (28) leads to an 
increased expression of the vasopressin V2 receptor in the inner medullary collecting duct of 
the rat (29).
FP receptor expression was increased by dDAVP treatment in mpkCCD cells. Activation of 
FP receptor leads to calcium mobilisation in most cell types, but in the collecting duct, FP 
receptor activation seems to inhibit cAMP generation via Gi proteins, thereby inhibiting water 
reabsorption (9). As FP receptor activation inhibits water reabsorption, this might be a 
compensatory mechanism to counteract AVP-stimulation, similar to the increase in EP1 
expression, or it might be a response to the lower PGF2a production.
As no DP receptor was detected in mpkCCDcl4 cells the role of the dDAVP-stimulated 
increase in PGD2 production after dDAVP treatment is unclear. However, PGD2 has been 
shown to bind to the FP receptor with an affinity close to that for the DP receptor, indicating 
that PGD2 may act on the FP receptor (30). The increase in PGD2 might counteract the 
dDAVP-induced increase in AQP2 expression, although levels are low compared to the 
PGE2 and PGF2a production.
While the TP receptor is expressed in mpkCCDcl4 cells, the expression of the IP receptor is 
inconclusive. Both thromboxane and PGI2 were produced in very low amounts in mpkCCDcl4
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cells and production was not affected by dDAVP. However, if these prostanoids might have 
any role in water reabsorption remains unclear.
Relation of the mpkCCD cell system to the in vivo situation.
The major prostaglandins produced in our cell system were PGE2 and PGF2a, while levels of 
PGD2, PGI2 and TxA2 were low, which is in agreement with in vivo findings, showing that 
PGE2 is the most abundant prostanoid in both renal cortex and medulla, followed by PGI2 
and PGF2a, with even lower amounts of thromboxane A2 and PGD2 (31). The synthases 
involved in the production of PGD2, PGE2 and PGF2a are detected in the nephron (32; 33). In 
the nephron, production of PGE2 and PGF2a has been shown to occur mainly in the collecting 
tubule (34). As both PGI synthase and thromboxane synthase mRNA is not detected in any 
tubular structure, their prostanoid products seem to be mainly produced by cells outside the 
tubuli, like the vasculature and glomeruli, respectively (32).
The effects of prostaglandins on AQP2 expression are conferred by PG receptors. In 
mpkCCDcl4 cells, EP1, EP4 and FP receptors are found, in agreement with expression in the 
collecting duct (8; 35). Neither DP and EP2 receptors seem to be expressed in mpkCCDcl4 
cells as well as in the kidney (8; 36). TP and IP receptors are mainly localized in the 
glomerulus and vasculature, respectively, but have also been located to the collecting duct 
(37; 38), in agreement with the expression seen in mpkCCDcl4 cells, although results for IP 
were inconclusive.
Both EP1 and EP3 activity inhibits vasopressin-stimulated water reabsorption. EP1 
activation, inducing calcium mobilization (8), was found in the mpkCCD cells, in agreement 
with in vivo data. However, a limitation of our cell model is the absence of the EP3 receptor, 
which is found in vivo in the collecting duct. EP3 activation inhibits cAMP generation via Gi 
(8), and might therefore inhibit AVP-stimulated AQP2 transcription by inhibiting the cAMP- 
PKA-CREB pathway. If EP3 receptor expression is also increased by dDAVP, like EP1, 
could not be investigated in our study. Both EP2 and EP4 receptors signal via Gs-stimulated 
cAMP generation. EP2 receptor mRNA is not detected in the kidney, while EP4 is expressed 
in the collecting duct, (8), in agreement with mpkCCDcl4 cells expression.
In conclusion, our study shows that in mpkCCDcl4 cells, both PGE2 and PGF2a decrease 
dDAVP-stimulated AQP2 expression, while in the absence of dDAVP, PGE2 increases AQP2 
levels. This difference in PGE2 effects might be explained by the different receptor subtype 
expression induced by dDAVP treatment. In addition, dDAVP application significantly 
increases both the production of PGD2 and PGE2, while levels of PGF2a are decreased.
Based on our data above that a negative feedback is mediated by the signaling pathways 
activated instead of the agonist, it is likely that in vivo vasopressin increases, besides AQP2,
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the expression of EP1 and EP3 and decreases expression of EP4. Consequently, upon 
conditions with increased PGE2 release, such as lithium-NDI or bilateral uteral obstruction, 
vasopressin-induced AQP2 expression would be reduced via activation of these EP1/3 
receptors. This has to be established in future studies.
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Hypotonicity-induced reduction of AQP2 transcription
Abstract
The syndrome of inappropriate antidiuretic hormone secretion is characterized by excessive 
water uptake and hyponatremia. The extent of hyponatremia, however, is less than 
anticipated, which is ascribed to a defense mechanism, the vasopressin-escape, and is 
suggested to involve a tonicity-determined down-regulation of the water channel aquaporin-2 
(AQP2). The underlying mechanism, however, is poorly understood. To study this, we used 
the mouse cortical collecting duct (mpkCCD) cell line.
MpkCCD-cells, transfected with an AQP2-promoter luciferase construct showed a reduced 
and increased AQP2 abundance and transcription following culture in hypotonic and 
hypertonic medium, respectively. This depended on tonicity rather than osmolality and 
occurred independent of the vasopressin analogue dDAVP, cAMP levels or protein kinase A 
activity. Although prostaglandins and nitric oxide reduced AQP2 abundance, inhibition of 
their synthesis did not influence tonicity-induced AQP2 transcription. Also, cells in which the 
cAMP or tonicity responsive element (CRE/TonE) in the AQP2-promoter were mutated 
showed a similar response to hypotonicity. Instead, the tonicity-responsive elements were 
pin-pointed to nucleotides -283 to -252 and -157 to -126 bp of the AQP2 promoter.
In conclusion, our data indicate that hypotonicity reduces AQP2 abundance and 
transcription, which occurs independent from vasopressin, cAMP, and the known TonE and 
CRE in the AQP2-promoter. Increased prostaglandin and nitric oxide, as found in vivo, may 
contribute to reduced AQP2 in vasopressin-escape, but do not mediate the effect of 
hypotonicity on AQP2 transcription. Our data suggest that two novel segments (-283 to -252 
and -157 to -126 bp) in the AQP2-promoter mediate the hypotonicity-induced AQP2 down- 
regulation during vasopressin-escape.
Introduction
Renal water reabsorption is regulated by the hormone arginine vasopressin (AVP). AVP 
binding to its V2 receptor in renal principal cells induces a cAMP cascade leading to 
increased translocation of the water channel aquaporin-2 (AQP2) to the apical membrane, 
resulting in water reabsorption from the pro-urine (1). In addition to this short-term effect, 
cAMP increases AQP2 transcription through phosphorylation of the transcription factor 
CREB (cAMP Responsive Element Binding Protein), which binds to a cAMP Responsive 
Element (CRE) at -210 in the AQP2 promoter (2; 3). The increase in transcription is a more 
long-term effect, requiring hours to take effect.
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AVP synthesis and release are regulated by alterations in plasma osmolality as well as non- 
osmotic, baroreceptor-mediated, pathways (4). Osmolality not only affects plasma AVP, but 
also appears to have direct effects on the urine concentrating ability and AQP2 expression. 
In the syndrome of inappropriate antidiuretic hormone secretion (SIADH), for example, levels 
of AVP are inappropriately high relative to plasma osmolality, resulting in free-water retention 
and hypotonicity. Under these circumstances, however, the free-water excretion is 
considerably higher than would be expected from the vasopressin concentrations (5). This 
phenomenon, called the vasopressin escape, indicates that there are mechanisms 
counteracting vasopressin action. In a rat animal model, it has been shown that the onset of 
this escape coincides with a decrease in the AQP2 expression in the renal collecting duct (6). 
Hypotonicity and/or volume expansion have been proposed to mediate this AVP-independent 
direct regulation of AQP2 expression (7).
Alternatively, an AVP-independent increase of AQP2 expression has been suggested to 
occur with hypertonicity. Valtin and Edwards already reported that water deprivation of AVP- 
deficient Brattleboro rats leads to hypertonicity, increased papillary interstitial osmolality, and 
concentration of the urine (8). Similarly, Li et al. found that hypertonicity due to 
hyperglycemia or increased NaCl levels increases AQP2 expression in Brattleboro rats (9).
At present, it is still largely unknown how the AVP-independent expression of AQP2 is 
regulated at the molecular level. In mouse collecting duct principal cells (mpkCCDc14), Hasler 
et al. showed that hypertonicity decreases the expression of AQP2 on the short term, but 
increases its expression on the long term (10). Here, hypertonicity did not affect the stability 
of AQP2 mRNA or protein, indicating that hypertonicity increases AQP2 abundance by 
increasing its transcription.
One of the proteins suggested to be involved in the hypertonicity response is the tonicity- 
responsive enhancer binding protein (TonEBP). This protein is upregulated with hypertonicity 
in cultured cells and in the kidney medulla (11; 12) and TonEBP knockdown or inhibition, but 
also mutation of its tonicity responsive element (TonE) in the AQP2 promoter, reduced AQP2 
expression in mpkCCD cells (13; 14). Moreover, in TonEBP-/- mice and mice transgenic for 
dominant-negative TonEBP, AQP2 expression was decreased (15; 16). However, the role of 
TonEBP and its TonE element in AQP2 expression regulation is still controversial. In Madin 
Darby Canine Kidney (MDCK) cells, for example, Kasono et al. observed a hypertonicity- 
induced increase in AQP2 transcription only when the AQP2 promoter was -6,1 kb or longer 
and therefore did not involve TonE, which localizes at 489 bases upstream of the AQP2 
transcription start site (7). Moreover, the severe atrophy of the renal medulla in the 
TonEBP-/- and dominant-negative TonEBP overexpressing mice complicates the 
interpretation of its direct involvement in AQP2 regulation.
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In addition to TonE, other promoter elements have been suggested to be involved in 
hypertonicity-induced AQP2 expression, as Li et al. reported that NFATc binding sites 
downstream of TonE are also important for hypertonicity-induced AQP2 expression in 
mpkCCD cells, because following mutation of all five sites hypertonicity-induced AQP2 
expression was lost to a great extent (14).
Thus far, the effects of hypotonicity on AQP2 expression and the underlying mechanisms 
have not been studied in great detail. Thus, it is unclear whether the regulatory changes 
during hypotonicity mirror the regulation under hypertonic conditions, and involves changes 
in TonEBP or in the classical AVP-cAMP signaling cascade elements. To decipher this, we 




Mouse mpkCCDcl4 cells (18) were grown in a modified defined medium (DMEM:Ham’s F12 
1:1 vol/vol; 60 nM sodium selenate, 5 ^g/ml transferrin, 2 mM glutamine, 50 nM 
dexamethasone, 1 nM triiodothyronine, 10 ng/ml epidermal growth factor, 5 ^.g/ml insulin, 20 
mM D-glucose, 2% foetal calf serum, and 20 mM HEPES (pH 7.4)), resulting in a medium of 
355 mOsm. Cells were seeded at a density of 1.5x105 cells/cm2 on semi-permeable filters 
(Transwell®, 0.4 ^m pore size, Corning Costar, Cambridge, MA) and cultured for 8 days. 
Unless stated otherwise, the cells were treated for the last 96 hrs with 1 nM 1-deamino-8-D- 
arginine vasopressin (dDAVP) at the basolateral side, to induce AQP2 expression. When 
used H89 (10 ^M, Calbiochem, San Diego, CA) was added to both the apical and basolateral 
side. Tonicity was changed by adding solute to NaCl-free defined medium (made identical to 
defined medium used above). Tonicity was changed at both sides of the cells. Osmolality 
was measured using a Knauer K-7400 semi-micro osmometer (Berlin, Germany).
Constructs
To generate an AQP2 promoter-luciferase reporter construct (pGL3-AQP2-3.0-luc), we first 
added the neomycine selection marker to pGL3-basic (pGL3-neo). For this, the neomycin 
cDNA preceded by an SV40 promoter was cut from pcDNA 3.1 (Invitrogen, Carlsbad, CA, 
USA) using XmnI and SalI, and ligated into a blunted BamHI and SalI site of pGL3-basic 
(Promega, Madison, WI, USA). Next, a 3.3 kb fragment, containing the mouse AQP2 
promoter (-2970 till +60 upstream of the transcription start site) was obtained by PCR using
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the primers GAAGATCTGGTCTGGGCCACGGGGGTGGCTCTTCC and 
GGTGCACCGAGCCTCCTCCTCAGCC on mouse genomic DNA. Following digestion with 
BglII, which cuts the primer (restriction site underlined) and at -2970 in the AQP2 promoter, 
the product was ligated into the BglII site upstream of the luciferase cDNA in pGL3-neo.
For pGL3-AQP2-0.4-luc (containing -408 till +60 of the AQP2 promoter), pGL3-AQP2-3.0-luc 
was cut with SacII and KpnI, blunted and religated. Constructs lacking 31 bp segments of the 
-0.4 kb promoter were made by 3 points PCR using different primers (table 1) using pGL3- 
AQP2-0.4-luc as a template. Mutations in CRE were introduced in pGL3-AQP2-0.4-luc using 
site-directed mutagenesis (Stratagene, La Jolla, CA) with mutagenesis primers indicated in 
table 1. This mutation has been shown to inactivate the AQP2 promoter (2). Mutations in 
TonE, reported to reduce hypertonicity-induced AQP2 transcription (13), were introduced in 
pGL3-AQP2-3.0-luc using primers as shown in table 1. To generate pGL3-CRE(21)-luc, a 
DNA fragment containing 21 CRE-elements was cut from pCRE121-3 (19) with SalI and XhoI 
and ligated into the XhoI site of pGL3-neo. Proper orientation and sequences were confirmed 
by sequence analysis.
MpkCCD cells were stably transfected using the calcium-phosphate precipitation technique 
as described (20). Transfected colonies were selected with G418 (0.25 mg/mL) and pooled 
to level out differences between individual colonies.
Luciferase Assay
Luciferase activity was measured using the Luciferase Assay System (Promega, Madison, 
WI) following the manufacturer’s instructions. Luminescence was measured for 10 seconds 
using an EG&G Berthold Lumat LB9507 luminometer (Bad Wildbad, Germany). To verify that 
equal amounts of protein per sample were used for the luciferase assay, protein 
concentration was determined using the BioRad (Richmond, CA) protein assay as described
(21). Light absorbance at 595 nm was measured using a helios omega spectrophotometer 
(Thermo Scientific, Rockford, IL, US).
Immunoblotting
mpkCCDcl4 cells from 1.13 cm2 filter were lysed in 200 .^l Laemmli/DTT buffer, sonicated and 
incubated for 30 min. at 37°C. PAGE, blotting and blocking of the PVDF membranes were 
done as described (22). Membranes were incubated overnight with 1:3000-diluted affinity- 
purified rabbit R7 AQP2 (23), 1:2000 rabbit CREB (Sigma, St. Louis, MO) or 1:2000 rabbit 
CREB-pS133 antibodies (Sigma St. Louis, MO) in Tris-Buffered Saline Tween-20 (TBS-T) 
supplemented with 1% w/v non-fat dried milk. Blots were incubated for 1 hr with 1:5000- 
diluted goat anti-rabbit IgG’s (Sigma, St. Louis, MO) as secondary antibody coupled to 
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horseradish peroxidase. Proteins were visualized using enhanced chemiluminescence (ECL, 
Pierce, Rockford, IL). Densitrometric analyses were performed using Biorad quantification 
equipment (Bio-Rad 690c densitometer, Chemidoc XRS) and software (QuantityOne). Equal 
loading of the samples was confirmed by staining of the blots with coomassie blue G250 
(Serva, Heidelberg, Germany).
Table 1: Overview of prim er sets
Primer forward primer (5’-3 ’) reverse primer (5’-3 ’)
Del. 1 (-408 to -377 bp) ggggtaccgtttggggtaaggcattg cgtcttccatg gtgg ctttacc
Del. 2 (-377 to -346 bp) ccacatttcctcacaagccttttagtc gactaaaaggcttgtgaggaaatgtgg
Del. 3 (-346 to -315 bp) cttccttggccacagcctcctctgc cagaggaggctgtggccaaggaagg
Del. 4 (-315 to -283 bp) aggtcactggactcattgtgggggctg agcccccacaatgagtccagtgaccttc
Del. 5 (-283 to -252 bp) tggtgctggtgggctccatggggtaac taccccatggagcccaccagcaccag
Del. 6 (-252 to -220 bp) cagccctgaggcaaaacagagacgtc gacgtctctgttttgcctcagggctgc
Del. 7 (-220 to -189 bp) ctgaggaaaaaacgaggaattaatgaggag ctcctcattaattcctcgttttttcctcag
Del. 8 (-189 to -157 bp) cttatctggagtccgctaagatggggtg caccccatcttagcggactccagataag
Del. 9 (-157 to -126 bp) gtcagctgtgaaacaggagcagggatg catccctgctcctgtttcacagctgac
Del. 10 (-126 to -95 bp) ttcgggtgggggggagcacagggttg aaccctgtgctcccccccacccgaag
Del. 11 (-95 to -64 bp) aagtccgccatgccaccccacgtgc cacgtggggtggcatggcggacttg
Del. 12 (-64 to -34 bp) caggaacgcctcctggccctataagtg cacttatagggccaggaggcgttcctg
mutation CRE cgaggaaaacagagtggtcaatccttatctggagtcc ggactccagataaggattgaccactctgttttcctcg
mutation TonE ccaagaccttttgccttttaaatttgtcccaggccagccag ctggctggcctgggacaaatttaaaaggcaaaag
cAMP assay
MpkCCD cells were seeded on filters for 8 days, either with or without 1 nM dDAVP for the 
last 4 days. The last 24 hrs, cells were grown in hypotonic or isotonic medium. The 
phosphodiesterase inhibitor 3-isobutyl 1 methylxanthine (IBMX) was added to both the apical 
and basolateral medium to a final concentration of 500 ^M 30 min. before harvesting. In the 
cells grown without dDAVP, dDAVP was added to the basolateral side 15 min before 
harvesting. cAMP was measured using the cAMP-Glo assay (Promega, Madison, WI) 
according to manufacturer’s instructions.
Statistical analyses
Student’s T-test was applied to compare two groups with Gaussian distribution. Levene’s test 
was used to compare variances. P-values below 0.05 were considered significant. For 
multiple comparisons, Bonferroni correction was applied. Data are presented as mean +/- 




mpkCCD-cells as a model for tonicity-induced AQP2 expression
Hypertonicity has been shown to affect AQP2 transcription (10). To develop an easy readout 
cellular system for AQP2 transcription and to test whether mpkCCD cells are a proper cell 
model for these analyses, we generated pooled colonies of mpkCCD cells stably-transfected 
with the pGl3-AQP2-3.0-luc construct (mpkCCD-AQP2-3.0-luc), or a construct lacking the 
AQP2 promoter (mpkCCD-luc). To first test whether the promoter conferred vasopressin 
sensitivity, the mpkCCD-AQP2-3.0-luc and mpkCCD-luc cells were grown on semi­
permeable filters for 8 days of which the last 4 days with or without 1 nM dDAVP (17). 
Subsequent analysis revealed a 2.5-fold higher luciferase activity in mpkCCD-AQP2-3.0-luc 
cells with dDAVP than without dDAVP, while luciferase activity was hardly observed in 
mpkCCD-luc cells, and was not increased by dDAVP (Fig. 1A). As endogenous AQP2 
abundance was increased in both pooled colonies treated with dDAVP (Fig. 1B), it was 
concluded that the dDAVP-induced luciferase activity in mpkCCD-AQP2-luc cells is due to 
AQP2 promoter-specific transcription. To test whether changes in osmolality affect AQP2 
expression in mpkCCD-AQP2-luc cells, cells were grown for 8 days in isotonic medium (120 
mM NaCl; 355 mOsm/kg H2O). dDAVP was added during the last 4 days. In the last 24 hrs 
the cells were exposed to media made hypotonic or hypertonic using different concentrations 
of NaCl. Following lysis, immunoblotting revealed that a decreased osmolality coincided with 
reduced AQP2 abundance and vice versa (Fig. 1C). This was reflected in transcription from 
the 3-kb AQP2 promoter luciferase reporter construct, because luciferase activity increased 
with hyperosmolality and decreased with hypo-osmolality (Fig. 1D).
Changes in the concentration of NaCl affect both the osmolality and tonicity. To determine 
whether a change in osmolality or in tonicity regulates AQP2 transcription in mpkCCD cells, 
cells were grown and treated with dDAVP as described above. During the last 24 hrs, cells 
were incubated in hypotonic medium (275 mOsm) or in a medium of 355 mOsm of which 80 
mOsm was made up by different solutes. Subsequent luciferase activity measurements 
revealed that cell impermeant solutes such as sorbitol and sucrose mimicked the effect of 
NaCl, whereas a cell permeant solute such as urea had no effect (Fig. 1E). Thus, these data 
indicate that changes in tonicity, rather than osmolality, affect AQP2 transcription in both 
directions and that the 3.0 kb AQP2 promoter luciferase construct is a useful read-out 
system. To simulate the in vivo situation of hyponatremia, NaCl was used to change tonicity 
in all further experiments.
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Figure 1. m pkCCD cells as a model for tonicity-induced AQP2 expression. A ,B) mpkCCD-AQP2- 
3.0-luc and mpkCCD-luc cells were grown to confluence, the last 4 days with or without dDAVP. Cells 
were lysed and analyzed for luciferase activity (A) or for AQP2 expression (B). Immunoblotting the 
lysates for AQP2 revealed non-glycosylated (AQP2; 29 kDa) and complex-glycosylated (g-AQP2; 40­
45 kDa) AQP2 in lanes of mpkCCD cells treated with dDAVP. Molecular mass (in kDa) is indicated on 
the left. C,D) MpkCCD-AQP2-3.0-luc cells were grown to confluence and treated with 1 nM dDAVP for 
4 days. During the last 24 hrs cells were exposed to different osmolalities (indicated) using NaCl. Cells 
were lysed and analyzed for AQP2 expression (C) and luciferase activity (D). E) mpkCCD-AQP2-luc 
cells were grown as above. During the last 24 hrs, cells were grown in hypo-osmotic medium, 
containing B0 mM NaCl (hypo 275 mOsm), or medium with a osmolality of S55 mOsm, by adding NaCl 
(Con), urea, sorbitol or sucrose (indicated). Cells were lysed and luciferase activity was determined. In 
all experiments above, the mean values of luciferase activity per condition (+/- SEM) were determined 




Does the final or change in tonicity determine the AQP2 expression?
At present, it is unclear whether the change in tonicity or the tonicity itself determines AQP2 
expression. To test this, dDAVP-treated mpkCCD-AQP2-3.0-luc cells were grown in medium 
of 355 or 275 mOsm for 8 days. In the last 24 hours medium was either unchanged or 
replaced by a medium of the other osmolality. Analysis of the luciferase activity revealed that 
under both conditions AQP2 transcription was 2-fold higher in cells grown for the last day in 
355 versus 275 mOsm medium (Fig. 2). These experiments clearly indicate that the final, 
and not the change in, tonicity determines AQP2 expression.
Role of nitric oxide and prostaglandins
Murase et al. reported that endogenous nitric oxide (NO) synthesis was significantly 
increased in vasopressin escape rats and that inhibition of NO synthesis with L-NAME 
decreased urine volume and partially restored AQP2 expression (24). In addition, the 
excretion of prostaglandin E2, which is known to reduce AVP-stimulated water reabsorption 
in the collecting duct (25; 26), is increased in vasopressin escape and prevention of this 
increase with the prostaglandin synthesis blocker indomethacin resulted in a delay in the 
onset of escape (27). To test whether inhibition of NO synthesis and prostaglandins directly 
affect tonicity-induced changes in AQP2 expression, mpkCCD-AQP2-3.0-luc cells were 
grown and treated with dDAVP as above, but for the last 24 hours changed to medium with 
different osmolalities in the presence or absence of 10 ^M indomethacin or 1 mM L-NAME. 
Immunoblot analysis of AQP2 levels revealed that indomethacin and L-NAME treatment 
resulted in increased AQP2 protein expression levels (Fig. 3A, B). This increase with 
indomethacin and L-NAME was observed for every tonicity tested. However, comparison of 
the AQP2 expression levels revealed no differences in the tonicity response between control, 
indomethacin or L-NAME-treated cells. Moreover, AQP2-promoter driven transcription of 
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Figure 2. The final tonicity, and not the  
change in tonicity, determ ines the effect on 
AQP2 expression. mpkCCD-AQP2-luc cells 
were grown in isotonic (355 mOsm) or 
hypotonic (275 mOsm) medium for 8 days. In 
both conditions, cells were incubated in 
hypotonic or isotonic medium during the last 24 
hours. RLU = relative light units. Mean values 
of luciferase activity (+/- SEM) were determined 
from three independent filters per condition.
Grown in 275 355 mOsm
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Figure 3. Role of nictric oxide and prostaglandins in tonicity-regulated AQP2 expression. A)
mpkCCD-AQP2-3.0-luc cells were grown to confluence, the last 4 days with dDAVP. During the last 24 
hrs, cells were exposed to different osmolalities (indicated), in the absence or presence of 
indomethacin or L-NAME, blockers for prostaglandin and nitric oxide synthesis, respectively. Cells 
were lysed and analyzed for AQP2 abundance by immunoblotting The molecular mass (in kDa) is 
indicated on the left. B) Relative abundances of AQP2 derived from figure A, normalized for AQP2 
abundance of control cells grown under isotonic conditions. C) O f samples as described above 
luciferase activity was determined. Significant differences (p<0.05) are indicated by an asterisk.
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3C). These data indicate that, although NO and prostaglandins decrease AQP2 abundance, 
they do not affect tonicity-induced changes in AQP2 expression.
dDAVP-dependence of tonicity-induced AQP2 transcription
Tonicity can change AQP2 abundance independent of AVP in vivo (7; 9). To test whether an 
AVP-independent effect of tonicity on AQP2 expression is also observed in our cells, 
mpkCCD-AQP2-3.0-luc cells were again treated with different NaCl-concentrations for the 
last 24 hrs, but now in the presence or absence of dDAVP for 4 days before harvesting. 
While luciferase levels were higher in samples treated with dDAVP, the relative changes in 
luciferase activity with changing tonicity in dDAVP-treated and -untreated samples were 
similar (Fig. 4). These data show that in mpkCCD cells, the effect of tonicity on AQP2 
expression is independent of vasopressin receptor stimulation.
Figure 4. Role of dDAVP in tonicity induced 
AQP2 transcription. mpkCCD-AQP2-luc cells 
were grown as above, the last 4 days with or 
without (Con) dDAVP. During the last 24 hours, 
cells were grown in isotonic, hypertonic or 
hypotonic medium. After harvesting, luciferase 
activity was determined.
Con dDAVP
TonE in tonicity-induced AQP2 transcription
Regulation of AQP2 expression by tonicity through the TonE-element, located 489 bp 
upstream of the AQP2 transcription start site, is controversial. To test the relevance of TonE 
in tonicity-affected AQP2 expression under our conditions, we generated pooled colonies of 
mpkCCD-AQP2-3.0-luc cells in which the TonE element was inactivated as reported (13), 
and subjected these and the mpkCCD-AQP2-3.0-luc cells to hypo- and hypertonicity. 
Surprisingly, changing to hypotonic (275 mOsm) or hypertonic (435 mOsm) medium revealed 
a similar change in luciferase activity in the TonE mutants cells as found for mpkCCD-AQP2- 
3.0-luc cells (Fig. 5A).
To further investigate this, we generated mpkCCD cells stably-transfected with a construct in 
which luciferase expression is driven by 408 bp of the AQP2 promoter, thus lacking the TonE 
element (pGL3-AQP2-0.4-luc). Following subjection to hypo- and hypertonicity, qualitatively 
similar changes in AQP2 transcription were found for the 3.0 and 0.4 kb promoter with both 
changes (Fig. 5B). Combined, these data indicate that TonE is not involved in the tonicity-
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induced regulation of AQP2 expression under 
the present conditions. In addition, our data 
suggest the presence of yet another tonicity- 
responsive element in the 408 bp segment of 
the AQP2 promoter.
Role of CREB in tonicity-induced AQP2 
transcription
In this 408 bp segment is the CRE, located at
position -210, which is involved in AVP-
induced AQP2 transcription (2; 3). To test
whether CRE also has a role in tonicity-
induced regulation of AQP2, cells were
stably-transfected with pGL3-CRE(21)-luc, a
construct in which luciferase transcription is
driven by a promoter existing of 21 tandemly-
placed CREs. Following growth and
incubation with dDAVP as above, a reduced
luciferase activity was observed with
hypotonicity (Fig 6A). From this we conclude R° l6- ° f TonE ’ln~t(° n’c’ty"’nd.Uc?d3 v a ’ AQP2 transcription' mpkCCD cells, stably-
that hypotonicity does decrease CRE- transfected with a -3.0 kb AQP2 promoter
regulated transcription. (Control) or toe same ^ ^ t e r ,  ^ n te in ^  a
mutated TonE sequence (mutTonE) (A), or 
As tonicity-regulated AQP2 expression together with mpkCCD cells transfected with
appeared to be AVP-independent (Fig. 4) a - 0 4 kb AQP2 iprom° leo i B) were grown asabove, of which the last 24 hours in isotonic,
while CRE-mediated transcription is changed hypertonic or hypotonic medium. Cells were
with hypotonicity (Fig. 6A), we investigated lysed and sutyert^ to luciferase activity
measurements. Mean values of luciferase
which part of the AVP-cAMP-CREB-AQP2 activity (+/- SEM) were determined from 
promoter pathway was involved. three independent fifers per _____
As cAMP levels show a peak right after dDAVP addition, but are reduced to low levels within 
120 minutes following addition (28), we tested the effect of hypotonicity on dDAVP-induced 
cAMP levels on the long and short term. For the long term, cells were grown as above, 
treated with dDAVP for 4 days, incubated in hypotonic or isotonic medium during the last 24 
hours and treated with the phosphodiesterase inhibitor IBMX during the last 30 minutes. 
cAMP levels were not changed by hypotonicity (Fig. 6B). To investigate whether there is an 
effect of hypotonicity on short term cAMP generation, cells were grown without dDAVP, 
incubated in hypotonic or isotonic medium during the last 24 hours and subsequently treated
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with IBMX for the last 30 minutes and with dDAVP for the last 15 minutes. Analysis revealed 
that the dDAVP-induced cAMP levels were not changed (Fig. 6B).
To test if the effect of tonicity on AQP2 transcription involves protein kinase A (PKA), we 
tested whether the hypotonicity-induced decrease in AQP2 transcription was still observed 
when we would block PKA activity with H89, a PKA-selective inhibitor. Cells were grown for 8 
days and 24 hrs before harvesting, medium was replaced with iso- or hypotonic medium with 
dDAVP with or without 10 .^M H89. H89 decreased luciferase activity in cells grown in both 
iso- and hypotonic medium, indicating that PKA is involved in AQP2 transcription at both 
tonicities. However, the H89-induced down-regulation of AQP2 transcription of about 30% 
was the same for both tonicities (Fig. 6C), indicating that neither PKA, nor cAMP or dDAVP 
are involved in the hypotonicity-induced reduction in AQP2 transcription.
A tonicity-induced decrease in transcription can be caused by a reduced CREB activity, 
which can be the result of a decrease in total CREB and/or CREB-phosphorylation at Ser133 
(29). Indeed, immunoblotting showed a small, but significant decrease in total and CREB- 
pS133 with hypotonicity (Fig 6D,E). The relative changes in total and CREB-pS133 were 
similar, indicating that the decrease in CREB-pS133 is due to the decrease in total CREB.
To investigate the role of the CRE element in the AQP2 promoter, mpkCCD cells were 
stably-transfected with the pGL3-AQP2-0.4-luc construct in which the CRE-element was 
inactivated. Subsequently, these and mpkCCD-AQP2-0.4-luc cells were subjected to the 
hypotonicity assay with or without dDAVP. As anticipated, dDAVP treatment increased 
luciferase activity significantly in mpkCCD-AQP2-0.4-luc cells, but not in cells containing the 
CRE mutant (Fig. 6F). In both cell models, however, hypotonicity led to a similar decrease in 
luciferase activity, which indicated that the AQP2 CRE element is not essential for the 
response to hypotonicity.
AQP2 promoter segments involved in the decreased transcription under hypotonic conditions 
Because the CRE in the AQP2 promoter was shown not to be essential for the hypotonicity- 
effect (Fig. 6F), we further analyzed the -0.4kb AQP2 promoter for the hypotonicity element 
by generating twelve AQP2 promoter deletion constructs in which in each 31 bp (three 
rounds of the DNA helix) was deleted (Fig. 7A), leaving the relative orientation of the 
transcription factor binding sites intact. Cells stably-transfected with these constructs were 
tested for their response to 24 hrs of hypotonicity in the presence of dDAVP. While most cells 
with these constructs yielded significantly-reduced luciferase activity with hypotonicity, 
luciferase activity was not significantly reduced in cells containing constructs lacking 
nucleotides -284 to -254 (segment No. 5) and -158 to -127 (No. 9) (Fig. 7B).
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Figure 6. Role of CREB in tonicity-induced AQP2 transcription. A) mpkCCD cells, stably- 
transfected with a luciferase gene driven by a multi-CRE promoter, were grown as described above 
and grown for the last day in hypotonic or isotonic medium in the presence of dDAVP, lysed and 
analysed for luciferase activity. B) mpkCCD cells were grown as above and either incubated with 
dDAVP for 4 days or only 15 minutes before harvesting. In both conditions, cells were cultured in 
hypotonic or isotonic medium during the last 24 hours. After harvesting, cAMP levels were measured. 
C) mpkCCD cells, stably-transfected with a luciferase reporter construct containing 0.4 kb of the 
AQP2 promoter. were grown as above. The last 24 hours, cells were treated with dDAVP and the 
PKA-inhibitor H89 (10 ^M) and grown in hypotonic or isotonic medium, lysed and analyzed for 
luciferase activity. D) mpkCCD cells were grown as described under A. Cells were lysed and 
subjected to immunoblotting for CREB and S133-phosphorylated CREB (indicated). In the CREB- 
pS133-blot, the upper band represents phosphorylated CREB, whereas the lower band represents 
ATF-1 which is also recognized by this antibody. Molecular masses (in kDa) are indicated on the left. 
E) Relative abundance of total and S133-phosphorylated CREB derived from fig. D and normalized 
for their expression in isotonic medium. F) mpkCCD cells stably-transfected with constructs encoding 
luciferase preceded by the -0.4 kb AQP2 promoter (Con) or the same promoter, containing a mutated 
CRE sequence (mutCRE), were grown as above, with or without dDAVP and the last 24 hours in 
hypotonic or isotonic medium. After harvesting, luciferase activity was determined. Mean values (+/- 
SEM) were determined from three independent filters per condition. Significant differences (p<0.05) 
are indicated by an asterisk.
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Figure 7. AQP2 prom oter segm ents involved in hypotonicity-response. A) Position of the 31-bp 
segments deleted from the AQP2 promoter in relation to the transcription start site. B) mpkCCD cells 
stably-transfected with a -0.4 kb AQP2 promoter construct, containing deletions as indicated in A, 
were grown as above. The last 24 hours, cells were grown in hypotonic or isotonic medium. After 
harvesting, luciferase activity was determined. The relative luciferase activity is normalized for 
differences in transfection efficiencies by dividing the values obtained in the hypotonic medium by the 
values obtained in the isotonic medium.
Discussion
mpkCCD cells are a proper model to study tonicity-induced regulation of AQP2 expression 
Our data reveal that mpkCCD cells are a proper model to study hyper- and hypotonicity- 
induced changes in AQP2 expression and transcription. First, following transfection of a 
luciferase reporter construct preceded by a 3.0 kb AQP2 promoter, we showed that dDAVP 
induced an increase in AQP2 protein expression as well as transcription in mpkCCD cells 
(Fig 1A,B). This illustrated that the 3.0 kb promoter of AQP2 is sufficient for the response to 
dDAVP, and is consistent with data of others using the human AQP2 promoter of a similar 
length in other cells (2; 3; 30; 31). Secondly, both AQP2 protein expression and transcription 
were increased with hypertonicity (Fig. 1C,D), which is in line with the hypertonicity-induced 
increased AQP2 protein expression seen in vivo (9) and in vitro (10).
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We also observed a down-regulation of AQP2 in response to hypotonicity in vitro. This down- 
regulation of AQP2 was prevented when re-adjusting osmolality with sorbitol, sucrose, or 
NaCl, but not urea (Fig. 1E). It is therefore tonicity, and not osmolality, that affects AQP2 
expression, which is in agreement with previous results (10). Besides, we showed that the 
final tonicity and not the change in tonicity determined the extent of AQP2 transcription (Fig. 
2).
Hypotonicity-induced AQP2 down-regulation is independent of dDAVP, prostaglandins and 
nitric oxide production
Similar to in vivo and other in vitro studies with hypertonicity (7; 9), we show that the 
hypotonicity-induced decrease in AQP2 expression is independent of dDAVP, as the relative 
effects of hypotonicity were similar in the absence or presence of dDAVP (Fig. 4).
We investigated this further. Hypotonicity did not affect the cAMP-PKA pathway, as cAMP 
levels were not changed by hypotonicity and PKA blockade with H89 had no effect on the 
hypotonicity-induced down-regulation of AQP2. The decrease in luciferase activity in cells 
treated with H89 shows that this drug was still active (Fig. 6C).
Interestingly, hypotonicity significantly decreased luciferase activity in cells possessing 
several CRE-elements coupled to the luciferase cDNA (Fig. 6A), indicating that tonicity does 
affect CRE-mediated transcription. This decrease can be attributed to a decrease in total 
CREB protein levels, which was similar to the fractional decrease in CREB phosphorylation 
on serine-133 (Fig.6D,E). CRE, however, appeared not essential for the tonicity response of 
AQP2 expression, as mutating or deleting the CRE-sequence in the AQP2 promoter had no 
effect on the tonicity-mediated AQP2 transcription (Fig 6F,7) Considering the observed 
reduced expression of luciferase with hypotonicity from the CRE-luciferase construct, it may 
be that the 21 tandemly-placed CREs in this construct makes it more sensitive to detect 
CRE-mediated transcription than the AQP2 promoter. Alternatively, hypotonicity-regulated 
expression of AQP2 gene transcription is dominated by transcription factor binding sites 
other than its CRE. In either case, our data indicate that the CRE element in the AQP2 
promoter is irrelevant for the reduced transcription of the AQP2 gene with hypotonicity, which 
is in line with our data that cAMP levels and PKA activity are not changed with hypotonicity 
(Fig.6A-C) and with the finding of us and others that the effect of tonicity is AVP independent.
A candidate involved in the cellular signaling leading to the hypotonicity-mediated decrease 
in AQP2 transcription is nitric oxide (NO), as it has been shown that NO decreases AQP2 
expression (32; 33) and renal NO synthase expression correlates inversely with medullary 
tonicity (34; 35). Similarly, Murase et al. found that endogenous NO synthesis was
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significantly increased in the vasopressin escape animals and that treatment with L-NAME 
decreased urine volume and partially increased AQP2 expression (24). In agreement with 
this, blocking NO synthesis by L-NAME resulted in increased AQP2 protein abundance in 
mpkCCD cells (Fig. 3A). L-NAME did however not affect the tonicity-mediated change in 
AQP2 abundance (Fig. 3B). Moreover, the tonicity-induced changes in AQP2 transcription 
were not changed with L-NAME (Fig 3C). These data reveal that, although NO decreases 
AQP2 abundance in mpkCCD cells, NO does not affect AQP2 gene transcription and is not 
involved in the tonicity-regulated change in AQP2 expression.
Another mechanism involved might be an increased prostaglandin production. Prostaglandin 
E2 is known to reduce AVP-stimulated water reabsorption in the collecting duct (25; 26). 
Moreover, Gross et al. showed an increased urinary prostaglandin E2 excretion in 
vasopressin escape and preventing this increase with indomethacin resulted in a delay in the 
onset of escape (27). In agreement with these data, blocking prostaglandin production with 
indomethacin resulted in an increased AQP2 protein expression in our mpkCCD cells (Fig. 
3A). No effect was seen on AQP2 promoter-driven luciferase activity, however, indicating 
that the decrease of AQP2 abundance with prostaglandins occurs at the protein or mRNA 
stability level, rather than AQP2 gene transcription. In addition and similar to the effect of L- 
NAME, indomethacin treatment did not affect the tonicity-induced AQP2 expression, 
suggesting that prostaglandin production is not affected by tonicity, and is not involved in the 
tonicity-regulated expression of AQP2.
In the context of the in vivo data, our data indicate that paracrine-produced increased levels 
of prostaglandins and/or NO in the kidney may indeed contribute to the reduced AQP2 
abundance observed in vasopressin escape animals, but that they cannot explain the effect 
of tonicity on AQP2 gene transcription.
Tonicity-induced AQP2 transcription is TonE independent
The role of TonE in tonicity-regulated AQP2 expression is controversial. In our experiments, 
the TonE in the AQP2 promoter was not important for AQP2 transcription regulation by 
tonicity, because (1) introduction of a TonE-mutation identical to the mutation introduced by 
Hasler et al. in a -3.0 kb AQP2 promoter had no effect on tonicity-induced AQP2-transcription 
(Fig. 5A) and (2) luciferase activity obtained from the -0.4 kb AQP2 promoter, which lacks 
TonE, and the -3.0 kb promoter were similarly influenced by the different tonicities used to 
culture the cells in (Fig. 5B).
Our data are in contrast to those obtained by Hasler et al., who were using the same cell 
model, but under different conditions (13). Growing the cells for only 2 days of which the last 
day in serum-free medium and without dDAVP stimulation, Hasler et al. found an absence of 
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the hypertonicity-induced AQP2-promoter driven luciferase activity in mpkCCD cells when 
the TonE was mutated. We tested whether this could be due to the different experimental 
conditions. Indeed, growing the cells in the same way, we saw a significant reduction, but not 
complete absence, in hypertonicity-induced luciferase activity in the TonE mutant cells 
compared to the mpkCCD-AQP2-3.0-luc cells (not shown). This difference was caused by 
the shorter growth period, as growing the cells for 8 days, the last 24 hours with hypertonic 
serum-free medium without dDAVP, did not show any difference in the hypertonic-response 
between the promoters with an intact or mutated TonE element (not shown). As in our 
experience, mpkCCD cells are only polarized after 4 days of culture (not shown), we believe 
that growing the cells for 8 days as used in our experiments, better mimics the in vivo 
situation.
Our data seem in contrast to in vivo data, as TonEBP-/- mice and mice transgenic for 
dominant-negative TonEBP showed decreased AQP2 expression (15; 16). However, the 
severe atrophy of the renal medulla in the TonEBP-/- and dominant-negative TonEBP 
overexpressing mice complicates the interpretation of the direct involvement of TonE in 
tonicity-regulation of AQP2 expression. To resolve this apparent discrepancy, investigation of 
the role of TonE and TonEBP in a conditional knockout mouse in which the structure of the 
renal medulla would be intact is needed.
The segments from -283 to -252 and -157 to -126 bp of the AQP2 promoter are involved the 
hypotonicity-induced AQP2 down-regulation
Using a -0.4 kb promoter, hypo- and hypertonicity showed qualitatively similar changes in 
AQP2 transcription as compared to the -3.0 promoter (Fig. 5B), indicating that a tonicity- 
responsive element is present in the 408 bp AQP2 promoter. With subsequent segment 
deletions, the location of this TonE element could be pinpointed to two 31 bp promoter 
segments (5 and 9) in the -0.4 kb AQP2 promoter, covering nucleotides -283 to -252 and - 
157 to -126 bp.
Li et al. reported that the effect of hypertonicity on AQP2 transcription depended on the 
NFATc-sites in the AQP2 promoter (14). The NFATc-sites tested by Li et al. are localized in 
segments 1, 6 and 7 of the -0.4 kb promoter. Two segments are located more upstream; one 
of them representing the TonE-sequence. In our experiments, the upstream segments, nor 
segments 1, 6 or 7 appeared important in the hypotonicity-response. One explanation for this 
difference could be the differences in experimental conditions, as Li et al. used unpolarized 
mpkCCD cells and looked at an effect of tonicity after 6 hours. This time period of subjection 
to a changed tonicity indeed seems of relevance, because Hasler et al. have shown that the 
response to a change in tonicity with 3 hours is opposite to that obtained after 24 hours (10).
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Another explanation could be that in the experiments performed by Li et al. all the NFATc- 
sites were mutated simultaneously, while we only deleted one or two sites at once. The 
inactivation of multiple NFATc-sites could influence the tonicity-effect whereas deletion of 
only one or two sites could give too small a change to detect.
To possibly identify the transcription factors involved, segments 5 and 9 were analyzed for 
potential transcription factor binding sites using TRANSFAC databases (36). In segment 5, 
binding sites for nuclear factor kappa B (NF-kappaB) and SP1 were identified and in 
segment 9, a GATA binding site was found (Fig. 8).
Based on literature, these transcription factors could well mediate the change in AQP2 gene 
transcription with tonicity, as data in intestinal epithelial cells suggest activation of NF-kappaB 
and stimulation of NF-kappaB-mediated transcription by osmotic stress (37). Similarly, 
hypertonicity activates NF-kappaB in renal medullary interstitial cells and water deprivation 
increases renal NF-kappaB-driven reporter gene expression in transgenic mice (38). In 
addition, GATA may play a role in tonicity-regulated AQP2 transcription, because hypertonic 
stress induces transcription of GATA-2 in placental trophoblast stem cells (39). It remains to 
be established whether these transcription factors and their promoter elements are 
responsible for the tonicity effect on AQP2 transcription.
Figure 8. Transcription factor binding sites. Transcription factor binding sites identified in the 
283 to -252 and -157 to -126 bp regions of the AQP2 promoter using TRANSFAC databases.______
In conclusion, we showed that in mpkCCD cells, tonicity-induced AQP2 expression is 
mediated by transcription factors other than TonEBP or CREB and that it occurs in an AVP- 
independent manner. The tonicity responsiveness seems to involve AQP2 promoter 
segments covering nucleotides -283 to -252 and -157 to -126 bp of the AQP2 promoter. 
Identification of transcription factors and signaling proteins involved in hypotonicity-regulated 
AQP2 expression in follow-up experiments will provide us a better insight in physiological 
regulation of AQP2 expression and renal water reabsorption by tonicity and may lead to the 
discovery of targets for modulation of pathophysiological conditions of osmoregulation, such 
as with SIADH.
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Long-term regulation of AQP2 by vasopressin
Abstract
Urine concentration involves the hormone vasopressin (AVP), which stimulates cAMP 
production in renal principal cells, resulting in translocation and transcription of aquaporin-2 
(AQP2) water channels, greatly increasing the water permeability, leading to a concentrated 
urine. As cAMP levels decrease shortly after AVP addition, whereas AQP2 levels still 
increase and are maintained for days, we investigated in the present study the mechanism 
responsible for the AQP2 increase after long-term dDAVP application using mouse collecting 
duct (mpkCCD) cells.
While 30 min dDAVP incubation strongly increased cAMP, cAMP was lower with 1 day, and 
was even further reduced with 4 days dDAVP, although still significantly higher than in 
control cells. 1 day dDAVP incubation increased AQP2 promoter dependent transcription, 
which was blocked by the protein kinase A (PKA) inhibitor H89. Moreover, phosphorylation of 
the cAMP responsive element binding protein (CREB) and CRE-dependent transcription was 
observed after short-term dDAVP stimulation. With 4 days of dDAVP, AQP2 transcription 
remained elevated, but this was not blocked by H89, and CRE-dependent transcription and 
CREB phosphorylation were not increased,
Exchange protein directly activated by cAMP (Epac) 1 and 2 were found to be endogenously 
expressed in mpkCCD cells. Application of dDAVP increased the expression of Epac1, while 
Epac2 was reduced. Incubation with a specific Epac activator after dDAVP pretreatment 
increased both AQP2 abundance and transcription compared to cells left unstimulated the 
last day.
In conclusion, the PKA-CRE pathway is involved in the initial rise in AQP2 levels after 
dDAVP stimulation, but not in the long-term effect of dDAVP. Instead, long-term regulation of 
AQP2 may involve the activation of Epac.
Introduction
The kidney plays a key role in regulating water balance. In states of hypernatremia or 
hypovolemia, the hormone arginine-vasopressin (AVP) is released from the pituitary. Binding 
of AVP to the vasopressin type-2 receptor stimulates a rise in intracellular cAMP in the renal 
collecting duct principal cells, leading to activation of protein kinase A (PKA), phosphorylation 
of aquaporin-2 (AQP2) water channels at Ser256 and subsequent redistribution of AQP2 
from intracellular vesicles into the apical membrane (1-4). Driven by the transcellular osmotic 
gradient, water will enter principal cells through AQP2 and exit the cells through the 
basolaterally located AQP3 or AQP4 water channels, resulting in concentrated urine.
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Besides this short-term regulation, AVP also increases transcription of AQP2 and hence 
increases AQP2 abundance (5; 6). Changes in expression of AQP2 have been attributed to 
PKA-induced phosphorylation of the cAMP responsive element binding protein (CREB) 
which stimulates transcription from the AQP2 promoter via the cAMP Responsive Element 
(CRE) (7-9).
Interestingly, cAMP levels peak immediately after addition of the stable AVP analogue 
dDAVP, but are reduced to low levels within 120 minutes following addition in AQP2- 
transfected MDCK cells (10). AQP2 levels, however, continue to rise during the first three 
days of dDAVP exposure in mouse collecting duct (mpkCCD) cells (11). Therefore, the 
purpose of this study was to delineate whether cAMP and CREB are involved in the long­
term maintenance of increased AQP2 levels with dDAVP.
As cAMP not only activates PKA, but also the exchange protein directly activated by cAMP 
(Epac), and both Epac1 and Epac2 are expressed in renal principal cells (12), Epac might 
have a role in AQP2 regulation as well. This is further suggested by Yip, showing that Epac 
might have a role in the vasopressin-stimulated apical targeting of AQP2 in perfused inner 
medullary collecting ducts (13).
Here, we investigated the involvement of the PKA-CREB pathway as well as Epac in the 
long-term AQP2 regulation in the mpkCCD cell line.
Materials and Methods
Cell culture
MpkCCD cells were cultured as described previously (6). Cells were seeded at a density of
1.5x105 cells/cm2 on semi-permeable filters (Transwell®, 0.4 .^m pore size, Corning Costar, 
Cambridge, MA) and cultured for 8 days. For the last 24 or 96 hrs, the cells were incubated 
with 1 nM dDAVP to the basolateral side, to induce an increase in AQP2 expression. During 
this 96 hrs incubation period, the medium was daily refreshed. The PKA blocker H89 (10 pM, 
Calbiochem, San Diego, CA) or the Epac activator 007-AM (8-pCPT-2’-O-Me-cAMP-AM, 
kind gift of Dr. H. Rehmann, UMC Utrecht, Utrecht, The Netherlands, 0.1 pM) were added to 
both sides of the filters for the last 24 hours.
Transfection and generation of stable mpkCCD cell lines with a 3.0 kb AQP2 promoter- 
luciferase reporter construct was described previously (14). Transfection and generation of a 
stable mpkCCD cell line with pGL3-CRE(21)-luc, a construct in which luciferase transcription 
is driven by a promoter existing of 21 tandemly-placed CREs, was described previously as 
well (14).
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Immunoblotting
MpkCCD cells from 1.13 cm2 filters were lysed in 200 .^l Laemmli buffer, sonicated and 
heated for 30 min at 37°C. PAGE, blotting and blocking of the PVDF membranes were done 
as described (15). Membranes were incubated for 16 hrs at 4°C with 1:3000-diluted affinity- 
purified rabbit R7 AQP2 antibodies (16), 1:2000 anti-cAMP responsive element binding 
protein (CREB) antibody (Sigma, St. Louis, MO, USA), 1:2000 anti-phosphorylated CREB 
antibody (Sigma, St. Louis, MO, USA), 1:1000 diluted mouse anti-Epac1 5D3 (17) or mouse 
anti-Epac2 3C12 antibodies (raised against the C-terminus of Epac2 protein, kind gift of Dr. 
Johannes L. Bos, University of Utrecht, The Netherlands) in Tris-Buffered Saline Tween-20 
(TBS-T) supplemented with 1% non-fat dried milk.
Blots were incubated for 1 hr with 1:5000-diluted goat anti-rabbit IgG’s or 1:2000-diluted goat 
anti-mouse IgG’s (Sigma, St. Louis, MO) as secondary antibody coupled to horseradish 
peroxidase. Proteins were visualized using enhanced chemiluminescence (ECL, Pierce, 
Rockford, IL).
Luciferase assay
Luciferase activity was measured using the Luciferase Assay System (Promega, Madison, 
WI, USA) according to the manufacturer’s instructions. Luminescence was measured for 10 
seconds using an EG&G Berthold Lumat LB9507 luminometer. To verify that equal amounts 
of protein per sample were used for the luciferase assay, protein concentration was 
determined using the BioRad protein assay (München, Germany), according to 
manufacturer’s instructions.
cAMP measurement
MpkCCD cells were seeded on filters for 8 days, the last 4 days with or without 1 nM dDAVP. 
The last day, the cells were incubated for 30 min with 0.5 mM phosphodiesterase inhibitor 3- 
isobutyl 1 methylxanthine (IBMX; Sigma, St. Louis, MO, USA). For short-term cAMP 
measurement, cells were treated for 30 minutes with IBMX with or without dDAVP. cAMP 
was measured using the cAMP enzyme immunoassay kit (Sigma, St. Louis, MO, USA) 
according to manufacturer’s instructions. Results were related to a standard curve based on 
the measurement of defined cAMP solutions done in triplicates.
Statistics
Students unpaired t-test was used when two groups with Gaussian distribution were 
compared. For multiple comparisons, Bonferroni correction was applied. A p value of less 
than 0.05 is considered significant. Data are presented as mean and bars are standard error 




Short and long-term effects of dDAVP on cAMP levels and AQP2 transcription 
At long-term incubation, dDAVP-induced AQP2 expression and plasma membrane 
accumulation is sustained, but cAMP levels drop to low levels within 120 minutes in MDCK 
cells (10). To investigate if cAMP levels are still increased after long-term dDAVP stimulation 
or return to basal levels, mpkCCD cells were grown to confluence for 4 days after which they 
were incubated with or without 1 nM dDAVP for the last 4 days, of which the last 30 minutes 
in the presence of the phosphodiesterase inhibitor IBMX. As a positive control, mpkCCD 
cells were grown similarly, but treated with dDAVP and IBMX only for the last 30 minutes. 
Analysis revealed that the cAMP levels were around 4 times higher in long-term dDAVP- 
stimulated cells as compared to control cells, whereas cells stimulated with dDAVP for only 
30 minutes had cAMP levels approximately 40 times higher than control cells (Fig. 1A). 
Allthough cAMP levels were lower after long-term dDAVP stimulation, Li et al. have shown 
that AQP2 abundance is still maximally stimulated after 4 days dDAVP in mpkCCD cells (11). 
Considering a half-life of 4 hours for AQP2 in mpkCCD cells (18), the sustained expression 
of AQP2 over a period of 4 days indicates a sustained AQP2 gene transcription.
Previously, we showed that dDAVP increases luciferase activity and AQP2 protein 
expression in pooled colonies of mpkCCD cells stably transfected with a 3.0 kb AQP2
dDAVP - dDAVP 0 1 4 days dDAVP
30 min 4 days
Figure 1. Effect o f dDAVP on cAMP generation A) MpkCCD cells were grown for 8 days and 
incubated with dDAVP for the last 4 days or 30 minutes. During the last 30 minutes, IBMX was added. 
Cells were lysed and cAMP production was measured. B) mpkCCD-AQP2-3.0-luc cells were grown for 
8 days, the last 1 or 4 days with or without 1 nM dDAVP. The cells were lysed and light emission was 
measured. For A-B: Data are the mean of three samples (+/- SEM). Significant differences (p<0.05) 
are indicated by an asterisk.______________________________________________________________________
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promoter luciferase construct (mpkCCD-AQP2-3.0-luc; (14)). This dDAVP-induced luciferase 
activity in mpkCCD-AQP2-3.0-luc cells was due to AQP2 promoter-specific transcription, as 
in mpkCCD cells stably-transfected with the luciferase reporter construct without the AQP2 
promoter, luciferase activity was hardly observed, and this was not increased by dDAVP 
(14). Therefore, to test the long and short-term dDAVP effects on AQP2 transcription, 
mpkCCD-AQP2-3.0-luc cells were treated as above, except that the short-term incubation 
lasted one day instead of 30 minutes, because 30 minutes was too short to observe changes 
in transcription (not shown). As shown in figure 1B, both short and long-term dDAVP 
application resulted in an increased luciferase activity compared to unstimulated cells, and 
there was no difference in the level of transcriptional activity after 1 or 4 days of dDAVP 
stimulation.
Role of PKA in the dDAVP-induced increase in AQP2 transcription
Although the observed sustained, but lower, cAMP production after 4 days stimulation with 
dDAVP may provide an explanation for the long-term increased AQP2 expression, we 
wanted to investigate whether the cAMP signaling cascade is really important during long­
term dDAVP stimulation. To study this, mpkCCD-AQP2-3.0-luc cells were grown as 
described above, and incubated for the last 24 hours or 4 days with dDAVP and the last 24 
hours with or without the PKA blocker H89. As luciferase has a half-life of 2-4 hours (19; 20), 
the obtained luciferase activity will reflect the AQP2-transcription during the day incubated 
with H89. Analysis of luciferase-activity revealed that addition of H89 after 3 days of dDAVP 
stimulation did not reduce AQP2 transcription. In contrast, and in line with an essential role of 
PKA in initiating AQP2 gene transcription with dDAVP, H89 reduced AQP2 transcription 




Figure 2. Role of PKA in the dDAVP-AQP2  
pathway. MpkCCD cells containing an AQP2- 
promoter-luciferase construct were treated with 
dDAVP for the last 1 or 4 days, with or without the 
PKA blocker H89 for the last 24 hours. The cells 
were lysed and light emission was measured. Data 
are the mean of three samples (+/- SEM). Significant 
differences (p<0.05) are indicated by an asterisk.
- H89 H89
1 d dDAVP 4 d dDAVP
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initial stimulation of AQP2 
transcription, PKA activity 
is not essential for AQP2 
transcription after
prolonged activation by 
dDAVP.
Effect of dDA VP on CREB 
and CRE-mediated
transcription
PKA is known to activate 
CREB through
phosphorylation of its 
serine 133 (S133), which 
has been reported to 
increase AQP2 gene 
transcription via the CRE 
element in the AQP2 
promoter (7; 8; 21).
To investigate CRE- 
mediated transcription 
after long-term dDAVP 
administration, we stably- 
transfected mpkCCD cells 
with pGL3-CRE(21)-luc, a 
construct in which 
luciferase transcription is 
driven by a promoter 
existing of 21 tandemly- 
placed CREs. As 
luciferase has a half-life of 
2-4 hours (19; 20), 
luciferase activity derived 
from this promoter 
consisting only of intact 
CRE elements allows us to
Figure 3. Role of CREB in dDAVP-induced AQP2 transcription. A)
MpkCCD cells containing an CRE-luciferase construct were treated 
with or without dDAVP for 1 or 4 days. The cells were lysed and light 
emission was measured. B) MpkCCD cells were grown to confluence 
and incubated with or without dDAVP for the last 4 days or 30 
minutes. Cells were lysed and subjected to immunoblotting for total 
CREB (C) and pS133-CREB (pC). For A-B: Data are the mean of 
three samples (+/- SEM). Significant differences (p<0.05) are 
indicated by an asterisk.
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evaluate the role of CRE-mediated transcription during dDAVP stimulation for 1 or 4 days. 
While incubation with dDAVP for 1 day yielded a more than two-fold increase in luciferase 
activity, luciferase activity was not different from untreated cells after 4 days of dDAVP 
stimulation (Fig. 3A). As CRE-mediated transcription is increased after 1 day dDAVP, but not 
after 4 days, these data suggest that CRE-mediated transcription is important to initiate, but 
not to maintain, dDAVP-induced transcription from the AQP2 promoter.
To test whether the difference in CRE-mediated transcription after long-term dDAVP 
stimulation could result from a change in the abundance and S133 phosphorylation of CREB, 
the effect of dDAVP on CREB was investigated by incubating mpkCCD cells with dDAVP for 
30 minutes, to look at the initial response, and 4 days to investigate the effects of long-term 
dDAVP stimulation. Immunoblot analysis revealed that dDAVP application for 30 minutes 
decreased total abundance of CREB, but strongly increased the abundance of pS133 CREB 
(Fig. 3B). After 4 days of dDAVP treatment, total CREB was similarly diminished as after 30 
minutes of dDAVP treatment, but now p133-CREB was undetectable. These data indicate 
that after an initial activation of CREB by phosphorylation at S133, the reduced abundance of 
total and S133-phosphorylated CREB may underlie the absence of CRE-mediated 
transcription upon long-term dDAVP treatment.
Expression of Epac1 and 2 in mpkCCD cells
As our data indicate that PKA and CREB are not involved in the long-term transcription of 
AQP2, and as cAMP levels were still increased after 4 days dDAVP stimulation, as 
compared to untreated cells, we wanted to test whether Epac1 and/or its close relative 
Epac2 could be involved.
To test whether mpkCCD cells do express the Epac proteins and whether their abundance is 
influenced by dDAVP, mpkCCD cells were grown on filters for 8 days of which the last 4 days 
with or without dDAVP. Immunoblotting for Epac1 and Epac2 revealed a band of the 
anticipated mass of 96 kDa for Epac1 and 116 kDa for Epac2 in untreated cells (Fig. 4). 
Upon incubation with dDAVP for 4 days, Epac1 levels increased significantly, while Epac2 
levels were reduced. Epac1 and 2 abundance is thus dDAVP-sensitive.
Effect of Epac activity on AQP2 expression
To investigate whether Epac activation affects AQP2 promoter-dependent transcription and 
AQP2 abundance, mpkCCD-AQP2-3.0-luc cells were again grown 8 days, in the presence or 
absence of 0.1 .^M of the Epac-specific activator 007-AM during the last 24 hrs. As positive 
controls, mpkCCD-AQP2-3.0-luc cells incubated with dDAVP for 1 or 4 days were taken 
along. Immunoblot analysis, however, revealed that, in contrast to dDAVP, 007-AM treatment 
alone did not stimulate AQP2 abundance (Fig. 5A), nor AQP2 promoter driven luciferase
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activity (Fig. 5B). Th ese  data indicate 
that Epac activation alone is not 
enough to stim ulate A Q P 2  gene  
transcription.
To determ ine w hether Epac activation
could stabilize expression of A Q P 2
initially stim ulated by d D A V P ,
m p kC C D -A Q P 2-3 .0 -lu c  cells grown
as above w ere  incubated with dD A V P
for 3 days, followed by one day with
or without dD A V P, or w ithout dD A VP,
but in the presence of 007-A M .
Interestingly, luciferase activity
analysis revealed that 007 -A M
treatm ent significantly increased
A Q P 2  transcription com pared to
unstim ulated cells (Fig. 5C),
suggesting that Epac is involved in
—--------- ; z --------------------- :— :---------, _ _ _ — ---------- , _ A QP 2  transcription. To investigate
Figure 4. Epac expression in m pkCCD cells. mpkCCD r  3
cells were grown to confluence and incubated with or w hether the effects seen on A Q P 2
without dDAVP for 4 days. Cells were then lysed and
subjected to immunoblotting for Epac1 and 2. The signals transcription are reflected in A Q P 2
from immunobloting were densitometrically ^antifted  and protein abundance, the sam e sam ples  
Epac signals were normalized for coomassie blue staining
(indicated). Values are means +/- SEM. Significant w ere  imm unoblotted for A Q P 2  (Fig. 
differences (p<0.05) between control and experimental 
groups are indicated by an asterisk. 5D ). 007 -A M  treatm ent significantly  
increased A Q P 2  abundance
com pared to cells left unstimulated, confirming the ability of Epac to stim ulate A Q P 2  
expression. T h e  A Q P 2  abundance of 007 -A M  treated cells w as how ever significantly lower 
than cells incubated with d D A V P  during the last day.
Discussion
Short and long-term dDAVP-incubation increase AQP2 transcription by different pathways 
It has previously been shown that A V P  increases A Q P 2  transcription by the cA M P -P K A - 
C R E B  pathway (6 -8). This pathway is also activated in m pkC C D  cells after dD A V P  
stimulation, as shown by the dD AVP-stim ulated increase in cA M P  levels, the PKA  
dependence of A Q P 2  transcription and the dD A V P -m ed iated  increase in C R E B
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phosphorylation as well as CRE dependent transcription (Fig. 1-3). However, our data 
indicate that there is a different pathway involved in the long-term regulation of dDAVP- 
induced AQP2 transcription. Although both short- and long-term dDAVP administration 
increased intracellular cAMP levels, this increase was clearly lower after long-term 
stimulation (Fig. 1). Long-term regulation of AQP2 transcription seemed to be independent of 
PKA, as H89 did not reduce AQP2 promoter-mediated transcription on the long term, 
whereas it did strongly reduce initial stimulation of AQP2 expression (Fig. 2). This cannot be 
explained by a lack of dDAVP stimulation after 4 days, as removal of dDAVP during the last 
day decreased AQP2 transcription (Fig. 5C) and likely also leads to decreased cAMP levels. 
The initial increase in AQP2 transcription observed after 1 day of dDAVP incubation was 
dependent on PKA, although the effect of the PKA blocker did not fully reduce luciferase 
activity (compare Fig. 2 and 5B). As the in vitro IC50 of H89 for PKA is approximately 50 nM
(22), the 10 ^M concentration used in our experiments is anticipated to block PKA 
completely. This suggests that PKA is not the only factor involved in the increased AQP2 
transcription or H89 is not stable over the 24 hours incubation as used in our experiments. 
Another difference between the long and short-term regulation of AQP2 is the involvement of 
CREB. While acute dDAVP treatment increased CREB phosphorylation and CRE-dependent 
transcription, CREB expression and phosphorylation were reduced to nearly undetectable 
levels with long-term dDAVP treatment. In agreement with this, long-term dDAVP incubation 
did not increased CRE-mediated transcription. These changes may be the consequence of a 
cellular desensitization to dDAVP. Continuous stimulation of CREB is known to lead to the 
synthesis of ICER (inducible cyclic AMP response element repressor), reducing CRE- 
dependent transcription (23). Furthermore, cAMP stimulation has been shown to desensitize 
PKA (24), potentially explaining the absence of CREB phosphorylation and role of PKA in 
long-term AQP2 regulation.
The temporary increase in CREB phosphorylation as seen in our experiments, is in 
agreement with previous studies, where forskolin treatment leads to a rapid phosphorylation 
of CREB within 15 minutes after treatment which starts to decay already after 30 minutes, 
returning to baseline levels within 8 hours (25-27). In agreement with our results, Zhang et al. 
also observed a decrease in total CREB levels already after 30 minutes forskolin treatment in 
HEK293 cells (26). dDAVP treatment for 96 hours has also previously been shown to 
decrease total CREB levels in mpkCCD cells (11).
Long-term dDAVP induces a small cAMP response compared to short-term dDAVP 
stimulation
In our study, both short- and long-term dDAVP administration increases intracellular cAMP
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Figure 5. Effect of the Epac activation on AQP2 expression. A) MpkCCD cells were grown for 8 
days and were treated with 007-AM or dDAVP during the last 24 hours, or with dDAVP for 4 days. 
Cells were then lysed and subjected to immunoblotting for AQP2. B) MpkCCD cells containing an 
AQP2-promoter-luciferase construct were treated as in A. The cells were lysed and light emission was 
measured. C) MpkCCD cells containing an AQP2-promoter-luciferase construct were incubated with 
dDAVP for 3 days, followed by 24 hours unstimulated (-), 007-AM or dDAVP treatment. The cells were 
lysed and light emission was measured. D) MpkCCD cells were incubated with dDAVP for 3 days, 
followed by 24 hours unstimulated (-), 007-AM or dDAVP treatment. The cells were lysed and 
subjected to immunoblotting for AQP2. For A-D: Data are the mean (+/- SEM) of three samples. 
Significant differences (p<0.05) are indicated by an asterisk.________________________________________
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levels, although this increase was clearly lower after long-term stimulation (Fig. 1). 
Previously, it has been shown that cAMP levels peak immediately after addition of dDAVP, 
but are reduced to very low levels within 120 minutes following addition in AQP2-transfected 
MDCK cells (10).
An increased cAMP level after long-term dDAVP as found in our study is in agreement with a 
previous study, showing that in vivo, in rats subjected to intramuscular injections with dDAVP 
for 3 days, cAMP was still increased compared to untreated rats (28). Later, Dublineau et al. 
also showed that in isolated collecting ducts of similarly treated rats, addition of 1 nM AVP 
evoked a smaller cAMP response than in untreated rats (29). Both our studies and those of 
Dublineau point to desensitization of the cellular system to vasopressin.
A possible explanation for the lower cAMP production after 4 days dDAVP is a lower receptor 
expression on the cell surface, in line with earlier observations that V2R receptor activation 
leads to its internalization (30). Adenylate cyclase 6, which is expressed in the collecting 
duct, has also been shown to be desensitized upon continued activation of PKA (31; 32). 
Long-term dDAVP treatment also results in an increased cAMP breakdown in vivo, as cAMP 
stimulation leads to an upregulation of cAMP phosphodiesterases (33). However, as our 
cAMP measurements were done in the presence of the phosphodiesterase inhibitor IBMX, 
an increased breakdown by increased phosphodiesterase activity cannot explain the 
difference in cAMP levels in our experiments
Epac activation increases AQP2 transcription and abundance after pretreatment with dDAVP 
Our results indicate that long-term regulation of AQP2 by dDAVP may involve Epac. In 
agreement with in vivo studies, where both Epac1 and Epac2 proteins were found in the 
collecting duct, mpkCCD cells endogenously express Epac1 and Epac2 proteins (Fig. 4). 
Epac1 is mainly expressed in intercalated cells, although it is also found in principal cells in 
the outer medulla. Epac2 is highly expressed in all principal cells along the entire collecting 
duct (12). Yip showed that Epac activation increases vasopressin-stimulated translocation of 
AQP2 to the apical membrane (13).
In mpkCCD cells, Epac1 expression was stimulated by dDAVP, while Epac2 expression was 
reduced (Fig. 4), suggesting that dDAVP regulates Epac protein abundance. Moreover, Epac 
activity increases both AQP2 transcription and AQP2 protein abundance after sustained 
dDAVP stimulation (Fig. 5), although AQP2 abundance was not maintained to the same level 
as with dDAVP. As after prolonged dDAVP incubation cAMP levels are still increased 
compared to control cells, Epac activation by the increased cAMP levels may form part of the 
PKA independent pathway to maintain high AQP2 levels at long-term dDAVP incubation. The 
reduced level of maintaining AQP2 abundance may be due to instability of the Epac 
stimulator over the 24 hour period used, or may indicate that Epac is not the only factor
111
Chapter 5
involved in stimulating long-term AQP2 expression. It remains to be established whether 
Epac has a similar role in vivo.
In conclusion, our study shows that the PKA-CRE pathway is involved in the initial increase 
in AQP2 abundance after dDAVP stimulation, but not in the long-term effect of dDAVP. 
Instead, long-term regulation of AQP2 may involve the activation of Epac.
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Abstract
Demeclocycline and minocycline are antibiotics of the tetracycline group, which display 
aquaretic effects. Because of the effect on water diuresis, demeclocycline is currently used to 
treat sustained hyponatremia in patients with the syndrome of inappropriate antidiuretic 
hormone secretion. Though these compounds are thought to act in the distal part of the 
nephron, their exact mechanism of action has not yet been described. We show that 
demeclocycline and minocycline decrease the protein level of the water channel aquaporin-2 
in the mpkCCD mouse collecting duct cell line in a time and concentration dependent 
manner. This effect is abolished by inhibiting protein synthesis. Moreover, demeclocycline 
decreased luciferase activity using a 3.0 kb AQP2 promoter reporter construct. These 
observations suggest that the effect of demeclocycline on aquaporin-2 is mediated via 
decreased transcription. Our data further indicate that demeclocycline decreases AQP2 gene 
transcription by decreasing adenylate cyclase expression and cAMP generation.
Introduction
The kidney is the main organ for regulating water homeostasis. In states of hypernatremia or 
hypovolemia, the hormone arginine-vasopressin (AVP) is released from the pituitary. 
Subsequent binding of AVP to the vasopressin type-2 receptor in the basolateral membrane 
of renal collecting duct principal cells induces a signaling cascade (1). This includes Gs 
protein mediated activation of adenylate cyclase, a rise in intracellular cAMP, activation of 
protein kinase A (PKA), and subsequent phosphorylation of aquaporin-2 (AQP2) water 
channels at Ser256. This results in the redistribution of AQP2 from intracellular vesicles to 
the apical membrane (2-4). Driven by the transcellular osmotic gradient of sodium and urea, 
water will enter principal cells through AQP2 and will exit the cells through AQP3 or AQP4 
located in the basolateral membrane, resulting in concentrated urine. Besides this short-term 
regulation, AVP regulates AQP2 on the long term by increasing its transcription, as activated 
PKA mediates phosphorylation of the cAMP responsive element binding protein (CREB) (5; 
6). CREB stimulates AQP2 transcription via the cAMP Responsive Element (CRE) in the 
AQP2 promoter (7; 8).
High levels of AVP leading to hyponatremia with or without hypervolemia occur in several 
diseases, like the syndrome of inappropriate antidiuretic hormone secretion (SIADH), 
congestive heart failure and severe liver cirrhosis (9-11). In these diseases, AQP2 
abundance is increased, indicating that AQP2 plays an important role in the water retention 
in these pathological states (12-14).
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Demeclocycline is a bacteriostatic antibiotic of the tetracycline group, which has been shown 
to cause water diuresis and nephrogenic diabetes insipidus (15; 16). Because of the effect 
on water diuresis, demeclocycline is currently used to treat sustained hyponatremia in 
patients with SIADH (17). Demeclocycline has been shown to restore the sodium plasma 
concentration in SIADH patients to normal levels, permitting unrestricted water intake in 
these patients (18).
Wilson et al. showed that the aquaretic effect of demeclocycline is exerted by selective 
inhibition of the water reabsorption in the distal part of the nephron (19). Others have shown 
that demeclocycine inhibits the AVP-induced osmotic water flow in the toad urinary bladder 
(15; 20; 21), a model system of the mammalian collecting duct. Just like demeclocycline, the 
tetracycline antibiotics minocycline, doxycycline and tetracycline have been shown to reduce 
the water flow in toad bladders (20), and tetracycline has been reported to decrease urinary 
concentrating ability in men (19), suggesting that other tetracycline antibiotics affect 
collecting duct function and urinary concentrating ability as well.




MpkCCD cells were cultured as described previously (22). Cells were seeded at a density of
1.5x105 cells/cm2 on semi-permeable filters (Transwell®, 0.4 .^m pore size, Corning Costar, 
Cambridge, MA) and cultured for 8 days. Unless stated otherwise, the cells were exposed to 
1 nM of the stable AVP analogue dDAVP at the basolateral side for the last 96 hrs, to induce 
AQP2 expression. Tetracycline hydrochloride (Sigma T3383), minocycline hydrochloride 
(Sigma M9511), or demeclocycline hydrochloride (Sigma 30910) were added to the apical 
and basolateral side of the filters for the last 2-24 hours with or without 50 ^M cycloheximide 
or 10 ^M forskolin. At the end of the experiment transcellular electrical resistance was 
measured using a Millicell-ERS meter (Millipore corp., Bedford, MA, USA).
Transfection and generation of a stable mpkCCD cell line with a 3.0 AQP2 promoter- 
luciferase reporter construct was previously described (23).
Immunoblotting
MpkCCD cells from 1.13 cm2 filter were lysed in 200 ^l Laemmli buffer, sonicated and heated 
for 30 min at 37°C. PAGE, blotting and blocking of the PVDF membranes were done as 
described (24). Membranes were incubated for 16 hrs at 4°C with 1:3000-diluted affinity-
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purified rabbit R7 AQP2 antibodies (25), 1:200 anti-adenylate cyclase 3 or 1:200 anti­
adenylate cyclase 5/6 (both gifts from C. Serradeil-Le Gal, Sanofi Recherche, Toulouse, 
France), all in Tris-Buffered Saline Tween-20 (TBS-T) supplemented with 1% non-fat dried 
milk.
Blots were incubated for 1 hr with 1:5000-diluted goat anti-rabbit IgG’s (Sigma, St. Louis, 
MO) as secondary antibody coupled to horseradish peroxidase. Proteins were visualized 
using enhanced chemiluminescence (ECL, Pierce, Rockford, IL). Densitrometric analyses 
were performed using Biorad quantification equipment (Bio-Rad 690c densitometer, 
Chemidoc XRS) and software (QuantityOne). Equal loading of the samples was confirmed by 
subsequent staining of the blots with coomassie blue.
PNGaseF treatment
To 15 ^l cell lysate, 30 ^l Milli-Q water, 5 ^l G7 buffer, 5 ^l NP-40 and 1 ^l PNGaseF were 
added before 1 hr incubation at 37°C. Subsequently 7.5 ^l Laemmli buffer was added before 
proceeding to immunoblotting.
cAMP measurement.
MpkCCD cells were seeded on filters for 8 days, the last 4 days with or without 1 nM dDAVP. 
The last day, the cells were exposed overnight to 50 ^M demeclocycline, followed by 30 min 
of treatment with 0.5 mM phosphodiesterase inhibitor 3-isobutyl 1 methylxanthine (IBMX; 
Sigma, St. Louis, MO, USA). cAMP was measured using the cAMP-Glo assay (Promega, 
Madison, WI, USA) or cAMP enzyme immunoassay kit (Sigma, St. Louis, MO, USA) 
according to manufacturer’s instructions. Results were related to a standard curve based on 
the measurement of defined cAMP solutions done in triplicates.
Luciferase assay
Luciferase activity was measured using the Luciferase Assay System (Promega, Madison, 
WI, USA) according to the manufacturer’s instructions. Luminescence was measured for 10 
seconds using an EG&G Berthold Lumat LB9507 luminometer.
To verify that equal amounts of protein per sample were used for the luciferase assay, 
protein concentration was determined using the BioRad protein assay (München, Germany), 
according to manufacturer’s instructions.
Statistics
Students unpaired t-test was used when two groups with Gaussian distribution were 
compared. For multiple comparisons, Bonferroni correction was applied. A p value of less
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than 0.05 is considered significant. Data are presented as mean and bars are standard error 
of the mean (SEM).
Results
The effect of tetracycline antibiotics on AQP2 expression
The structures of the tetracycline antibiotics demeclocycline, minocycline and tetracycline are 
shown in Fig. 1.
OH O OH O O
Tetracycline
Figure 1. Structures of dem eclocycline, m inocycline and tetracycline
To study the effect of demeclocycline on AQP2 expression, mpkCCD cells were grown for 8 
days, the last 4 days in the presence of 1 nM dDAVP to induce maximal endogenous AQP2 
expression (26). During the last 24 hours, the cells were exposed to different concentrations 
of demeclocycline. Demeclocycline dose-dependently decreased the AQP2 protein 
abundance in mpkCCD cells, setting in at 50 ^M (Fig. 2A). Analysis of the transcellular 
resistance revealed that this varied between 2-3 kOhm until 50 ^M, but that this was 
significantly decreased at 100 ^M (Fig. 2B), indicating that at demeclocycline concentrations 
higher than 50 ^M the cell monolayer was affected.
To investigate whether minocycline and tetracycline also reduce AQP2 expression, mpkCCD 
cells were exposed to different concentrations of these compounds during the last 24 hrs.
122
Effect of demeclocycline on AQP2 expression
Minocycline dose-dependently decreased AQP2, effects setting in at 25 ^M (Fig. 2C). At this 
concentration, the transcellular resistance was not different from lower concentrations, but 
this was again affected at higher concentrations (not shown).
Tetracycline displayed a non-significant (p=0.15) tendency to decrease AQP2 expression at 
100 ^M (Fig. 2D). The transcellular resistance was not affected (not shown).
As demeclocycline is clinically used for its aquaretic action, we used 50 ^M demeclocycline 
concentrations in all following experiments. We investigated the time frame for AQP2 down- 
regulation by demeclocycline and found that the effect was already present after 8 hrs (Fig 
2E). Coomassie labeling secured that loading and overall protein amount were equal among 
all samples.
Effect of demeclocycline on AQP2 transcription
The effect of demeclocycline on AQP2 expression could be caused by a decrease in AQP2 
protein/mRNA synthesis, and/or an increase in degradation. To investigate the involvement 
of protein degradation, cells were incubated with demeclocycline with or without co­
incubation with the protein synthesis inhibitor cycloheximide. In the presence of 
cycloheximide, demeclocycline did not affect AQP2 abundance, whereas demeclocycline still 
decreased AQP2 abundance in control cells (Fig. 3A). These data suggested that 
demeclocycline does not increase AQP2 degradation but affects AQP2 transcription or RNA 
stability.
To further investigate whether demeclocycline reduces AQP2 transcription, pooled colonies 
of mpkCCD cells stably-transfected with a 3.0kb-AQP2 promoter followed by luciferase 
cDNA (pGL3-AQP2-3.0-Iuc) were used. As described before (23), dDAVP increased 
luciferase activity compared to unstimulated cells. Luciferase activity was reduced with 
demeclocycline, indicating that demeclocycline decreases AQP2 transcription (Fig. 3B).
Effect of demeclocycline on cAMP production
Because AQP2 transcription is upregulated by AVP-induced cAMP levels, it was investigated 
whether demeclocycline affects cAMP production. For this, cells were stimulated with dDAVP 
as above, the last 24 hours with or without demeclocycline, and IBMX was added for the last 
30 minutes. As anticipated, dDAVP increased the amount of cAMP, which was about three­
fold (Fig. 4). Co-incubation with demeclocycline decreased the amount of cAMP both in 
unstimulated cells and dDAVP-stimulated cells.
Effect of demeclocycline on adenylate cyclases
cAMP is produced by adenylate cyclases, which are stimulated by AVP-mediated activation
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Figure 2. Effects of tetracycline antibiotic concentrations on the AQP2 protein level in mpkCCD  
cells. A) MpkCCD cells were grown to confluence and exposed to 1 nM dDAVP for 4 days. For the last 
24 hrs the cells were incubated with various concentrations demeclocycline (DM). Cells were lysed and 
subjected to AQP2 immunoblotting. B) Transcellular resistance of cells as described in A. C) Cells 
were grown as described in A. During the last 24 hrs, cells were incubated with various concentrations 
minocycline (Mi). Cells were lysed and subjected to AQP2 immunoblotting. D) Cells were grown as 
described in A. During the last 24 hrs, cells were incubated with various concentrations tetracycline 
(TC). Cells were lysed and subjected to AQP2 immunoblotting. E) Cells were grown as described in A. 
During the last 2-24 hrs cells were incubated with 50 pM demeclocycline. A-E: Molecular masses (in 
kDa) are indicated on the left. Concentrations are in pM. The signals for non-glycosylated and 
complex-glycosylated AQP2 were densitometrically quantified. Mean values of normalized AQP2 
expression per condition are relative to control (+/- SEM). Significant differences (p<0.05) from control 
(-) are indicated by an asterisk.
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Figure 3. Effect of dem eclocycline on AQP2 transcription A) MpkCCD cells were grown to 
confluence and exposed to 1 nM dDAVP for 4 days. For the last 8 hrs the cells were incubated with 
with 50 ^M demeclocycline (DM) with or without cycloheximide. Cells were lysed and subjected to 
AQP2 immunoblotting. Mean values of normalized AQP2 expression per condition are relative to 
control (+/- SEM). B) MpkCCD cells containing a 3.0 kb AQP2-promoter-luciferase construct were 
grown to confluence and exposed to 1 nM dDAVP for 4 days, with or without 50 ^M demeclocycline 
during the last 24 hrs. The cells were lysed and light emission was measured. Data are the mean of 
three samples and relative to control (+/- SEM). Significant differences (p<0.05) are indicated by an 
asterisk.
of the V2R. To determine whether the decreased cAMP levels are due to effects of 
demeclocycline at steps before or directly at adenylate cyclase, mpkCCD-AQP2-3.0-luc cells 
were incubated with or without demeclocycline in the presence or absence of the adenylate 
cyclase activator forskolin for 1 day or dDAVP for 4 days before harvesting. As anticipated, 
both dDAVP and forskolin significantly increased AQP2-promoter driven luciferase activity 
(Fig. 5). While cells exposed to demeclocycline still showed an increased luciferase activity 
with forskolin and dDAVP as compared to unstimulated controls, demeclocycline caused a 
similar decrease in the luciferase activity in all conditions. These results indicate that
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demeclocycline directly affects adenylate cyclase activity instead of affecting V2R or Gs 
stimulation.
We next investigated the effect of demeclocycline on the expression of adenylate cyclase 
(AC) 3 and 6, which have been shown to be expressed in collecting duct principal cells (27­
29). Following exposure to dDAVP for 4 days, demeclocycline application resulted in a 
reduction of AC3 abundance to less than 40% of control levels after 24 hrs, while at 8 hrs a 
slight, but insignificant reduction is already observed (Fig. 6A). Demeclocycline incubation 
also resulted in a small but significant decrease in abundance of AC5/6 after 8 hours, and 
resulted in a decrease to 25% of control levels after 24 hours. Please note that an antibody 
recognizing both AC5 and AC6 was used and that for quantification, samples were treated 
with PNGaseF to remove glycosylation of AC5/6 (Fig. 6B, lower panel).
Discussion
Reduction of AQP2 abundance by tetracycline antibiotics
In this study we show that the tetracycline antibiotic demeclocycline down-regulates the AVP 
regulated water channel AQP2 in a time and concentration-dependent manner in mpkCCD 
cells. Besides demeclocycline, also minocycline decreased AQP2 expression, while only a 
small effect of tetracycline on AQP2 expression was seen.
The decrease in AQP2 expression explains the aquaretic effect of tetracycline antibiotics, 
which was previously shown to effect water reabsorption in the distal part of the nephron and 
the toad urinary bladder, a model system of the mammalian collecting duct (15; 19-21). 
Demeclocycline down-regulated AQP2 in mpkCCD cells at concentrations that are in line 
with those measured in urine from patients (30), indicating that the effect observed are at 











Figure 4. Effect of dem eclocycline on 
cAMP production. MpkCCD cells were 
grown to confluence, incubated with or without 
dDAVP for 4 days and with or without 
demeclocycline (DM) for the last 24 hours. 
During the last 30 minutes, IBMX was added. 
Cells were lysed and cAMP production was 
measured. Bars are mean values of three 
samples (+/- SEM). Significant differences 
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suggest that at 50 demeclocycline there is no decrease in cell viability but still AQP2 
down-regulation. However, the loss of resistance at 100 ^M suggests that the cells are 
seriously affected by demeclocycline at higher concentrations, which is also in line with 
reports on the risk of nephrotoxicity of demeclocycline (31; 32). Minocycline down-regulated 
AQP2 at similar concentrations as demeclocycline, which is in line with the effect of 
minocycline on the water flow seen in toad urinary bladders (20). Overt diabetes insipidus is 
not seen with this agent, probably because minocycline is clinically used in much lower 
doses than demeclocycline (20).
Figure 5. dDAVP-dependence of dem eclocycline-induced AQP2 down-regulation. MpkCCD cells 
containing a 3.0 kb AQP2-promoter-luciferase construct were incubated with or without 4 days 1 nM 
dDAVP, 24 hrs 10 ^M forskolin and/or 24 hrs 50 ^M demeclocycline (DM). The cells were lysed and 
light emission was measured. Data are the mean of three samples (+/- SEM). Significant differences 
(p<0.05) are indicated by an asterisk._____________________________________________________________
In this study we see a small effect of tetracycline on AQP2 expression. Tetracycline has been 
reported to decrease urinary concentrating ability in man as well as in toad urinary bladders, 
however, its effect were clearly smaller than that of demeclocycline (19; 20), which is in line 
with our data and indicating the link between protein levels of AQP2 and aquaretic ability.
Reduced adenylate cyclase abundance and activity explains the diuretic effect of 
demeclocycline
We show that the protein synthesis inhibitor cycloheximide abolishes the effect of 
demeclocycline, implying that a decrease in AQP2 production explains the decrease in AQP2 
abundance. Using an AQP2 promoter-luciferase reporter construct, it was shown that 
demeclocycline decreases AQP2 transcription.
Our results show that demeclocycline down-regulates dDAVP-stimulated AQP2 expression, 
as well as basal and forskolin-stimulated AQP2. As demeclocycline affects forskolin-
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Figure 6. Effect of dem eclocycline on AC expression. A) MpkCCD cells were grown to confluence 
and incubated with 1 nM dDAVP for 4 days, with or without 50 ^M demeclocycline (DM) for various 
time periods. Cells were lysed and subjected to AC3 immunoblotting. B) Cells as described in A were 
subjected to AC5/6 immunoblotting (upper panel). Samples were treated with PNGaseF to remove 
glycosylation and again subjected to AC5/6 immunoblotting (lower panel). Mean values of normalized 
AQP2 expression per condition are relative to control (+/- SEM). Significant differences (p<0.05) from 
control (-) are indicated by an asterisk.____________________________________________________________
stimulated AQP2 expression, this indicates that the effect of demeclocycline is independent 
of V2R receptor or Gs stimulation and seems to be further in the signaling cascade.
A vasopressin independent effect was also suggested by a study of Horattas et al, who 
showed that in patients undergoing surgery, the plasma AVP concentration was increased 
after demeclocycline-treatment, but the effect of AVP on urinary concentrating ability 
decreased (33).
In regard to an effect on intracellular cell signaling, we found a blunting of dDAVP-induced 
cAMP production, which is in line with findings of Dousa and Wilson showing a decreased 
basal and AVP-induced cAMP generation in renal medulla tissue (34). Our results also show 
a decreased expression of both adenylate cyclase 3 and 6 after demeclocycline application, 
which explains the lower cAMP generation.
In conclusion, our data show that the aquaretic effect of tetracycline antibiotics such as 
demeclocycline and minocycline are mediated via down-regulation of the AVP regulated 
water channel AQP2. Demeclocycline decreases AQP2 gene transcription by decreasing 
adenylate cyclase expression and cAMP generation.
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Lithium reduces AQP2 transcription independent of prostaglandins
Abstract
Vasopressin (AVP) stimulated translocation and transcription of aquaporin 2 (AQP2) water 
channels in renal principal cells is essential for urine concentration. 20% of patients treated 
with lithium develop nephrogenic diabetes insipidus (NDI), a disorder in which the kidney is 
unable to concentrate urine. In vivo and in mouse collecting duct (mpkCCD) cells, lithium 
treatment coincides with decreased AQP2 abundance and inactivation of glycogen synthase 
kinase (Gsk) 3p. This is paralleled in vivo by an increased renal cyclooxygenase 2 (COX-2) 
expression and urinary prostaglandin PGE2 excretion. PGE2 reduces AVP-stimulated water 
reabsorption, but its precise role in lithium-induced down-regulation of AQP2 is unclear.
Using mpkCCD cells, we here investigated if prostaglandins contribute to lithium-induced 
down-regulation of AQP2. In these cells, lithium application reduced AQP2 abundance, 
which coincided with Gsk3p inactivation and increased COX-2 expression. Inhibition of COX 
by indomethacin, reducing PGE2 and PGF2a, or dexamethasone-induced down-regulation of 
COX-2 increased AQP2 abundance, while PGE2 addition reduced AQP2 abundance. 
However, lithium did not change the prostaglandin levels, and indomethacin and 
dexamethasone did not prevent lithium-induced AQP2 down-regulation. Further analysis 
revealed that lithium decreased AQP2 protein abundance, mRNA levels and transcription, 
while PGE2 reduced AQP2 abundance by increasing its lysosomal degradation, but not by 
reducing AQP2 gene transcription.
In conclusion, our data reveal that in mpkCCD cells, prostaglandins decrease AQP2 protein 
stability by increasing its lysosomal degradation, indicating that in vivo paracrine produced 
prostaglandins might have a role in lithium-induced NDI via this mechanism. However, 
lithium affects also AQP2 gene transcription, which is prostaglandin independent.
Introduction
The hormone arginine vasopressin (AVP) is secreted from the pituitary gland during states of 
hypernatremia or hypovolemia. AVP binds to the vasopressin type-2 receptor in the 
basolateral membrane of renal connecting tubule and collecting duct principal cells, which 
initiates a signaling cascade that results in the redistribution of aquaporin-2 (AQP2) water 
channels from intracellular vesicles to the apical membrane (1; 2). Driven by an osmotic 
gradient, water will enter principal cells through AQP2 and will exit through AQP3 or AQP4 in 
the basolateral membrane, resulting in concentrated urine. Besides this acute mechanism of 
regulation, chronic AVP stimulation also increases AQP2 expression via phosphorylation of
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the cAMP responsive element binding protein (CREB), thereby stimulating transcription of 
the gene via the cAMP responsive element (CRE) in the AQP2 promoter (3-5).
Lithium is the drug of choice for the treatment of bipolar disorders. It is also used regularly to 
treat schizoaffective disorders as well as depression. In addition, lithium is also under 
consideration as a therapeutic for many diseases including Alzheimer’s disease, AIDS and 
amyotrophic lateral sclerosis (6-8). Lithium is a frequently prescribed drug and is used by 1 in 
1000 of the population (9). Approximately 20% of patients undergoing lithium treatment 
develop symptomatic nephrogenic diabetes insipidus (NDI), a disorder characterized by 
polyuria and polydipsia due to a urinary concentrating defect (10). This makes lithium- 
induced NDI the most common form of NDI.
Studies in rats have shown that lithium-induced NDI occurs in conjunction with AQP2 down- 
regulation (11; 12) and in line with this, lithium treatment reduces urinary AQP2 excretion in 
humans, indicating a decreased renal AQP2 expression (13). Lithium has been shown to 
inactivate glycogen synthase kinase (Gsk) 3p in mice. The development of NDI and 
inactivation of Gsk3p are temporally related to an increased cyclooxygenase-2 (COX-2) 
expression in the kidney, leading to an increased urinary prostaglandin E2 (PGE2) excretion 
(14). As PGE2 reduces AVP-stimulated water reabsorption in the collecting duct (15; 16), this 
could suggest an important role for PGE2 in lithium-NDI development. This is also suggested 
by studies showing that blocking prostaglandin production by indomethacin reduces the urine 
volume of lithium-treated rats (17) as well as of lithium-induced NDI patients (18; 19).
In vitro, mouse collecting duct (mpkCCD) cells are a good model system to study the effects 
of lithium on AVP-induced AQP2 expression. Following induction of endogenous AQP2 
expression, addition of clinically-relevant concentrations of lithium to the apical side caused a 
reduction in AQP2 abundance and resulted in Gsk3p inactivation (20; 21). In the present 
study, we used the mpkCCD model system to gain additional insights into the mechanism 




Mouse mpkCCDcl4 cells were essentially grown as described (22). Cells were seeded at a 
density of 1.5x105 cells/cm2 on semi-permeable filters (Transwell®, 0.4 .^m pore size, Corning 
Costar, Cambridge, MA) and cultured for 8 days. Unless stated otherwise, the cells were 
treated for the last 96 hrs with 1 nM dDAVP to the basolateral side, to maximally induce 
AQP2 expression (20). Cells were incubated with 1 mM lithium chloride at the basolateral
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side and 10 mM lithium chloride at the apical side for the last 24 or 48 hrs. Cells were 
incubated with 20 ^M zinc chloride at both sides of the cells during the last 48 hrs. 1 ^M 
dexamethasone, 10 ^M indomethacin, 1 ^M PGE2 (all from Sigma, St. Louis, MO, USA) or 1 
^M PGF2a (Calbiochem, San Diego, CA) were administered at both sides of the cells during 
the last 48 hours.
Constructs
Transfection and generation of a stable mpkCCD cell line with a 3.0 AQP2 promoter- 
luciferase reporter construct was previously described (23). Transfection and generation of a 
stable mpkCCD cell line with an 0.4 kb AQP2 promoter-luciferase reporter construct as well 
as pGL3-CRE(21)-luc, a construct in which luciferase transcription is driven by a promoter 
existing of 21 tandemly-placed CREs, was described previously as well (23). 
pGL3-AQP2-2.5-luc, containing -2.5 kb till +60 bp of the AQP2 promoter, was made by 
cloning the BglII - blunted SspI fragment of the AQP2 promoter into the BglII - blunted KpnI 
sites of pGL3-AQP2-3.0-luc. pGL3-AQP2-1.7-luc (-1710 till +60) was made by digesting 
pGL3-AQP2-3.0-luc with KpnI, followed by religation. For pGL3-AQP2-1.4-luc, possessing - 
1350 till +60 bp of the AQP2 promoter, a BglII - blunted SphI fragment of the promoter was 
cloned into the BglII - blunted KpnI sites of pGL3-AQP2-3.0-luc. For pGL3-AQP2-1.1-luc (­
1110 till +60), pGL3-AQP2-3.0-luc was cut with BamHI and KpnI, blunted and religated. For 
pGL3-AQP2-0.9-luc (-900 till +60), pGL3-AQP2-3.0-luc was cut with XhoI -  KpnI, blunted 
and religated. For pGL3-AQP2-0.7-luc (-650 till +60 bp) a 0.7 kb AQP2 HincII - BglII fragment 
from the AQP2 promoter was cloned into BglII - blunted KpnI sites of pGL3-AQP2-3.0-luc. 
For pGL3-AQP2-0.2-luc (-220 till +60), pGL3-AQP2-3.0-luc was cut with AatII -  KpnI, blunted 
and religated.
MpkCCD cells were stably transfected using the calcium-phosphate precipitation technique 
as described (24). Transfected colonies were selected with G418 (0.25 mg/ml) and pooled to 
level out differences between individual colonies.
Immunoblotting
MpkCCDcl4 cells from 1.13 cm2 filter were lysed in 200 .^l Laemmli buffer and 15 .^l samples 
were analyzed. PAGE, blotting and blocking of the PVDF membranes were done as 
described (25). Membranes were incubated for 16 hrs with 1:3000-diluted affinity-purified 
rabbit R7 AQP2 antibodies (26), 1:1000 diluted rabbit anti-Ser9-Gsk3p (Cell Signaling 
Technology Beverly, MA, USA), 1:5000 diluted mouse anti-Gsk3p (BD Transduction 
Laboratories; Lexington, KY, USA), 1:1000 diluted mouse anti-COX-2 (Cayman Chemicals, 
Ann Arbor, MI, USA) in Tris-Buffered Saline Tween-20 (TBS-T) supplemented with 1% w/v 
non-fat dried milk. Next, blots were incubated for 1 hr with 1:5000-diluted goat anti-rabbit
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IgG’s or 1:2000 goat anti-mouse IgG’s (Sigma, St. Louis, MO) coupled to horseradish 
peroxidase. Proteins were visualized using enhanced chemiluminescence (ECL, Pierce, 
Rockford, IL). Films were scanned using a Bio-Rad 690c densitometer and signals were 
analyzed using Bio-Rad software. Two-fold dilution series of a control sample was blotted in 
parallel to allow semi-quantification. Equal loading of the samples was confirmed by 
subsequent staining of the blots with Coomassie Brilliant Blue G250 (Serva, Heidelberg, 
Germany)
Luciferase Assay
Luciferase activity was measured using the Luciferase Assay System (Promega, Madison, 
WI) following the manufacturer’s instructions. Luminescence was measured for 10 seconds 
using an EG&G Berthold Lumat LB9507 luminometer.
RT-PCR
MpkCCD cells were grown on semi-permeable filters for 8 days as described above, and 
total RNA was isolated using TriZol extraction reagent (Gibco, Life Technologies, Rockville, 
MD), according to the manufacturer’s instructions. To remove genomic DNA, total RNA was 
treated with DNase (Promega, Madison, WI) in DNase buffer, incubated for 1 hr at 37 °C, 
extracted with phenol/chloroform and precipitated. RNA was reverse-transcribed into cDNA 
using MMLV Reverse Transcriptase and random primers (Promega, Madison, WI). During 
cDNA production, a control reaction without the reverse transcriptase enzyme was 
conducted to exclude amplification of genomic DNA.
SYBR Green Real-time quantitative PCR was performed on an iQ5 Real-Time PCR 
Detection System from Bio-Rad by utilizing the SYBR Green PCR Master Mix (Applied 
Biosystems, Foster City, CA) and primers for the prostaglandin receptors or the mouse 
AQP2 gene. To amplify AQP2 mRNA, primers binding to exon 2 
(CTCCACAACAATGCAACAGC) and exon 3 (GAGCAGCCGGTGAAATAGAT) were used. 
To amplify AQP2 pre-mRNA, the exon 3 primer was used together with an intron 2 primer 
(GGCAGTCTCAGCTGTCCTGA). Primers for prostaglandin receptors were designed to be 
intron overlapping (see Table 1). Signals for the house-keeping gene, which was amplified in 
parallel were used to normalize for differences in the amount of starting cDNA, using either 
primers for p-actin or ribosomal 18S (Table 1).
Prostanoid analysis
Samples were prepared as described (27) with minor modifications. Briefly, cell culture 
supernatants were spiked with ~1 ng of deuterated internal standards, and the methoximes 
were obtained through reaction with an O-methylhydroxylamine hydrochloride-acetate buffer.
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After acidification to pH 3.5, prostanoid derivatives were extracted, and the 
pentafluorobenzylesters were formed. Samples were purified by thin layer chromatography, 
and a broad zone with RF 0.03-0.4 was eluted. After withdrawal of the organic layer, 
trimethylsilyl ethers were prepared by reaction with bis(trimethylsilyl)-trifluoroacetamide and 
thereafter subjected to GC/MS/MS analysis on a Finnigan MAT TSQ700 GC/MS/MS 
(Thermo Electron Corp., Dreieich, Germany) equipped with a Varian 3400 gas 
chromatograph (Palo Alto, CA) and a CTC A200S autosampler (CTC Analytics, Zwingen, 
Switzerland).
Table 1: Overview of prim er sets





ß actin GTATGCCTCTGGTCGTACCAC ACGATTTCCCTCTCAGCTGTG
18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
Results
Effect of lithium on Gsk3 and COX-2
In vivo, lithium treatment has been reported to lead to the inhibition of Gsk3p, which is 
suggested to lead to increased COX-2 abundance and prostaglandin release (14; 28). COX-
1 and COX-2 catalyze the production of prostaglandins (29) and the released prostaglandins 
activate prostaglandin receptors in a paracrine fashion, resulting in reduced AVP-induced 
water permeability in the collecting duct (15; 16; 30; 31).
To test whether a similar response to lithium is seen in mpkCCD cells, these cells were 
grown for 8 days, the last 4 days in the presence of dDAVP to induce AQP2 expression, and 
treated with lithium for the last 48 hrs. As in patients on lithium therapy, the concentration of 
lithium in serum is around 1 mM and around 10 mM in urine (9), cells were treated with 10 
mM at the apical and 1 mM at the basolateral side. While AQP2 levels were decreased with 
lithium, Gsk3p activity was reduced as shown by the increased Ser9-phosphorylation of 
Gsk3p, while the total amount of Gsk3p was unchanged (Fig. 1A). Zinc also inhibits Gsk3p 
activity (32). Therefore we incubated mpkCCD cells with zinc to determine whether inhibition 
of Gsk3p by another metal ion also affects AQP2 abundance. 20 .^M zinc reduced AQP2 
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Figure 1. Effect of lithium on Gsk3 and COX-2 expression. A) MpkCCD cells were grown to confluence and 
treated with 1 nM dDAVP for 4 days. For the last 48 hrs the cells were treated with 20 pM zinc at both sides or 10 
mM lithium at the apical side with 1 mM at the basolateral side. Cells were lysed and subjected to immunoblotting 
for AQP2, total Gsk3p and Ser9-phosphorylated Gsk3p. B) Samples as in A were subjected to COX-2 
immunoblotting. Molecular masses (in kDa) are indicated on the left. The signals were densitometrically 
quantified. Mean values of normalized expression per condition are relative to control (+/- SEM). Significant 
differences (p<0.05) from control are indicated by an asterisk.
changing total Gsk3p expression levels (Fig. 1A). Both lithium and zinc significantly 
increased COX-2 abundance (Fig. 1B).
Effect of COX-2 on AQP2 expression in mpkCCD cells
Dexamethasone decreases COX-2 mRNA and protein abundance in various cell types (33; 
34). Because previous studies have shown that prostaglandins inhibit AVP-induced water 
reabsorption in vivo (15; 16), we investigated whether dexamethasone-decreased COX-2 
expression inversely correlates with AQP2 abundance in mpkCCD cells. Incubation with 1 
^M dexamethasone caused a significant down-regulation of COX-2 and increase of AQP2 
abundance (Fig. 2A). However, dexamethasone did not affect lithium-induced upregulation of 
COX-2 nor down-regulation of AQP2 (Fig. 2A).
To test if indomethacin, which inhibits both COX-1 and COX-2 activity, increases AQP2 
abundance, cells were grown as described above, the last 48 hrs in the presence of 10 .^M 
indomethacin. Even though COX-2 abundance was increased, immunoblotting revealed
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increased AQP2-abundance with indomethacin (Fig. 2B), underscoring the correlation 
between COX activity, prostaglandin release and AQP2 abundance. Interestingly, even in the 
presence of indomethacin, lithium decreased AQP2 abundance and increased abundance of 
COX-2 (Fig. 2B), suggesting that the effect of lithium on AQP2 abundance may not be solely 
generated through prostaglandins, or that indomethacin did not completely block the effect of 
lithium on prostaglandin production.
Involvement of prostaglandins and their receptors in lithium-induced down-regulation of 
AQP2 in mpkCCD cells
COX-1 and 2 catalyze the conversion of arachidonic acid to prostaglandin H2 (PGH2). PGH2 
serves as a substrate for several prostaglandin and thromboxane synthases, which generate 
various prostaglandins and thromboxanes. These newly generated products bind their 
respective G-protein coupled receptors from the extracellular side, and activate their 
respective intracellular signaling pathways (Fig. SA). Since lithium treatment increased COX-
2 abundance, we questioned which prostaglandin could mediate the lithium-induced down- 
regulation of AQP2.
The prostaglandin receptors EP1, EP4, FP and TP could be detected by RT-PCR in 
mpkCCD cells, while results for the IP receptor were inconclusive. The same receptors were 
found after lithium treatment (data not shown). The release of the agonists of these receptors 
was investigated in cells treated with or without lithium, to determine the effect of lithium on 
prostanoid production. MpkCCD cells were grown as above, and incubated with lithium for 
the last 24 hours. The medium was collected and the amounts of prostaglandins were 
determined. Prostaglandin concentrations from fresh medium (before addition to cells) were 
subtracted. In dDAVP-treated cells, the amounts of PGE2 and PGF2a produced were clearly 
above the detection limit, while levels of 6-keto-PGF1a (a stable metabolite of PGI2) and TxB2 
(a stable metabolite of TxA2) were low and close to or similar to the levels detected in fresh 
medium (Fig. SB). There was no significant difference in the concentration of prostaglandins 
released into the apical or basolateral compartment (not shown). The concentrations of 
PGE2, 6-keto-PGF1a, PGF2a and TxB2 were not significantly changed with lithium.
As co-incubation with indomethacin increased AQP2 abundance compared to lithium alone 
(Fig. 2B), we also analyzed prostaglandin levels from cells treated with lithium and 
indomethacin. Compared to lithium-treated cells, indomethacin significantly decreased PGE2 
and PGF2a levels (Fig. SB), suggesting that a reduction of these prostaglandins is involved in 
the attenuating effect of indomethacin on lithium-induced AQP2 down-regulation.
As lithium did not affect prostanoid production in mpkCCD cells, we investigated if a change 
in prostanoid receptor expression could explain the AQP2 down-regulation. The effect of
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Figure 2. Effect of COX-2 on AQP2 expression. A) MpkCCD cells were grown to confluence and 
treated with 1 nM dDAVP for 4 days. For the last 4B hrs the cells were treated with 1 ^M 
dexamethasone with or without lithium. B) MpkCCD cells were grown as in A. For the last 4B hrs the 
cells were treated with 10 ^M indomethacin with or without lithium. For A-B: Cells were lysed and 
subjected to immunoblotting for AQP2 and COX-2. C=control, Li=lithium, D=dexamethasone, 
In=indomethacin.
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lithium on the relative expression of the different prostanoid receptors was analyzed by Q- 
PCR and normalized for the amount of ribosomal 18S. As shown in figure 3C, the expression 
of FP and EP1 receptors was significantly decreased with lithium, while the expression of the 
TP or EP4 receptors was unchanged. As signalling via the FP and EP1 receptors is expected 
to inhibit water reabsorption (31; 35), a down-regulation of these receptors cannot explain the 
decrease in AQP2 expression conferred by lithium.
Effect of lithium on AQP2 transcription
Previously, we showed that lithium decreases AQP2 mRNA levels (20), suggesting an effect 
of lithium on AQP2 transcription and/or mRNA stability. Gene transcription results in the 
formation of a pre-mRNA transcript consisting of introns and exons, which is spliced to 
mRNA within minutes. While pre-mRNA levels are mainly determined by transcriptional 
rates, mRNA levels are regulated by both transcription/splicing and degradation (36). 
Therefore, when lithium affects transcription only, the AQP2 mRNA / pre-mRNA ratio should 
not decrease, but if lithium has an effect on mRNA stability, the relative amount of AQP2 
mRNA would be decreased compared to AQP2 pre-mRNA levels. So, to investigate this, Q- 
RT-PCR was performed on mpkCCD cDNA using primers amplifying AQP2 mRNA (exon 2 
and 3 primer) and pre-mRNA (intron 2 and exon 3 primer). Following 4 hours of lithium 
treatment, AQP2 pre-mRNA was decreased to 40% of control levels, whereas a non­
significant decrease in AQP2 mRNA levels was observed (Fig 4A). After 6 hours, both AQP2 
mRNA and pre-mRNA were decreased to 30-40%, which was sustained until at least 24 
hours. Together, these data reveal that lithium reduces AQP2 mRNA levels by reducing 
AQP2 gene transcription and not by reducing AQP2 mRNA stability.
If lithium affects AQP2 transcription, one would also expect that the production of an AQP2 
irrelevant transcript driven by the AQP2 promoter would show reduced expression after 
lithium treatment. To test this hypothesis, mpkCCD cells were stably transfected with pGL3- 
AQP2-3.0-luc, a construct containing luciferase cDNA under control of a 3 kb fragment of the 
mouse AQP2 promoter, generating mpkCCD-AQP2-luc cells. Moreover, mpkCCD-luc cells 
were generated as a negative control, by stably transfecting the luciferase construct lacking 
the AQP2 promoter (pGL3-luc). Pooled colonies were seeded on filters and grown with or 
without dDAVP for the last 4 days and treated with or without lithium during the last 48 hours. 
Basal luciferase activity was around 100 times lower in mpkCCD-luc cells compared to 
mpkCCD-AQP2-luc cells (Fig. 4B). Moreover, dDAVP application significantly increased 
luciferase activity in mpkCCD-AQP2-luc, but not mpkCCD-luc cells, revealing that dDAVP 
efficiently stimulates transcription from the 3.0 kb AQP2 promoter. Importantly, lithium 
significantly decreased the dDAVP-induced luciferase activity in mpkCCD-AQP2-luc cells to 
about 60%, which underscores our data above that lithium reduces AQP2 gene transcription.
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Figure 3. Effect of lithium on prostaglandin production in mpkCCD cells A) COX converts 
arachidonic acid to PGH2. PGH2 is subsequently metabolized to five major prostaglandins through 
their respective synthases. These prostaglandins act on their specific receptors: PGD2 receptor (DP), 
PGE2 receptor (EP) 1-4, PGF2a receptor (FP), PGI2 receptor (IP) and the thromboxane A2 receptor 
(TP). B) mpkCCD cells were grown to confluence and treated with 1 nM dDAVP for 4 days. For the 
last 24 hrs the cells were treated with 10 mM lithium with or without 10 pM indomethacin. Medium was 
collected and prostaglandin concentrations were determined. C) mpkCCD cells were grown as in A, 
the last 24 hours with or without lithium. By quantitative RT-PCR the relative expression of the 
prostaglandin receptors was analyzed. B-C: Bars are mean values of at least three samples (+/- 
SEM). Significant differences (p<0.05) from control are indicated by an asterisk. C=control, Li=lithium, 
In=indomethacin.
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Figure 4. Effect of lithium on AQP2 transcription A) MpkCCD cells were grown to confluence and 
treated with 1 nM dDAVP for 4 days and with 10 mM lithium for various time periods. RNA was 
isolated and Q-PCR was performed, using exon-primers, detecting the AQP2 mRNA (M), and an 
intron and exon primer pair, to detect the unspliced pre-mRNA (P). The signals obtained from the 
house-keeping gene P-actin, were used to normalize for difference in the amount of starting cDNA. 
Mean values are relative to control (+/- SEM). B) MpkCCD cells containing a 3.0 kb AQP2-promoter- 
luciferase construct or a control construct without promoter were grown to confluence and treated with 




Effect of prostaglandins on AQP2 transcription
As lithium reduces AQP2 transcripton of the 3 kb fragment of the promoter, this establishes 
a model system to further study the transcriptional mechanisms leading to AQP2 down- 
regulation by lithium. To test whether lithium-induced reductions in AQP2 transcription result
from the release of prostaglandins, mpkCCD- 
AQP2-luc cells were grown without or with 
dDAVP for 4 days, and incubated for the last 
48 hours with or without indomethacin, PGE2 
or PGF2a. dDAVP application again 
significantly increased luciferase activity (Fig. 
5A). Indomethacin, however, did not further 
increase the luciferase activity, and PGE2 or 
PGF2a application did not reduce luciferase 
activity, which suggests that prostaglandins 
do not affect AQP2 transcription. In addition 
to these prostaglandins, incubation with 
PGD2, the PGI2 analogue carbacyclin, or the 
thromboxane analogue U4661 did not reduce 
luciferase activity (data not shown).
To establish whether the effect on luciferase 
expression mimics the effect on AQP2 mRNA 
levels, Q-RT-PCR assays were done. 
Consistent with the data above, AQP2 mRNA 
levels were not changed with PGE2 or PGF2a 
or indomethacin, while the lithium control
Figure .5- Efle c  ,?f , pr??ag!andinf  0n AQP2 showed a clear reduction in mRNA (Fig 5B). transcription A) MpkCCD cells containing a 3.0
kb AQP2-promoter-luciferase construct were The absence of any effect of prostaglandins 
grown to confluence and treated with or without 1
nM dDAVP for 4 days, with or without on AQP2 mRNA levels indicated that they
¡n^m^acm , P G E 2 or PGF2a during the last 48 reduce AQP2 abundance by affecting AQP2 hrs. Cells were lysed and light emission was
measured. B) MpkCCD cells were grown to protein stability. In mpkCCD cells, chemical 
confluence and treated with 1 nM dDAVP for 4
days and with lithium, indomethacin, PGE2 or messengers like ATP and d°pamine
PGF2a during the last 48 hrs. RNA was isolated counteract vasopressin-induced AQP2 and Q-PCR was performed, using AQP2 mRNA
primers. The signals obtained from the 18S were abundance by targeting it for lysosomal 
used to normalize for difference in the amount of
starting cDNA. A-B: Data are the mean of three degradation, which can be blocked wrth the
samples and relative to contro| (+/- SEM). inhibitor chloroquine (37). Therefore, to test Significant differences (p<0.05) are indicated by
an asterisk. the effect of prostanoids on AQP2 stability
146
Lithium reduces AQP2 transcription independent of prostaglandins
directly, cells were incubated with dDAVP 
for 4 days of which the last day with or 
without lithium or PGE2, all in the 
presence or absence of the lysosome 
inhibitor chloroquine. Immunoblotting 
revealed that, in contrast to lithium, PGE2 
addition did not decrease AQP2 
abundance in the presence of chloroquine 
(Fig. 6). Both lithium and PGE2 reduced 
AQP2 abundance in the absence of 
chloroquine.
Together, these data reveal that 
prostaglandins reduce the dDAVP- 
induced AQP2 abundance solely by 
increasing lysosomal degradation of 
AQP2. This indicates that the effect of 
lithium on AQP2 transcription is mediated 
independently of prostaglandins.
Mapping of the AQP2 promoter segments 
involved in the inhibitory effect of lithium
on AQP2 transcription Figure 6. Effect of chloroquine on AQP2
abundance. mpkCCD cells were grown for 8 days 
To further investigate how lithium affects and treated with 1 nM dDAVP for 4 days and with 
x x- x r ■ l l lithium or PGE2 during the last 24 hrs, all with orAQP2 sites of interest were without chloroquine. Cells were lysed and subjected
determined. It is well-known that the CRE, to immunoblotting foi" AQp2. Molecular masses (in
kDa) are indicated on the left. Data are the mean of 
which localizes at -210 in the mouse three samples and relative to control (+/- SEM).
Significant differences (p<0.05) are indicated by an 
asterisk. C=control, Li=lithium, P= PGE2.AQP2 promoter, is essential for dDAVP- 
induced AQP2 transcription (4; 38).
Moreover, Gsk3 has been shown to phosphorylate CREB at Ser129, increasing the 
transcriptional response to cAMP in PC12 and F9 cells (39). To directly analyse the effect of 
lithium on the CRE element in mpkCCD cells, pooled colonies were made of mpkCCD cells 
stably transfected with pGl3-CRE(21), a luciferase reporter construct, driven by a promoter 
consisting of 21 CREs in a row. dDAVP application resulted in a significant increase in CRE- 
mediated luciferase activity in mpkCCD cells, consistent with an increase in cAMP and 
CREB activity (Fig. 7). Co-incubation with lithium, however, did not affect this dDAVP- 
induced increase. As endogenous AQP2 abundance was reduced by lithium (not shown),
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Figure 7. CRE-dependence of lithium- 
induced AQP2 down-regulation. MpkCCD 
cells containing a CRE-luciferase construct 
were treated with or without 1 nM dDAVP or 10 
mM lithium for the last 24 hours. The cells were 
lysed and light emission was measured. Data 
are the mean of three samples (+/- SEM). 
Significant differences (p<0.05) are indicated by 
an asterisk.
Con dDAVP dDAVP + Li
To identify the segment(s) in the AQP2 promoter that are responsible for the reduced AQP2 
transcription with lithium, mpkCCD cells were stably transfected with luciferase reporter 
constructs with AQP2 promoter segments ranging from 3.0 till 0.2 kb upstream from the 
transcription start site. dDAVP treatment resulted in a significant increase in luciferase 
activity in all cells, except cells transfected with a 0.2 kb promoter, which lacks the CRE (Fig. 
8). Interestingly, lithium decreased the basal luciferase activity to about 70% of control in all 
constructs, and, in cells responsive to dDAVP stimulation, reduced dDAVP-stimulated activity 
to unstimulated levels (40 -  50% reduction). In cells transfected with the 0.2 kb promoter 
segment, dDAVP reduced AQP2 promoter-driven transcription by nearly 60%, which was 
further reduced to 70% with additional lithium. These results indicated that the putative 
lithium-sensitive promoter segments are within the most proximal 200 bp.
Discussion
mpkCCD cells as a model system to study lithium-induced regulation of AQP2 expression 
Our data reveal that mpkCCD cells are a proper model to study lithium-induced changes in 
AQP2 expression. The 1 mM lithium used at the basolateral side in our experiments is similar 
to serum lithium levels found in patients, which are generally between 0.6 and 1.5 mM (9). 
From the cortex to the medulla of the collecting duct, lithium is concentrated as 
micropuncture studies in rats showed an increased lithium concentration in the early distal 
nephron and a more severe increase in the final urine (40). Also, in lithium-treated patients, 
lithium concentrations of 10-15 mM are found in their urine (41; 42). Collecting duct 
concentrations of lithium may thus vary between 1 mM in the cortex to 10-15 mM in the 
medulla. Based on these in vivo concentrations, we chose to use 10 mM lithium at the apical 
side in our experiments.
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Figure 8. AQP2 promoter part involved in the lithium-response. MpkCCD cells containing an 
AQP2-promoter of various lengths (in kb) followed by luciferase cDNA were treated with 1 nM dDAVP 
for 4 days, with or without 10 mM lithium for the last 24 hours. After harvesting, luciferase activity was 
determined. Mean values of luciferase activity (+/- SEM) were determined from three independent 
filters per condition. Significant differences (p<0.05) from control are indicated by *, significant 
differences from dDAVP are indicated with #.
First, we show that incubation of the cells with lithium at these clinically relevant 
concentrations did lead to a down-regulation of AQP2. This is in agreement with our previous 
studies (20; 21) and consistent with AQP2 down-regulation observed in vivo in lithium-NDI 
rats (11; 12; 21). In this study, we further show that the AQP2 down-regulation coincides with 
inactivation of Gsk3p, in agreement with previous studies in lithium-NDI mice (14) and 
mpkCCD cells (21).
We furthermore show that Gsk3 inactivation coincides with an increased abundance of COX-
2, which is consistent with previous in vivo effects of Gsk3 on COX-2 (28) as well as the 
observed increase in COX-2 abundance observed in lithium-NDI mice (14). In addition, we 
show that changes in COX-2 expression or activity influence AQP2 abundance in mpkCCD 
cells, as shown by the administration of both dexamethasone, leading to specific down- 
regulation of COX-2 (43), or indomethacin, blocking both COX-1 and COX-2 (44). Similarly, 
treatment with a COX-2 inhibitor increases AQP2 abundance in rats with lithium-induced NDI 
or bilateral ureteral obstruction (17; 45).
Although COX-2 is highly expressed in renal interstitial cells (14; 46) it is at present 
controversial whether COX-2 is also expressed in collecting duct cells. While 
immunohistochemistry reveals strong COX-2 expression in the collecting duct in three 
studies (47-49), absence of it was suggested in three other studies (50-52). Using collecting 
ducts isolated from AQP2-GFP transgenic mice, Ye et al. recently showed a 10 times lower 
expression of COX-2 mRNA in collecting duct cells compared to kidney cells not originating
149
Chapter 7
from collecting ducts (53), suggesting constitutive COX-2 expression is low. Increased COX- 
2 levels, however, have been detected in collecting ducts of animals that were dehydrated or 
subjected to a chronic NaCl load (47; 49) indicating that COX-2 expression in collecting duct 
cells is increased under stress conditions. This suggests that COX-2 expression may also by 
induced in collecting duct cells during lithium treatment. Besides COX-2, COX-1 is highly 
expressed in the collecting duct (46).
The major prostaglandins produced in mpkCCD cells were PGE2 and PGF2a. In line with 
PGE2 and PGF2a being produced in mpkCCD cells, PGE2 and PGF2a have been shown to be 
mainly produced in the collecting ducts, being highest in the medulla (54).
Lithium treatment does not increase prostaglandin production in mpkCCD cells 
Since the abundance of COX-2 increased after treatment with lithium, we investigated which 
of the COX-derived compounds could mediate the lithium-induced down-regulation of AQP2. 
However, the lithium-induced increase in COX-2 abundance did not result in elevated 
prostaglandin levels in media of mpkCCD cells. This absence of increase in prostaglandins 
may be due to a lack of free arachidonic acid, which is rate-limiting in the production of 
prostaglandins (55-58).
Blocking COX by indomethacin increased AQP2 abundance in cells treated with or without 
lithium, suggesting that also in cells without lithium, AQP2 abundance is decreased by the 
action of endogenously produced prostaglandins. Indomethacin significantly reduced 
released PGE2 and PGF2a levels, but did not affect 6-keto-PGF1a (a stable metabolite of 
PGI2) or TxB2 (a stable metabolite of TxA2) levels, suggesting that a reduction of PGE2 
and/or PGF2a is involved in the attenuating effect of indomethacin on lithium-induced AQP2 
down-regulation.
However, as no effect of lithium on prostaglandin production was found in mpkCCD cells, this 
suggested that the effect of lithium on AQP2 expression in these cells occurs independently 
of prostaglandins. This is also suggested by the observation that, although indomethacin 
blocked COX activity leading to reduced prostaglandin production, it did not prevent the 
lithium-induced down-regulation of AQP2.
Dexamethasone reduces COX-2 abundance by decreasing COX-2 mRNA stability by 
inhibiting p38 (33). Interestingly, lithium did completely block the effect of dexamethasone on 
COX-2 expression, which suggests cross-talk between the p38 pathway and the Gsk3p- 
NFkB mediated effect on COX-2 transcription, or a direct effect of lithium on p38 activity.
The absence of a lithium-induced increase in PGE2 production in our cells illuminates a 
difference from in vivo, because in vivo lithium leads to a large increase in PGE2 production 
(14). This difference is likely due to the fact that in vivo, the lithium-induced increase in
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prostaglandins is thought to be derived from the interstitial instead of principal cells (14). In 
line with the beneficial effects of COX-2 inhibition on AQP2 abundance in lithium-NDI rats 
(17), however, addition of PGE2 to mpkCCD cells leads to AQP2 down-regulation.
Lithium decreases expression of the EP1 and FP receptors in mpkCCD cells 
Expression of EP1, EP4, FP, IP and TP receptors was detected in mpkCCD cells, while no 
expression was seen of the DP, EP2 and EP3 receptors. Of the prostaglandin receptors 
found to be expressed the EP1, FP and TP receptors couple to pathways counteracting the 
vasopressin-induced Gs-cAMP pathway. TP receptors are unlikely to be involved in AQP2 
down-regulation under normal circumstances, as TxA2 levels produced are low and 
indomethacin, leading to increased AQP2 abundance, does not reduce TxA2 production. 
Application of lithium decreased the expression of FP and EP1 receptors. However, as 
signalling via these receptors is expected to inhibit water reabsorption (31; 35), a down- 
regulation of these receptors cannot explain the decrease in AQP2 expression conferred by 
lithium, and may instead be a compensatory mechanism.
In agreement with the expression in mpkCCD cells, collecting duct cells express EP1, EP4, 
FP and TP receptors and lack DP and EP2 receptors (35; 59-61). While expression of the IP 
receptor in mpkCCD cells is inconclusive, also this receptor is found in the collecting duct 
(62). In contrast to the mpkCCD cells, however, the EP3 receptor, which couples to the AVP- 
counteracting Gi pathway, is also expressed in collecting ducts, and may thus, besides EP1 
and FP receptors, be involved in prostaglandin-dependent down-regulation of AQP2 in vivo. 
Conclusive evidence for the roles of particular prostaglandin receptors in mediating a 
prostaglandin-induced down-regulation of AQP2 in lithium-induced NDI awaits studies using 
collecting duct specific knockout of these receptors.
Lithium decreases AQP2 transcription independently of prostaglandins 
PGE2 application to mpkCCD cells reduced AQP2 abundance, in line with the inhibitory effect 
of PGE2 on AVP-stimulated water absorption in the collecting duct (15; 16). This 
prostaglandin-induced AQP2 down-regulation could be prevented by co-incubation with the 
lysosome inhibitor chloroquine, showing that the effect of prostaglandins on AQP2 
abundance is mediated by increasing AQP2 degradation. Interestingly, and in contrast to 
lithium, addition of PGE2 or PGF2a did not decrease AQP2 transcription or mRNA 
abundance. In line with this, indomethacin, blocking prostaglandin production, increased 
dDAVP-stimulated AQP2 protein abundance, but did not increase AQP2 transcription or 
mRNA levels. In agreement with previous results (20), we here found that lithium does not 
affect AQP2 degradation, but decreases AQP2 mRNA by decreasing AQP2 gene
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transcription. Our results show that that the lithium-sensitive AQP2 promoter segment is 
within the most proximal 200 bp.Together, these data indicate that in vivo the reduction of 
AQP2 abundance by lithium consists of at least two parts, being an increased AQP2 
degradation due to increased prostaglandin levels and a reduction of AQP2 gene 
transcription due to a prostaglandin-independent effect of lithium.
A limitation of our cell model is the absence of the EP3 receptor, which is found in vivo in the 
collecting duct. EP3 activation inhibits cAMP generation via Gi (35), and might therefore 
inhibit AVP-stimulated AQP2 transcription by decreasing CRE-mediated transcription. 
Although this might contribute to the AQP2 down-regulation, earlier studies show no 
decrease in cAMP after lithium treatment in vivo (20), suggesting that an in vivo effect of 
lithium on AQP2 transcription is EP3-independent.
Model of lithium-induced NDI
Based on the present and earlier data, we propose the following model (Fig. 9): lithium leads 
to AQP2 down-regulation in the principal cells, and, on the long term, to an increase in 
apoptosis as well as proliferation, resulting in a decreased fraction of principal cells (63-65). 
Lithium reduces AQP2 abundance through two mechanisms: at first, lithium enters renal 
medullary interstitial cells and, possibly, renal principal cells resulting in increased production 
of PGE2 (14; 66). Lithium entry in principal cells occurs through the epithelial sodium channel 
ENaC (21; 67), but the entry pathway of interstitial cells is unknown. In either cell type, this 
leads to inactivation of Gsk3p, which increases the abundance of COX-2 (14; 28) and 
release of prostaglandins. The increase in COX-2 expression has been reported to occur in 
the interstium in vivo (14), suggesting that the increased urinary PGE2 excretion is 
predominantly due to the medullary interstitial cells. The released prostaglandins are 
detected by prostaglandin receptors on principal cells leading to lysosomal degradation of 
AQP2 and a decline in urine concentrating ability.
Secondly, lithium decreases AQP2 abundance by reducing AQP2 gene transcription. The 
ENaC-mediated entry of lithium in principal cells leads to inactivation of Gsk3p (14; 21). In 
line with an important role of Gsk3p in AQP2 expression, other Gsk3p inhibitors also lead to 
a down-regulation of AQP2 expression in mpkCCD cells (21). The effect on transcription is 
prostaglandin independent, and is likely a consequence of inhibition of one of multiple 
pathways steered by Gsk3p, like signaling involving the transcription factors Nuclear factor of 
activated T-cells (NFAT), p-catenin, or hypoxia-inducible factor (HIF). The effect of lithium on 
AQP2 transcription is independent of cAMP levels or CRE, and involves the most proximal 
200 bp of the AQP2 promoter. This decreased AQP2 transcription will result in a further 
decline of the AQP2 abundance and of the urine concentrating ability.
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Figure 9. Model of the lithium-induced inhibition of AQP2-mediated water reabsorption.
Indicated are adenylate cyclase (AC), aquaporin-2 (AQP2), vasopressin (AVP), cyclic adenosine 
monophosphate (cAMP), cyclooxygenase-2 (COX-2), cAMP responsive element binding protein 
(CREB), Diacylglycerol (DAG), epithelial sodium channel (ENAC), prostaglandin E2 (PGE2), protein 
kinase A (PKA), protein kinase C (PKC), phospholipase C (PLC), prostaglandin receptor (PR), 
vasopressin V2 receptor (V2R). For details, see text.
In conclusion, our data show that in mpkCCD cells, lithium decreases AQP2 protein 
abundance as well as AQP2 gene transcription. Lithium decreases AQP2 transcription 
independently of the endogenous prostaglandin production in mpkCCD cells. Our data 
furthermore show that in mpkCCD cells, released prostaglandins decrease AQP2 protein 
stability by increasing its lysosomal degradation. Based on these observations, in vivo 
paracrine produced prostaglandins might have an additional role in lithium-induced NDI by 
decreasing AQP2 protein stability, without affecting AQP2 transcription. Such an effect would 
currently be difficult to adequately separate from the ‘direct’ effect of lithium on AQP2 
transcription and abundance in the intact animal. The two identified pathways leading to a 
decrease in AQP2 abundance might also have consequences for the clinical treatment of 
lithium-NDI. Both COX inhibitors and the ENaC blocker amiloride have been shown 
to individually reduce the NDI phenotype (18; 19; 68-70). However, since the effect of lithium 
on prostaglandin production in interstitial cells could be blocked by COX inhibitors, and the 
entry of lithium into the principal cells could be blocked by amiloride treatment, a beneficial 
effect of combining these two therapies for the treatment of lithium-NDI could potentially 
improve the treatment of lithium-NDI in the clinic. Future studies in humans addressing such 
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Amiloride attenuates lithium-induced NDI
Abstract
Lithium therapy frequently induces Nephrogenic Diabetes Insipidus (NDI) which coincides 
with a decreased aquaporin-2 (AQP2) expression and principal/intercalated cell ratio. 
Amiloride reduces lithium-NDI in some clinical case studies, but the mechanism is poorly 
understood. As amiloride blocks the epithelial sodium channel (ENaC) located in the apical 
membrane of principal cells, we hypothesized that ENaC is the main entry site for lithium and 
that amiloride may be beneficial by blocking lithium entry. Indeed, in a mouse collecting duct 
cell line (mCCDc11), the vasopressin-induced AQP2 expression was time- and dose- 
dependently reduced by clinically-relevant lithium concentrations, which could be prevented 
by co-incubation with amiloride or benzamil. Consistently, amiloride reduced transcellular 
lithium transport, the intracellular lithium concentration and lithium-induced inactivation of 
glycogen synthase kinase 3p. In vivo, simultaneous treatment of rats with amiloride 
attenuated the AQP2 down-regulation, reduction of principal/intercalated cell ratio and NDI 
phenotype compared to rats treated with lithium only.
In conclusion, we demonstrate in vitro and in vivo that ENaC is the major entry site for lithium 
in principal cells and that blocking lithium entry with amiloride attenuates lithium-NDI by 
preventing AQP2 down-regulation and the change in principal/intercalated cell ratio. As such, 
our data provide a rationale for the use of amiloride as a treatment for lithium-NDI.
Introduction
Lithium is regularly used to treat psychiatric diseases, such as bipolar disorders, 
schizoaffective disorders and depression. Lithium is prescribed to 0.1% of the population (1). 
Approximately 20% of patients develop nephrogenic diabetes insipidus (NDI), a disorder 
characterized by polyuria and polydipsia due to renal insensitivity to the antidiuretic hormone 
arginine vasopressin (AVP) (2). Therewith, lithium-NDI is the most common form of NDI. 
Lithium-NDI patients are at risk for dehydration-induced lithium toxicity, and prolonged lithium 
treatment might lead to end stage renal disease (1). However, since the symptoms of the 
underlying psychiatric disorder have a high impact on the quality of life, cessation of lithium 
therapy is not an option for most patients.
The kidney is the main organ for regulating water homeostasis. In states of hypernatremia or 
hypovolemia, AVP is released from the pituitary gland. Binding of AVP to the vasopressin 
type-2 receptor in the basolateral membrane of renal collecting duct principal cells results in 
the redistribution of aquaporin-2 (AQP2) water channels from intracellular vesicles to the 
apical membrane. Driven by an osmotic gradient, water will enter principal cells through
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AQP2 and will exit through AQP3 or AQP4 in the basolateral membrane, resulting in 
concentrated urine. Besides this short-term regulation, AVP also exerts a long-term 
regulation by increasing AQP2 expression (3).
From studies in rats, it became clear that lithium-NDI develops in two stages. At the short 
term (10 days), lithium-NDI coincides with AQP2 down-regulation and natriuresis, without 
gross changes in renal morphology (4-6). Chronic lithium treatment (4 weeks), however, also 
leads to a severe decrease in the fraction of principal cells. This is ‘compensated’ by an 
increase in the fraction of intercalated cells, which are involved in acid/base balance 
regulation (7; 8).
At present, it is unclear how lithium causes NDI and whether lithium-NDI can be attenuated. 
Some data, however, suggest that lithium may exert its effects by entering principal cells 
through the epithelial sodium channel, ENaC. First, NDI is due to an impaired water 
reabsorption in the connecting tubules and collecting ducts principal cells (9), where ENaC is 
expressed (10). Secondly, ENaC has a higher permeability for lithium than for sodium (11). 
Thirdly, lithium inhibits amiloride-sensitive sodium reabsorption in the toad urinary bladder 
and rat collecting duct, tissues known to express ENaC (12-14), and the ENaC-blocker 
triamterene increases lithium excretion (15). Moreover, it was shown in a limited number of 
lithium-NDI patients that blocking ENaC with amiloride significantly reduces urine volume and 
increases urine osmolality (16-18). The decreased urine volume is classically explained by 
an amiloride-induced hypovolemia followed by an increased proximal sodium and water 
retention. The increased urine osmolality was suggested to be caused by an amiloride- 
induced reduction of sodium reabsorption (16; 17).
Based on the above, we hypothesized that lithium enters principal cells through ENaC and 
that blocking ENaC by amiloride would reduce cellular entry of lithium, AQP2 down- 




Mouse mCCDc11 and mpkCCDcl4 cells were essentially grown as described (19; 20). Cells 
were seeded at a density of 1.5x105 cells/cm2 on semi-permeable filters (Transwell®, 0.4 pm 
pore size, Corning Costar, Cambridge, MA) and cultured for 8 days. Unless stated otherwise, 
the cells were incubated with 1 nM dDAVP to the basolateral side for the last 96 hrs, to 
induce AQP2 expression. Lithium and zinc chloride were administered as indicated. 10 pM of 
amiloride or benzamil, concentrations specifically blocking ENaC (21; 22), were administered
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to the apical side, unless indicated otherwise. BIO-Acetoxime (Calbiochem) was used as 
indicated. Medium with reduced sodium concentrations was made identical to the standard 
medium except that lower amounts of NaCl were added.
Lithium assays
For determination of transcellular lithium transport, mCCDcn cells were grown on 1.13 cm2 
filters. After 24 hrs incubation with 10 mM lithium in the presence or absence of amiloride at 
the apical side, the basolateral and apical media were collected and the lithium 
concentrations were determined with a flame photometer (Eppendorf 6341, Hamburg, 
Germany).
Determination of intracellular lithium concentrations was essentially as described (23). 
Shortly, mCCDc11 cells were grown on 4.7 cm2 filters. To determine the extent of lithium 
contamination from the extracellular side, fluorescein isothiocyanate dextran (FITC-dextran) 
was added to the lithium-containing medium to a final concentration of 10 ^M just before 
harvesting, after which the medium was mixed. Then, the filters were washed three times 
with isoosmotic sucrose (pH 7.3) at 4°C and cells were lysed by sonication in 1 ml Milli-Q 
water. Of 800 .^l sample, the amount of lithium was determined by flame photometry, from 
which the total amount of lithium in the sample was calculated.
Of 100 .^l sample, the amount of FITC-dextran was measured using spectrofluorophotometry 
(Shimadzu RF-5301, Japan) at 492 nM (excitation) and 518 nm (emission) wavelengths. By 
comparing the obtained values with a two-fold FITC-dextran dilution series, the FITC-dextran 
concentration in each sample was determined, from which the extent of extracellular Li+ 
contamination was calculated and subtracted from the total amount to obtain the intracellular 
lithium amount. With the used FITC-dextran concentration, a contamination above 1:5000 
would be detected. To correct for differences in cellular yield, the intracellular lithium amounts 
were normalized for the protein amount in each sample, which was determined using the 
Biorad Protein Assay (Munchen, Germany). The intracellular lithium concentration (in mM) 
was estimated by calculating the cellular water content, based on the assumption that 20% of 
the cell weight consists of cellular proteins and the remaining 80% is water (24).
Experimental animals
Male Wistar rats, 200-300 g, were obtained from the Animal Facility of the RUNMC. Rats 
were treated with lithium as described (5).
Control rats received normal rodent diet (ssniff® R/M-H V1534, ssniff Spezialdiaten GmbH, 
Germany. n=6). For lithium therapy, lithium chloride was added to the chow to give a 
concentration of 40 mmol/kg for the first week and 60 mmol/kg dry food for the next 3 weeks.
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Rats were then sacrificed (n=6). For amiloride treatment, amiloride was added to the lithium 
chow to a concentration of 200 mg/kg dry food for the entire 4 weeks (n=7). All rats had free 
access to water, food, and a sodium-chloride block (7). For the last 48 hrs of the experiment, 
the rats were housed in metabolic cages in order to measure water intake and urine output 
during the last 24 hours. All animal experiments were approved by the Animal Experiments 
Committee of the RUNMC.
Tissue preparation
Rats were anaesthetized with isofluorothane after which their blood was removed by heart 
puncture. Then, the rats were killed by cervical dislocation and the kidneys rapidly removed. 
One kidney was fixed for immunohistochemistry by immersion in 1% (wt/vol) periodate- 
lysine-paraformaldehyde for 2 hrs and 15% (wt/vol) sucrose in PBS overnight, while of the 
other kidney, the inner medulla, outer medulla and cortex were dissected for immunoblotting 
as described (25).
Blood and urine analyses
Blood serum was prepared by 16 hr incubation at 4°C, followed by centrifugation at 600 g for 
2-3 min. Urine was centrifuged at 4000 g for 5 min to remove sediment. Both serum and 
urine samples were analyzed for osmolality, sodium and lithium concentrations by standard 
procedures of the General Clinical Chemical laboratory of the RUNMC.
Immunoblotting
mCCDc11 cells from 1.13 cm2 filter were lysed in 200 .^l Laemmli buffer and 15 ^l samples 
were analyzed, while 5-10 .^g of kidney material was analyzed. PAGE, blotting and blocking 
of the PVDF membranes were done as described (26). Membranes were incubated for 16 
hrs with 1:3000-diluted affinity-purified rabbit AQP2 antibodies (27), 1:2000-diluted affinity- 
purified rabbit anti-v1 H-ATPase antibodies (gift from Dr. S. Nielsen, Denmark), 1:1000 
diluted rabbit anti-Ser9-Gsk3p (Cell Signaling Technology), 1:5000 diluted mouse anti-Gsk3p 
(BD Transduction Laboratories) or 1:100,000 diluted mouse anti-tubulin antibodies (gift from 
Dr. Kreis, Switzerland), in Tris-Buffered Saline Tween-20 (TBS-T) supplemented with 1% 
non-fat dried milk. ENaC detection was done as described (19). Blots were incubated for 1 hr 
with 1:5000-diluted goat anti-rabbit IgG’s or 1:2000 goat anti-mouse IgG’s (Sigma, St. Louis, 
MO) as secondary antibodies coupled to horseradish peroxidase. Proteins were visualized 
using enhanced chemiluminescence (ECL, Pierce, Rockford, IL). Films were scanned using 
a Bio-Rad 690c densitometer and signals were analyzed using Bio-Rad software. Two-fold 
dilution series of the respective proteins were blotted in parallel to allow semi-quantification.
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Equal loading of the samples was confirmed by parallel immunoblotting for tubulin or staining 
of the blots with coomassie blue.
immunohistochemistry
Immunohistochemical staining was performed on 7-^m sections of fixed frozen kidney 
samples, following antigen retrieval. The sections were blocked in goat serum dilution buffer 
(GSDB: 16% goat serum, 0.3% triton X-100, 0.3M NaCl in PBS) for 30 min and incubated for 
16 hours at 4°C with rabbit anti-a4 H-ATPase antibodies (1:3000, provided by Dr. F Karet, 
United Kingdom). Following washes and incubation with Alexa 488-conjugated goat anti­
rabbit antibodies, the sections were incubated with 1:50 diluted affinity-purified guinea pig 
AQP2 antibodies (28) for 1 hr at room temperature and Alexa 594-conjugated goat anti­
guinea pig secondary antibodies (Molecular Probes, Leiden, the Netherlands). TOTO®-3 
iodide (Invitrogen, Carlsbad, CA, USA) was used for counterstaining. Images were made 
using Bio-Rad MRC-1024 confocal laser scanning microscopy.
Quantification of principal and intercalated cells was performed on the confocal images of the 
fluorescent kidney sections. Tubules in >5 randomly selected areas of each kidney region of 
each animal were included. Only cells with distinct TOTO-3 staining were counted. Cells 
stained with H-ATPase/AQP2 staining were taken as intercalated/principal cells, respectively.
Data Analysis
Differences between groups were tested by the Student’s t-test corrected by the Bonferroni 
multiple-comparisons procedure. Differences were considered statistically significant for p <
0.05.
Results
mCCDc11 cells as a model for lithium-NDi.
To study the role of ENaC in lithium-NDI in vitro, a cell line needs to show (1) expression of 
all three ENaC subunits, (2) amiloride-inhibitable transcellular sodium transport, (3) deamino- 
8 D-arginine vasopressin (dDAVP)-induced expression of AQP2, and (4) lithium-induced 
down-regulation of AQP2.
MpkCCDcl4 cells show a lithium-induced AQP2 down-regulation (25) and an amiloride- 
inhibitable transcellular voltage difference. However, immunocytochemistry did not reveal 
ENaC expression in these cells (not shown), in contrast to the novel mouse cortical collecting 
duct mCCDc11 cell line (19). Therefore, we tested mCCDcl1 cells as a model. To test whether 
dDAVP induces AQP2 expression in these cells, confluent cells were incubated for 1-4 days
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with 1 nM dDAVP. Immunoblotting revealed the typical non-glycosylated 29 and complex- 
glycosylated 40-45 kDa AQP2 bands, besides a non-specific band of 35 kDa (Fig. 1A). 
Similar to mpkCCDc14 cells (25), maximal expression of AQP2 was seen after 72-96 hrs. To 
have steady AQP2 expression, cells were therefore incubated with dDAVP for 96 hours in 
the following experiments.
Figure 1. mCCDc11 cells: a proper cell model to study lithium-NDI. A) mCCDc11 cells were grown 
to confluence, treated for the indicated times (in hrs) with 1 nM dDAVP and subjected to AQP2 
immunoblotting or, after blotting, stained with coomassie blue. Non-glycosylated (29 kDa) and 
complex-glycosylated (40-45 kDa) forms of AQP2, and an a-specific band of 35 kDa, are detected. B) 
mCCDc11 cells, grown as above, were treated for 96 hrs with 1 nM dDAVP, and for the last 24 or 48 
hrs, in the absence (-) or presence of 1 mM lithium at the basolateral side and 1 or 10 mM lithium at 
the apical side. Cells were lysed and immunoblotted for AQP2. Blots were also stained with coomassie 
blue. Molecular masses (in kDa) are indicated on the left. The signals for non-glycosylated and 
complex-glycosylated AQP2 were densitometrically quantified and normalized for coomassie blue 
staining. Mean values of normalized AQP2 expression per condition are given as percentage of 
control (+/- SEM) and were determined from three independent filters per condition. Significant 
differences (p<0.05) from control (-) are indicated by an asterisk.
In patients on lithium therapy, the concentration of lithium is around 1 mM in serum and 
ranges between 1 and 10 mM in urine (1). To test whether these concentrations affect AQP2 
abundance, cells were incubated with 1 mM lithium at the basolateral side and with either 1 
or 10 mM lithium at the apical side for 24 or 48 hrs. Immunoblotting revealed that lithium 
reduced the AQP2 expression in a time- and dose-dependent manner, with an almost 
complete absence of AQP2 after a 48 hrs incubation in 10 mM lithium (Fig. 1B). This 
concentration of lithium did not affect cell viability as indicated by similar coomassie-stained
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protein levels (Fig. 1B) and a consistent transcellular resistance of >1000 Ohm/cm2 (not 
shown). Together, these data reveal that mCCDcl1 cells are a suitable model to investigate 
the role of ENaC in lithium-NDI.
The role of ENaC in AQP2 down-regulation and transcellular lithium transport 
ENaC is located in the apical membrane of collecting duct and mCCDc11 cells (19), and its 
activity is blocked by amiloride. To test whether ENaC mediates AQP2 down-regulation by 
lithium, mCCDc11 cells were incubated with lithium at only the basolateral (1 mM) or the 
apical (10 mM) side with or without amiloride for 48 hrs. Application of lithium at the apical 
side reduced AQP2 abundance to about 30% of control values, which was prevented by 
amiloride (Fig. 2A). In contrast, addition of lithium with or without amiloride to the basolateral 
compartment did not change AQP2 levels. Similar results were obtained with another ENaC 
blocker, benzamil (Fig. 2B).
If ENaC is the main entry site for lithium, cellular uptake of lithium and the lithium-induced 
down-regulation of AQP2 should be influenced by the sodium concentration. In pilot 
experiments, mCCDc11 cells were grown in medium containing lower concentrations of 
sodium at the apical side for variable time periods. Incubation of the cells for 12 hrs in 
medium containing 60, 90 or 150 mM sodium showed similar AQP2 expression, whereas 
lower concentrations of sodium or more prolonged incubations resulted in a reduction of 
AQP2 expression (data not shown). Therefore, we incubated the cells with lithium for 12 hrs 
in the presence of either 150, 90 or 60 mM sodium. Indeed, AQP2 expression negatively 
correlated to the sodium concentration (Fig. 2C), thus confirming competition between 
sodium and lithium and indicating that lithium enters the cells through a sodium-transporting 
protein.
If ENaC is the apical entry site for lithium, amiloride should reduce transcellular transport and 
the intracellular concentration of lithium. To test this, cells were incubated with 10 mM lithium 
at the apical side with or without amiloride. After 24 hrs, we observed a significant decrease 
of the lithium concentration at the apical side and an increase at the basolateral side, 
indicating that transcellular lithium transport occurred, which was inhibited by co-incubation 
with amiloride (Fig. 3A). We next determined intracellular lithium levels. A 24 hrs incubation 
of cells with 1 mM lithium at the basolateral side only resulted in an intracellular lithium 
concentration of 3±3 pmol lithium/^g protein, which corresponds to [Li+]i of 0.7 mM (Fig 3B). 
This is well above that of control cells (below detection limit; not shown), indicating that some 
lithium enters the cells from the basolateral side. Intracellular lithium concentrations were 
markedly higher when 1 or 10 mM lithium was added to apical side as well, resulting in 
concentrations of 3.0 and 26.0 mM, respectively. In the presence of amiloride, intracellular
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Figure 2. ENaC blockers reduce lithium-induced AQP2 down-regulation in mCCDc11 cells. A)
Confluent mCCDc11 monolayers were treated for 96 hrs with 1 nM dDAVP and incubated for the last 
48 hrs in the absence (-) or presence (+) of lithium and/or 10 ^M amiloride as indicated. At the 
basolateral and apical side, 1 mM and 10 mM lithium was used, respectively. B) Confluent mCCDc11 
monolayers were treated as above with 10 mM lithium with/without 10 ^M benzamil (Li + Ben) at the 
apical side for the last 24 hrs. C. mCCDc11 cells were grown as above and treated for the last 12 hours 
in medium containing a lower sodium chloride concentration at the apical side only, with or without 
lithium (indicated). For A, B and C, cells were lysed and immunoblotted for AQP2. Molecular masses 
(in kDa) are indicated on the left. Semi-quantification of the AQP2 signals, normalization, and 
statistical analysis were done as described in the legend of Figure 1. Mean values were determined 
from three independent filters per condition.
lithium concentrations were reduced by more than 75%. To determine whether the obtained 
data were cell line specific, we repeated some of the above experiments in mpkCCDcl4 cells. 
In these cells, amiloride also reduced the intracellular lithium concentration and prevented 
lithium-induced down-regulation of AQP2 (supplementary data Fig. S1).
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Figure 3. Amiloride blocks lithium transport. mCCDc11 cells were grown as described above. A) 
After a 24 hrs treatment with 10 mM lithium with/without amiloride at the apical side, media from the 
apical and basolateral compartments were collected and lithium concentrations determined. B) 
mCCDc11 cells were treated for the last 24 hrs with the indicated concentrations of lithium at the 
basolateral (bl) and/or apical (ap) side in the absence or presence of 10 ^M amiloride. After 24 hrs, 
lithium concentrations were determined. Intracellular lithium concentrations were corrected for 
contamination with extracellular lithium and normalized for the amount of protein. For A and B, the 
mean lithium concentration ([Li+] +/- SEM in mM [A] or pmol/^g protein [B]) was determined from at 
least three independent filters per condition. Asterisks indicate a significant difference (p < 0.05). C) 
mCCDc11 cells were treated with lithium on the apical (10 mM) and basolateral (1 mM) side for the 
indicated time periods (in hrs), lysed and analyzed for ENaC subunit expression. D) mCCDc11 cells 
were treated as under C with or without amiloride for 24 hours and analyzed for ß-ENaC. In C and D, 
molecular masses (in kDa) are indicated on the left.
Together, these data indicate that ENaC is the main cellular entry site for lithium in collecting 
duct cells and that blocking ENaC by amiloride prevents lithium-induced down-regulation of 
AQP2.
Effects of lithium and amiloride on ENaC subunit expression
In vivo, it has been shown that lithium treatment results in ENaC-downregulation (29). To see 
if similar effects occurred in vitro, mCCDc11 cells were incubated with lithium for 12 to 48 hrs. 
Indeed, lithium reduced the expression of ß-ENaC, but not of a or Y-ENaC (Fig. 3C). 
However, these cells showed an amiloride-dependent transcellular voltage (not shown),
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indicating that ENaC was still functionally expressed. Amiloride partially prevented the down- 
regulation of ß-ENaC (Fig. 3D).
Figure S1. Effect of amiloride in mpkCCDC|4 cells. A) Confluent mpkCCDC|4 monolayers were 
treated for 96 hrs with 1 nM dDAVP and incubated for the last 24 hrs in the absence or presence of 
lithium and/or 10 ^M amiloride as indicated. At the basolateral and apical side, 1 mM and 10 mM 
lithium was used, respectively. Proteins were immunoblotted for AQP2, of which the mass is indicated 
on the left (in kDa). Mean values of normalized AQP2 expression per condition are the mean of three 
independent experiments and are given as percentage of control (+/- SEM). B) Confluent mpkCCDCl4 
monolayers were treated as in A. 24 hrs after start of the lithium treatment, intracellular lithium 
concentrations were determined. These were corrected for contamination with extracellular lithium and 
normalized for the amount of protein. The mean lithium concentration ([Li+] +/- SEM in pmol/^g 
protein) was determined from three independent filters per condition. For A and B, asterisks indicate a 
significant difference (p < 0.05).______________________________________________________
Effects of lithium and amiloride on Gsk3fi
Rao et al. showed a decreased glycogen synthase kinase (Gsk) 3p activity in lithium-treated 
rats, suggesting a possible involvement of Gsk3p in the pathway leading to lithium-NDI (30). 
To test whether Gsk3p is also involved in the lithium-induced down-regulation of AQP2, total 
Gsk3p expression and the extent of Gsk3p-inactivating phosphorylation at Ser9 was 
analyzed in conjunction to AQP2 expression. While lithium application for 48 hours again 
caused down-regulation of AQP2, it did not change total Gsk3p expression levels, but 
strongly increased the Ser9-phosphorylation of Gsk3p (Fig. 4A). Zinc also inhibits Gsk3p (31) 
and BlO-acetoxime is a specific Gsk3-inhibitor (32; 33). Indeed, similar to lithium, 20 .^M, but 
not 1 .^M, zinc reduced AQP2 levels and increased phosphorylated Gsk3p, but did not affect 
total Gsk3p levels (Fig. 4A). In line with an important role of Gsk3p in AQP2 expression, BlO- 
acetoxime also decreased the expression of AQP2 (Fig 4B).
Since amiloride prevents lithium-induced down-regulation of AQP2, we also tested whether 
amiloride reduced the effect of lithium on Gsk3p. Indeed, while amiloride again protected the
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Figure 4. Effects of lithium on Gsk3p. Confluent mpkCCDc!4 monolayers were treated for 96 hrs with 
1 nM dDAVP. A) Cells were treated with 1 mM lithium at the basolateral side and 10 mM lithium at the 
apical side or 20 and 1 zinc at both sides for the last 48 hrs and subjected to AQP2, Gsk3p and 
Phospho-Gsk3p(Ser9) immunoblotting or, after blotting, stained with coomassie blue. B) mpkCCDcl4 
cells were treated with a specific Gsk3-inhibitor (BIO-Acetoxime) for the last 48 hrs and subjected to 
AQP2 immunoblotting. Concentrations are in nM. C) Cells were incubated for the last 48 hrs in the 
absence or presence of lithium with or without 10 ^M amiloride as indicated. At the basolateral and 
apical side, 1 mM and 10 mM lithium was used, respectively. Molecular masses (in kDa) are indicated 
on the left. Semi-quantification, normalization, and statistical analysis were done as described in the 
legend of Figure 1.
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lithium-induced down-regulation of AQP2, it did not affect total Gsk3p abundance, but 
significantly reduced the extent of lithium-induced phosphorylation of Gsk3p at Ser9 (Fig. 
4C).
Together, these data strongly suggest that in mpkCCDcl4 cells, lithium affects AQP2
expression by inactivating Gsk3p via 
amiloride.
Table 1. Blood and urine parameters
phosphorylation at Ser9, which is attenuated by
- Li Li + Am
Body weight (g) 287±11 212±7* 232±8*
Plasma osmolality (mOsm) 283±5 304±5* 288±3a
Plasma lithium (mmol/l) / 0.69±0.08 0.57±0.08
Plasma sodium (mmol/l) 141 ±1 142±2 141±2
Plasma urea (mmol/l) 5.9±0.3 4.0±0.3* 5.6±0.7
Plasma creatinine (^mol/l) 43±3 41±1 41±2
Urine volume (ml/day) 13±2 189±15* 108±24*a
Urine osmolality (mOsm) 1537±158 98±25* 400±93*a
Total lithium excretion (mmol/24 hrs) / 0.38±0.10 0.61±0.10
Total sodium excretion (mmol/24 hrs) 1.5±0.3 4.7±0.2* 11.4±1.9*a
Total potassium excretion (mmol/24 hrs) 3.2±0.5 2.4±0.4 3.0±0.3
Total urea excretion (mmol/24hrs) 10.9±0.2 6.8±0.5 8.6±1.3
Osmolar excretion (mOsm/24 hrs) 18.3±0.2 16.9±0.3 35.4±6.7
Creatinine clearance (ml/min) 0.93±0.05 0.42±0.09* 0.72±0.12
Urea clearance (ml/min) 1.31±0.25 1.20±0.07 1.15±0. 17
Lithium clearance (ml/min) / 0.65±0.10 0.98±0.25
Values are means +/- SEM. Significant differences between control (-) and other groups are indicated 
as *, significant differences between the lithium (Li) and lithium+amiloride group (Li + Am) are 
indicated as a. / indicates below detection limit.
The effect of amiloride on the development of lithium-NDI in rats
To analyze whether amiloride can prevent development of lithium-NDI in vivo, rats were kept 
on lithium chow for 4 weeks, with or without amiloride, while control rats received normal 
chow. All rats had free access to a salt block to compensate for the sodium losses that occur 
in lithium-NDI (34).
As anticipated (7; 8), the rats treated with lithium developed severe polyuria with reduced 
urine osmolality (Table 1). Amiloride treatment attenuated this polyuria and increased urine 
osmolality compared to lithium only. Serum lithium concentrations found in the lithium
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(0.69±0.08 mM) and lithium-amiloride (0.57±0.08 mM) groups were similar and in the 
therapeutic range, whereas serum lithium concentrations in control rats were below the 
detection limit (0.05 mM; Table 1). As observed more often (7; 35-38), lithium treated rats 
had a slightly lower body weight. We observed no differences in serum sodium or serum 
creatinine concentrations. However, there were differences in the urinary excretion of the 
various solutes. Lithium treatment resulted in increased sodium losses, which was further 
exaggerated by amiloride, confirming the need for the salt block. To investigate if there were 
differences in food intake, the excretion of potassium and urea was measured. Urinary 
excretion of these solutes was numerically although not-significantly lower in rats treated with 
lithium only. In rats treated with lithium and amiloride values were similar to control. Also, 
creatinine clearance was lower in lithium treated rats than in control rats. This was not the 
case in the amiloride-lithium treated rats.
The effect of amiloride on the renal collecting duct in lithium-NDI rats
Lithium-NDI is characterized by a decreased fraction of AQP2-expressing principal cells with 
a parallel increase of H-ATPase-expressing intercalated cells (7). We evaluated the effect of 
amiloride treatment on AQP2 and H-ATPase expression and the cellular composition in 
different regions of the kidney. We observed a significantly reduced expression of AQP2 in 
the cortex of lithium-treated animals (Fig. 5; Table 2). Amiloride significantly attenuated this 
decrease, but did not restore the AQP2 expression to the level of untreated rats. Similar 
results were obtained for the outer and inner medulla (Table 2). With respect to the 
expression of H-ATPase, we noted an increased expression in the cortex of lithium-treated 
rats, which was prevented by amiloride (Fig. 5). Similar data were obtained for the outer and 
inner medulla (Table 2).
Table 2. Effect of amiloride on collecting duct marker protein expression
AQP2
Li Li + Am
H-ATPase
Li Li + Am
cortex 100±6 4±2* 22±4*a 100±42 303±23* 150±19a
outer medulla 100±5 30±9* 53±6*a 100±30 179±17* 121±40
inner medulla 100±4 6±4* 42±4*a 100±29 129±13 65±20a
Mean values (+/- SEM) are expressed as percentages of the controls. Significant differences 
between control (-) and other groups are indicated as *, significant differences between the 
lithium (Li) and lithium+amiloride group (Li + Am) are indicated as a.
To investigate whether amiloride treatment also affects the ratio of principal and intercalated 
cells, kidney sections were labeled with antibodies against AQP2, H-ATPase, and nuclear 
TOTO-3. In agreement with previous studies (7; 8) and the immunoblot data, lithium
175
Chapter 8
treatment resulted in a decreased density of AQP2-expressing cells and increased density of 
H-ATPase-expressing cells (Fig. 6A). Amiloride treatment attenuated these changes.
We quantified the changes by calculating a principal/intercalated cell ratio. Lithium treatment 
significantly reduced the ratio in the cortex, an effect which was fully prevented by amiloride 
(control: 1.72±0.09; lithium: 0.83±0.06; lithium-amiloride: 1.78±0.15; Fig. 6B). Similar results 
were obtained for the outer medulla (control: 2.21±0.15; lithium: 1.02±0.07; lithium-amiloride: 
1.98±0.13) and the inner medulla (control: 2.66±0.56; lithium: 1.16±0.12; lithium-amiloride:
1.91±0.07), indicating that amiloride prevents the change in the ratio of principal/intercalated 
cells.
Li Li + Am
Figure 5. Amiloride prevents effect 
of lithium on AQP2 and H-ATPase 
expression in lithium-NDI rats.
Wistar rats were fed a normal diet (-; 
n=6), a diet containing lithium (Li; n=6) 
or a diet containing lithium and 
amiloride (Li+Am; n=7). After 4 weeks, 
one kidney was divided in cortex, outer 
medulla and inner medulla segments 
and solubilized. An equal amount of 
protein of the cortex of each rat was 
immunoblotted for AQP2, H-ATPase or 
tubulin (indicated). Molecular masses 
(in kDa) are indicated on the left._____
Discussion
mCCDc11 cells are a proper model to study lithium-induced AQP2 down-regulation 
A major handicap to study lithium-NDI at the cellular level was the lack of a suitable model. 
Our study indicates that mCCDc11 cells are an appropriate model for the following reasons. 
First, mCCDc11 cells express all three ENaC subunits in the apical membrane and 
demonstrate amiloride-inhibitable sodium transport (19). Secondly, and similar to collecting 
duct cells in vivo, mCCDc11 cells show a dDAVP-dependent increase in expression of 
endogenous AQP2 (Fig. 1A). Thirdly, and in line with in vivo findings (5), mCCDc11 cells show 
a time- and concentration-dependent decrease in AQP2 expression in response to 
therapeutically-relevant lithium concentrations (Fig. 1B).
ENaC is the main entry site for lithium and blocking ENaC prevents lithium-induced Gsk3fi 
inactivation and AQP2 down-regulation in vitro
With 1 mM lithium added to the basolateral side of mCCDc11 cells, a small but significant 
increase in the intracellular lithium concentration was observed (Fig. 3B). As the cells formed
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Li Li + Am
Con Li Li + Am
Figure 6. Amiloride prevents cell conversion in lithium-NDI rats. A) Of the rats described in the 
legend of Fig. 5, one kidney was removed and fixed. Cryosections were made and incubated with 
rabbit H-ATPase (green) and guinea pig AQP2 (red) antibodies, followed by Alexa-488-conjugated 
goat-anti-rabbit and Alexa-594-conjugated goat anti-guinea pig antibodies. TOTO-3 (blue) was used to 
counterstain the sections. Images were made with confocal laser scanning microscopy. Scale bars: 10 
^m. B) Of >5 defined areas of the kidney cortex of each control (n=6), lithium (n=6) and 
lithium+amiloride (n=7) rat, cells positive for aQp2 or H-ATPase were counted and expressed as the 
ratio of principal / intercalated cells (+/- SEM) (total cells control [-]: 1244; Li: 1393; Li + Am: 2064). 
Significant differences (*: p<0.05) are indicated.__________________________________________
a tight monolayer, this indicated that lithium can enter through a basolateral site. While the 
identity of this entry pathway remains to be established, it did not reduce AQP2 expression 
(Fig. 2A).
Upon addition of 1 mM lithium to the apical compartment, intracellular lithium concentrations 
increased about 3.5-fold to 3.0 mM (Fig. 3B), which resulted in slightly, but not significantly, 
reduced AQP2 levels (Fig. 1B). Addition of 10 mM lithium together with amiloride to the 
apical compartment resulted in similar intracellular lithium concentrations (Fig. 3B) and 
normal AQP2 levels (Fig. 2A). In contrast, AQP2 expression was strongly reduced with 10 
mM lithium at the apical side in the absence of amiloride (Fig. 1C), which coincided with an 
intracellular lithium concentration of 26 mM (Fig. 3B). The observed AQP2 reduction 
suggests that within 24 hours, AQP2 expression is down-regulated with a threshold of 
intracellular lithium concentrations between 3 and 26 mM, which are obtained with lithium
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concentrations of 1 mM at the basolateral side and 10 mM at the apical side. However, at 
prolonged incubation times, AQP2 down-regulation may be induced with lower extracellular 
lithium concentrations, as illustrated by the reduced AQP2 levels upon our incubation with 1 
mM lithium for 48 hours (Fig. 1B). In agreement with an important role of Gsk3p activity in 
lithium-NDI mice (30) and the protective effect of amiloride on lithium-induced down- 
regulation of AQP2, lithium, but also other Gsk3p inhibitors, increased inactivating Gsk3p 
phosphorylation and down-regulation of AQP2 expression in mpkCCDcl4  cells, which was 
partially prevented by co-treatment with amiloride (Fig. 4).
The observed intracellular lithium concentration of 26 mM is higher than the concentration in 
the extracellular fluid, which has been observed before (23). Immunocytochemistry did not 
reveal a difference in cell size between lithium-treated versus control cells, and, in similar 
experiments, intracellular potassium levels were not different between control, lithium or 
lithium+amiloride treated cells, indicating that this is not due to an increased intracellular 
volume in the lithium-treated cells. More likely, the strong inwardly-directed electrochemical 
potential for lithium and the fact that lithium is a poor substitute for sodium with the Na-K- 
ATPase to be transported to the extracellular fluid (39) cause intracellular accumulation of 
lithium.
Overall, our study provides strong evidence that ENaC is the major cellular entry pathway for 
lithium and that blocking ENaC reduces lithium-induced Gsk3p inactivation and prevents 
AQP2 down-regulation.
Co-treatment with amiloride attenuates lithium-NDI
As reported (5; 7), lithium also induced NDI in our experiments, as indicated by the increased 
urine volume and decreased urine osmolality (Table 1). Our data furthermore reveal that 
amiloride treatment decreased urine volume and increased urine osmolality (Table 1). While 
these changes point to a better urine concentrating ability, the observed changes could 
theoretically be due to differences in respectively solute intake or extracellular volume: an 
increased solute intake increases urine volume due to osmotic diuresis, whereas 
hypovolemia will reduce urine volume and increase urine osmolality. However, our data 
clearly indicate that the effects of amiloride cannot be explained by these factors. First, the 
urinary excretion of osmolytes was higher in the amiloride-lithium group than in the group 
receiving lithium only. Second, if anything, volume depletion was more likely to be present in 
lithium only treated rats as suggested by the lower body weight, and the reduction in 
creatinine clearance.
Consistent with this and the protective effect of amiloride in mCCDc11 cells, rats treated with 
amiloride and lithium had significantly increased AQP2 and decreased H-ATPase expression
178
Amiloride attenuates lithium-induced NDI
compared to rats treated with lithium only (Figs. 5-6; Table 2) and the lithium-induced change 
in principal/intercalated cell ratio was completely prevented (Fig. 6). Taken together, our data 
indicate that amiloride has a protective effect on lithium-NDI development by preventing the 
lithium-induced change in cellular composition and partial protection of AQP2 down- 
regulation, leading to a preserved concentrating ability of the collecting duct.
The completely prevention of the change in cell ratio and the partial protection of AQP2 
down-regulation by amiloride suggests that AQP2 expression is more sensitive to lithium 
than the integrity of the principal cells, which is in agreement with the fact that AQP2 down- 
regulation precedes the fractional decrease in principal cells in lithium-NDI development.(4; 
8). It furthermore suggests that the used amiloride concentration did not completely prevent 
the deleterious effect of lithium and it is unclear whether a residual effect of lithium can 
explain the fact that the concentrating ability of amiloride-treated rats is still lower than in 
control rats. One explanation for the reduced concentrating ability is that blockage of sodium 
reabsorption by amiloride could lead to a decrease in osmolality in the interstitium. However, 
considering the small contribution of sodium transport through ENaC to the interstitial 
osmolality, which is even less when NaCl is given ad libitum as done here, this is rather 
unlikely.
Alternatively, this could be due to an incomplete block of ENaC by amiloride in the kidney or 
due to cellular lithium influx via (an)other transporter(s)/channel(s). Amiloride was added to 
the food of the rats at a concentration of 200 mg/kg dry food, which is equivalent with 5 mg of 
amiloride. Assuming a volume of distribution of 3.4 l/kg and a t% of 21 hours, and a 
bioavailability of 10% (40; 41), this will lead to a plasma concentration of 3 ^M. Amiloride 
clearance has been estimated to be about 3 times the creatinine clearance (42), leading to a 
amiloride excretion of 9 ^mol per day and an end-urine concentration of 84 ^M, which, as the 
IC50 of amiloride is 0.1-0.5 ^M (22), very likely completely blocks ENaC. If these calculations 
hold for our rats, our data suggest that, in line with our in vitro data, some lithium may enter 
principal cells through another protein than ENaC.
In our lithium-induced NDI rats and as seen by others (8), we observed an increased 
expression of H-ATPase, which can be partly attributed to an increase in the number of 
intercalated cells (Figs. 5-6). It has been suggested that the observed reduction in AQP2 
expression with lithium is partially due to a loss of principal cells, either by differentiation of 
principal cells to intercalated cells or by selective cell death of principal cells (7; 8). 
Occasionally, and as seen by others (7), we observed cells to stain positive for both AQP2 
and H-ATPase, which may suggest that the change of principal/intercalated cell ratio in 
lithium-NDI is (partly) due to a transition of principal to intercalated cells. However, the 
numbers were too low to influence the counting of the principal/intercalated cell ratio. In line
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with a loss of principal cells, Christensen et al. found an increased number of apoptosis- 
inducing factor (AIF)-labeled collecting duct cells in the IMCD after 10 and 15 days of lithium 
treatment, suggesting that apoptosis of principal cells may be involved, at least in part, in the 
changes in cellular composition in lithium-induced NDI (8). However, they also found an 
increased proliferation of not only intercalated cells but also principal cells and, therefore, the 
change in cell composition could be the result of an increased number of intercalated cells 
without a loss of principal cells. If so, the reduced expression of AQP2 could be the result of 
a decreased expression per cell only. The exact underlying mechanism awaits further 
experiments.
Lithium-NDI also coincides with reduced expression of urea transporters UT-A1 and UT-B 
and Bedford et al. recently showed that amiloride treatment also significantly increases UT- 
A1 expression and conserves the osmotic gradient compared to rats treated with lithium only 
(43; 44). Considering our data, the changes in UT-A1 expression and osmotic gradient with 
lithium and lithium-amiloride, respectively, could be due to a decreased/increased expression 
per cell, but are likely (partially) explained by the changes in principal/intercalated cell ratio.
In conclusion, our data reveal that mCCDc11 cells form a proper model to study lithium-NDI. 
We demonstrate that ENaC forms the major entry pathway for lithium into principal cells and 
that blocking ENaC with amiloride reduces the lithium-induced AQP2 down-regulation, 
protects the cellular composition of the collecting duct and thereby attenuates lithium-NDI. As 
such, our data provide a rationale for the use of amiloride in treating lithium-NDI patients.
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Introduction
Maintaining water homeostasis by controlling both the blood osmolality and blood volume is 
essential for most physiological processes in the human body. Body water homeostasis is 
tightly controlled by regulating both water intake and urinary water excretion.
In states of hypernatremia, specific osmoreceptors in the hypothalamus are activated, which 
results in the sensation of thirst and subsequent water intake (1; 2). Furthermore, the 
hormone arginine vasopressin (AVP) is released from the pituitary into the blood stream (3). 
Besides osmolality, AVP secretion is also influenced by blood volume and blood pressure 
changes, sensed by baroreceptors (2; 4). The released AVP regulates the body's retention of 
water, causing the kidneys to concentrate the urine and reduce urine volume (2).
As outlined in this thesis, the aquaporin-2 (AQP2) water channel is one of the key players 
involved in renal water excretion and is critical to osmoregulation and the maintenance of 
body water homeostasis. Binding of AVP to its type-2 receptor, present on the basolateral 
membrane of renal collecting duct principal cells and connecting tubule cells, induces a 
signaling cascade, resulting in the redistribution of AQP2 water channels from intracellular 
vesicles to the apical membrane, greatly increasing the osmotic water permeability, leading 
to a concentrated urine (5-7). In addition to its effect on AQP2 localization, AVP also 
increases AQP2 transcription (8; 9). Once the water balance is restored, AVP levels drop 
and AQP2 is internalized, leaving the apical membrane watertight again.
Considering its important role in water homeostasis, it is not surprising that AQP2 is involved 
in several diseases associated with disturbed water homeostasis, including the syndrome of 
inappropriate antidiuretic hormone secretion (SIADH) and nephrogenic diabetes insipidus 
(NDI). AQP2 is tightly regulated, not only by AVP, but also by other hormones, compounds 
and medications. However, the exact molecular mechanisms which regulate AQP2 in 
different conditions are still unknown. This thesis aimed to gain insight into the physiological 
and pharmacological regulation of renal water reabsorption and AQP2 expression.
Physiological regulation of AQP2
Regulation of AQP2 by dopamine
Besides AVP, several other hormones and chemical messengers regulate water balance by 
antagonizing AVP-induced water transport. Examples are extracellular purines, dopamine, 
endothelin, epidermal growth factor and prostaglandins (10). The underlying mechanisms of 
their actions are poorly understood.
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Chapter 2 aimed to get more insight into the mechanism by which hormones and chemical 
messengers counteract the action of AVP on AQP2, by analyzing in detail the effect of ATP 
and dopamine on the AVP-induced AQP2 abundance, both in a collecting duct cell model 
(mpkCCD cells) as well is in kidney slices.
Dopamine has been shown to decrease AVP-induced water permeability and cAMP 
production in the cortical and inner medullary collecting duct of rats (11-13) and has been 
shown to cause AQP2 internalization from the plasma membrane into intracellular storage 
vesicles in Madin-Darby canine kidney (MDCK) cells (14). In line with these studies, in 
chapter 2 addition of dopamine to mpkCCD cells decreased total and plasma membrane 
abundance of AVP-induced AQP2, partly by increasing its internalization to vesicles. The 
reduction in AQP2 abundance could be blocked by co-incubation with chloroquine, a 
lysosomal degradation inhibitor, which indicates that dopamine induces lysosomal 
degradation of AQP2. Previously, it was demonstrated that AQP2 internalization and 
degradation is preceded by its monoubiquitination at Lys270 upon AVP removal or protein 
kinase C (PKC) activation (15). Similarly, dopamine increased AQP2 mono-ubiquitination. 
The AQP2 internalization was ubiquitin-dependent as the plasma membrane localization of 
AQP2-K270R, which cannot be mono-ubiquitinated, was unaffected by dopamine. A similar 
process occurs in vivo, as dopamine incubation of kidney slices, treated with the AVP 
analogue dDAVP, also resulted in the internalization of AQP2. Dopamine also reduced cAMP 
and AQP2 mRNA levels, suggesting an additional effect on AQP2 gene transcription. 
Interestingly, phorbol esters, activating PKC, only reduced AQP2 through the first pathway. 
Together, our results indicate that dopamine counteracts AVP-induced water permeability by 
increasing AQP2 degradation in lysosomes, preceded by ubiquitin-dependent internalization, 
and by decreasing AQP2 gene transcription by reducing the AVP-induced cAMP levels (Fig. 
1).
Of the dopamine receptors, the D4 receptor is expressed in the collecting duct and has been 
shown to mediate the diuretic effect of dopamine in the cortical collecting duct (12; 16). 
However, in the inner medullary collecting duct, the inhibitory effect of dopamine is 
suggested to be mediated through a2-adrenergic receptors, which can also be activated by 
high concentrations of dopamine (11). The receptor subtypes responsible for the observed 
AQP2 decrease in mpkCCD cells remain to be determined.
The major source of renal dopamine is its synthesis in proximal tubular cells and possibly in 
the inner medullary collecting duct (17; 18). Renal dopamine production is increased by 
expansion of the extracellular fluid volume with isotonic saline. Besides, the amount of 
sodium chloride in the diet has been shown to correlate with urinary dopamine excretion (18). 
Studies suggest that the chloride, and not the sodium, might be regulating renal dopamine 
production, as an increase in the intake of chloride, with or without sodium, increases urinary
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dopamine (19; 20). Physiologically, the diuretic effects of dopamine could contribute to 
counteracting an extracellular fluid volume expansion.
Figure 1. Dopamine inhibition of AQP2-mediated water reabsorption. Dopamine inhibits AVP- 
induced water transport by binding to its receptor, leading to an activation of PKC and internalization 
into lysosomes followed by degradation of aQp2. Dopamine also reduces cAMP levels, leading to a 
reduced AQP2 transcription. Indicated are adenylate cyclase (AC), aquaporin-2 (AQP2), vasopressin 
(AVP), cyclic adenosine monophosphate (cAMP), DAG Diacylglycerol (DAG), dopamine receptor 
(DR), protein kinase A (PKA), protein kinase C (PKC), phospholipase C (PLC) and vasopressin V2 
receptor (V2R).
Regulation of AQP2 by ATP
Like dopamine, the extracellular purine ATP has been shown to decrease AVP-induced 
water permeability and cAMP production in isolated inner medullary collecting ducts of rats 
and has been shown to cause AQP2 internalization in mpkCCD cells (21-23).
In agreement with these studies, we show in chapter 2 that addition of ATP to mpkCCD cells 
decreased total and plasma membrane abundance of AVP-induced AQP2 and increased its 
internalization into vesicles. Co-incubation with the lysosomal degradation blocker 
chloroquine prevented the reduction in AQP2 abundance, indicating that ATP induces 
lysosomal degradation of AQP2. ATP increased AQP2 mono-ubiquitination and the AQP2 
internalization was shown to be dependent on this ubiquitination as the plasma membrane 




Figure 2. Inhibition of AQP2-mediated water reabsorption by ATP. ATP inhibits AVP-induced 
water transport by binding to its receptor, leading to an activation of protein kinase C (PKC) and 
internalization into lysosomes followed by degradation of AQP2. ATP also reduces cAMP levels, 
leading to a reduced AQP2 transcription. ATP may mediate this effect partly indirectly by stimulating 
prostaglandin E2 (PGE2) release by increasing arachidonic acid (AA) release. PGE2 activates the AVP- 
counteracting EP receptors EP1 and EP3. Indicated are arachidonic acid (AA), adenylate cyclase 
(AC), aquaporin-2 (AQP), vasopressin (AVP), cyclic adenosine monophosphate (cAMP), 
cyclooxygenase (COX), diacylglycerol (DAG), membrane phospholipid (MPL), purinergic receptor 
(P2), protein kinase A (PKA), protein kinase C (PKC), phospholipase A (2 ) (PLA(2)), phospholipase C 
(PLC), and vasopressin V2 receptor (V2R).
Incubation of dDAVP-treated kidney slices with ATP also resulted in AQP2 internalization, 
indicating that a similar process occurs in vivo. ATP also reduced cAMP and AQP2 mRNA 
levels in mpkCCD cells, suggesting an additional reduction of AQP2 gene transcription.
In conclusion, our results indicate that ATP counteracts AVP-induced water permeability by 
increasing ubiquitination of AQP2, followed by internalization and AQP2 degradation in 
lysosomes, and by decreasing AQP2 gene transcription by reducing the AVP-induced cAMP 
levels (Fig. 2).
Various purinergic receptors have been identified in the collecting duct (24; 25). Of these, the 
basolaterally localized P2Y2 and apically localized P2X2 and P2Y4 have been suggested to 
be involved in the ATP-mediated reduction of AQP2 (21; 26). ATP is generally believed to be 
released locally in response to cell swelling or flow-induced shear stress (27). It could 
therefore be speculated that cell swelling under hypotonic conditions, for example in
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hyponatremia, could lead to ATP release, which would help to maximize water excretion by 
inhibition of AQP2-mediated water reabsorption. Recently it was shown that also AVP 
increases ATP release in perfused cortical collecting ducts (28). AVP would thus both 
stimulate AQP2-mediated water reabsorption, and stimulate the release of ATP, which would 
oppose water transport via a local inhibitory feedback mechanism.
Previously it was shown that, besides ATP, UTP inhibits AVP-induced water permeability as 
well, which could be mediated via the P2Y2 or P2Y4 receptor (21-23). UTP release has been 
shown to be stimulated by mechanical stress (29). Whether UTP release is, like ATP, also 
stimulated by AVP needs further investigation.
AQP2 regulation by Ser261-phosphorylation
Recently, it has been shown that, besides phosphorylation at Ser256, which is important for 
the AVP-induced AQP2 translocation to the apical membrane (7; 30; 31), AQP2 can also be 
phosphorylated at Ser261, Ser264 and Ser269 (32). Phosphorylated Ser261-AQP2 is mainly 
found in intracellular vesicles and Ser261 phosphorylation decreases upon AVP incubation 
(33). Although protein kinase A (PKA) is responsible for the phosphorylation of AQP2 at 
Ser256, Hoffert et al. demonstrated that PKA is unable to phosphorylate Ser261 (34). In vitro 
experiments demonstrated that JNK, p38, CDK5 and CDK9 could potentially be involved in 
the phosphorylation of AQP2 at Ser261 (35). Interestingly, we show in chapter 2 that both 
dopamine and ATP increased AQP2 phosphorylation at Ser261, both in mpkCCD cells as 
well as in kidney slices. Ser261 phosphorylation seemed to be preceded by AQP2 
ubiquitination, in agreement with recent results from Tamma et al. (36). However, this 
phosphorylation was not essential for the hormone-induced AQP2 internalization and 
degradation. The exact function of this phosphorylation site thus remains to be established.
Regulation of AQP2 by prostaglandins
Prostaglandins have a bifunctional role in water balance regulation. In particular, 
prostaglandin E2 (PGE2) has been shown to increase the osmotic water permeability of 
perfused collecting ducts in the absence of AVP (37; 38). Paradoxically, PGE2 decreases 
water reabsorption in the presence of AVP (37-39).
In chapter 3 we describe that in the absence of AVP, AQP2 abundance in mpkCCD cells was 
increased by PGE2, in line with the abovementioned effects of PGE2 on water reabsorption. 
In the presence of the AVP analogue dDAVP, PGE2 reduced AQP2 abundance. Besides 
PGE2, PGF2a application also reduced AQP2 abundance, which is in agreement with 
previous findings that PGF2a inhibits AVP-stimulated water permeability in the collecting duct 
(40; 41). Blocking prostaglandin production by indomethacin in dDAVP-stimulated mpkCCD
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cells increased AQP2 levels, showing that in cells without indomethacin, dDAVP-stimulated 
AQP2 abundance is decreased by the action of endogenously produced prostaglandins.
The major prostaglandins produced in mpkCCD cells were PGE2 and PGF2a. In agreement 
with these findings, PGE2 is the most abundant prostanoid in the kidney, followed by PGI2 
and PGF2a. (42). We showed that dDAVP application significantly increased PGE2 production 
in mpkCCD cells, in agreement with studies showing that AVP stimulates PGE2 synthesis in 
isolated collecting ducts (43; 44). PGF2a levels were decreased by dDAVP in mpkCCD cells, 
and PGD2 increased, although PGD2 levels were still low compared PGE2 and PGF2a. 
Although no PGD2 receptor (DP) was detected in mpkCCD cells, the increase in PGD2 
production could counteract dDAVP-induced AQP2 abundance via the prostaglandin PGF2a 
receptor (FP), as PGD2 has been shown to bind to the FP receptor with an affinity close to 
that for the DP receptor (45). The expression of the FP receptor was increased by dDAVP 
application to mpkCCD cells.
Incubation of mpkCCD cells with dDAVP resulted in an increased expression of the calcium 
mobilizing PGE2 receptor EP1, but decreased the expression of the EP4 receptor, coupling to 
Gs-stimulated cAMP generation. As the inhibitory effects of PGE2 on AVP-induced water 
reabsorption most likely occur through activation of EP1 and/or EP3 receptors (38; 46; 47), 
whereas the stimulatory effects of PGE2 on basal water transport could be mediated via the 
EP4 receptor, this suggests that the differences in PGE2-mediated actions on water 
permeability can most likely be attributed to the different relative expression of the E- 
prostanoid receptor subtypes (Fig. 3).
In contrast to in vivo, no expression of EP3 was found in the mpkCCD cells. EP3 activation 
is, besides EP1, also suggested to inhibit water reabsorption (48). Based on the observation 
above that the dDAVP signaling exerts a positive feedback on the receptor activating an 
opposite pathway, it would be expected that EP3 expression would also be increased in vivo 
after AVP release. However, this needs further investigation.
Altogether, our study shows that in mpkCCD cells, both PGE2 and PGF2a decrease dDAVP- 
stimulated AQP2 abundance, while in the absence of dDAVP, PGE2 increases AQP2 levels, 
explaining the effects on water reabsorption in vivo. The different PGE2 effects might be 
explained by the different receptor subtype expression induced by dDAVP. Based on our 
data, it is likely that in vivo AVP increases, besides AQP2, the expression of EP1 and EP3 
and decreases expression of EP4. Consequently, upon conditions with increased PGE2 
production, such as ATP release (see below), AVP-induced AQP2 abundance would be 
reduced via activation of these EP1/3 receptors.
In addition to its role in ambient water homeostasis, PGE2 has been suggested to play an 
important role in pathological conditions such as lithium-induced NDI and bilateral ureteral 
obstruction, associated with AQP2 down-regulation, increased abundance of the enzyme
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cyclooxygenase 2 (COX-2), involved in prostaglandin production, and increased urinary 
PGE2 levels (49; 50). Based on our data, these increased PGE2 production will lead to a 
decrease in AVP-induced AQP2 abundance via activation of the EP1/3 receptors. This has to 
be established in future studies.
Figure 3. Model of PGE2- 
mediated regulation of AQP2- 
mediated water reabsorption. In
the absence of AVP, prostaglandin 
E2 (PGE2) stimulates water 
reabsorption by binding to the EP4 
receptor, coupling to the Gs 
protein, leading to cAMP 
generation, followed by AQP2 
transcription and translocation. 
AVP induces the expression of the 
AVP-counteracting EP1 receptor, 
and possibly also EP3, and 
reduces EP4. Indicated are 
adenylate cyclase (AC) , 
aquaporin-2 (AQP2), vasopressin 
(AVP), cyclic adenosine 
monophosphate (cAMP),
Diacylglycerol (DAG), protein 
kinase A (PKA), protein kinase C 
(PKC), phospholipase C (PLC), 
and vasopressin V2 receptor 
(V2R).
Compensatory mechanisms of AQP2 regulation
It is interesting that, while dDAVP increases PGE2 production and release, the mRNA 
expression of the EP4 receptor is reduced, whereas that of the EP1 receptor is increased. As 
both are bound and activated by PGE2, these data suggest that it is not the agonist per se 
that determines the expression level of the receptors. Instead, our data indicate that the 
signaling cascade that is mainly activated exerts a negative feedback regulation on receptors 
stimulating the same pathway and a positive feedback on receptors activating an opposite 
pathway: dDAVP increases the cAMP-AQP2 pathway, which is also stimulated by EP4, 
whereas EP1 activates a pathway that leads to decreased AQP2 abundance and water 
permeability. Similarly, the increased FP receptor after dDAVP incubation of mpkCCD cells
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might be a compensatory mechanism to counteract AVP-stimulation as well, as FP receptor 
activation inhibits water reabsorption (40).
The reverse is seen in chapter 7, were incubation with lithium leads to an AQP2 down- 
regulation and at the same time a decrease in the expression of the FP and EP1 receptors. 
As signaling via these receptors is expected to inhibit water reabsorption (40; 51), a down- 
regulation of these receptors may be a compensatory mechanism in response to the lithium- 
induced AQP2 down-regulation. In a similar way, dDAVP increases the mRNA levels of the 
purinergic receptor subunit P2Y2 in mpkCCD cells, and targets the subunits P2Y2 and P2X2 
to the plasma membrane, where activation of these receptors leads to AQP2 internalization 
and a decrease in water permeability (21). The same mechanism can be seen in the 
opposite response, where endothelin, counteracting AVP-mediated water permeability (52), 
leads to an increased abundance of the vasopressin V2 receptor in the inner medullary 
collecting duct of the rat (53). These feedback mechanisms might function to locally fine-tune 
the AQP2-mediated water reabsorption.
Regulation of AQP2 by integrative action of AVP counteracting hormones 
As described above, several hormones or chemical messengers can counteract the AVP- 
stimulated water reabsorption. However, these hormones do not exert their effects 
completely independently, as for example the ATP-mediated AQP2 decrease may be 
mediated indirectly through prostaglandin receptors. Extracellular purines have been shown 
to stimulate P2Y2 receptor-mediated release of arachidonic acid leading to increased PGE2 
production (54), which activates the AVP-counteracting receptors EP1 and EP3 (Fig. 2). Like 
ATP, dopamine could potentially mediate AQP2 down-regulation indirectly via 
prostaglandins, as dopamine has been shown to stimulate prostaglandin production in 
isolated rabbit kidney and cultured inner medulla collecting duct cells (55; 56). However, the 
mechanism for this increased prostaglandin release is unclear.
Besides prostaglandins, dopamine might also exert its effect through increased nitric oxide 
(NO) release. NO is known to decrease AVP-induced AQP2 abundance as well (57; 58). 
Dopamine has been shown to increase both NO synthase activity in the medullary collecting 
duct and the urinary excretion of NO metabolites, and blocking NO production attenuated the 
diuresis and natriuresis caused by dopamine (59; 60), suggesting that part of the dopamine 
effect could be mediated by increased NO release.
Regulation of AQP2 by tonicity
Osmolality not only affects plasma AVP, but also appears to have direct effects on AQP2 
expression and urinary concentrating ability. SIADH, for example, goes with excessive water 
uptake and hypotonicity. The extent of hypotonicity, however, is much less than anticipated
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from the blood AVP concentrations (61), which is ascribed to a defense mechanism, the 
vasopressin escape, and has been shown to involve a down-regulation of AQP2 (62). 
Hypotonicity and/or volume expansion have been proposed to mediate this AVP-independent 
direct regulation of AQP2 expression (63).
Consistently, an AVP-independent increase of AQP2 expression has been suggested to 
occur with hypertonicity. Water deprivation, hyperglycemia or increased blood NaCl levels of 
AVP-deficient Brattleboro rats leads to hypertonicity, increased papillary interstitial 
osmolality, increased AQP2 abundance, and concentration of the urine (64; 65).
In mpkCCD cells Hasler et al. showed that hypertonicity decreases the protein abundance of 
AQP2 on the short term, but increases its abundance on the long term (66). Here, 
hypertonicity did not affect the stability of AQP2 mRNA or protein, indicating that 
hypertonicity increases AQP2 abundance by increasing its transcription. Proteins suggested 
to be involved in the hypertonicity response are the tonicity-responsive enhancer binding 
protein (TonEBP) and the nuclear factor of activated T cells c (NFATc) (67; 68).
In chapter 4 we described that mpkCCD cells transfected with an AQP2-promoter luciferase 
construct showed a reduced and increased AQP2 abundance and transcription following 
culture in hypotonic and hypertonic medium, respectively. This depended on tonicity rather 
than osmolality.
It has been shown that production of both PGE2 and NO, known to decrease AVP-induced 
AQP2 abundance (37; 39; 57; 58), are significantly increased in a vasopressin escape 
animal model. Although PGE2 and NO reduced AQP2 protein abundance in mpkCCD cells, 
inhibition of their synthesis did not influence tonicity-induced AQP2 transcription, indicating 
that the tonicity-regulated AQP2 transcription is independent of NO or PGE2. Increased 
prostaglandins and nitric oxide, as found in vivo in vasopressin escape (69; 70), may 
however contribute to reduced AQP2 levels, probably by increasing AQP2 degradation.
The effect of tonicity on AQP2 transcription occurred independent of the AVP analogue 
dDAVP, cAMP levels or PKA activity. Also, cells in which the cAMP responsive element 
(CRE) or the tonicity-responsive element (TonE) in the AQP2-promoter was mutated showed 
a similar response to hypotonicity. Instead, the tonicity-responsive elements were pin-pointed 
to nucleotides -283 to -252 and -157 to -126 bp of the AQP2 promoter. In these segments, 
binding sites for nuclear factor kappa B (NF-kappaB), SP1 and GATA were found. It remains 
to be established whether these transcription factors and their promoter elements are 
responsible for the tonicity effect on AQP2 transcription.
As we found in chapter 2 that ATP decreases AQP2 transcription and is released during 
hypotonicity-induced cell swelling, ATP might be a candidate involved in the signaling 




Identification of the transcription factors and signaling proteins involved in hypotonicity- 
regulated AQP2 expression in follow-up experiments will provide a better insight into the 
physiological regulation of AQP2 expression and renal water reabsorption by tonicity and 
may lead to the discovery of targets for modulation of pathophysiological conditions of 
osmoregulation, such as SIADH.
Long-term regulation of AQP2 by vasopressin
AVP stimulation leads to phosphorylation of AQP2 at Ser256 and subsequent redistribution 
of AQP2 water channels from intracellular vesicles into the apical membrane (5; 7; 30). 
Besides, it increases transcription of AQP2 and hence increases AQP2 abundance (8; 9). 
Changes in expression of AQP2 have been attributed to PKA-induced phosphorylation of the 
cAMP responsive element binding protein (CREB), which stimulates transcription from the 
AQP2 promoter via the CRE (71-73). Interestingly, cAMP levels peak immediately after 
addition of the stable AVP analogue dDAVP, but are reduced to low levels within 120 
minutes following addition in AQP2-transfected MDCK cells (74). AQP2 levels, however, 
continue to rise during the first three days of dDAVP exposure in mpkCCD cells (75). 
Therefore, the purpose of chapter 5 was to investigate the molecular mechanism responsible 
for the AVP-induced increase in AQP2 expression after long-term application of dDAVP 
using the mpkCCD cell line.
While short-term (30 min) dDAVP stimulation extensively increased cAMP levels, cAMP was 
strongly reduced with long-term (4 days) compared to short-term dDAVP stimulation, 
although it was still significantly higher than of control cells. dDAVP stimulation for 1 day 
increased AQP2 promoter dependent transcription, which could be blocked by H89, a 
specific inhibitor of PKA. Moreover, phosphorylation of CREB and CRE-dependent 
transcription were observed after short-term dDAVP application. With 4 days of dDAVP 
stimulation AQP2 abundance remained elevated, but this increase could no longer be 
blocked by H89. Moreover, CRE-dependent transcription and CREB phosphorylation were 
not increased with 4 days of dDAVP stimulation, indicating that the long-term regulation of 
AQP2 by dDAVP occurs independent of PKA and CREB.
The observed changes in the cAMP-PKA-CRE pathway may be the consequence of a 
desensitization to AVP. In agreement with our results, Dublineau et al. also showed that in 
isolated collecting ducts of rats treated with dDAVP for 3 days, addition of AVP evoked a 
smaller cAMP response than in untreated rats (76). However, Dublineau et al. also showed 
in similarly treated rats that, like in our mpkCCD cells, cAMP was still increased compared to 
untreated rats (77). A possible explanation for the lower cAMP production after 4 days 
dDAVP is a lower receptor expression on the cell surface, in line with earlier observations 
that V2R receptor activation leads to its internalization (78). The changes in the cAMP-PKA-
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CRE pathway may also be the consequence of an intracellular desensitization to dDAVP, 
which can be caused by several factors, as continuous stimulation of the cAMP-PKA-CRE 
pathway has been shown to lead to the synthesis of ICER (inducible cyclic AMP response 
element repressor) which reduces CRE-dependent transcription (79), a desensitization of 
PKA (80), or a desensitization of adenylate cyclase 6, expressed in the collecting duct (81; 
82). Although our experiments were done in the presence of a phosphodiesterase blocker, in 
vivo cAMP stimulation also leads to an upregulation of cAMP phosphodiesterases, which 
may further decrease cAMP levels (83).
In conclusion, our study shows that the PKA-CRE pathway is involved in the initial increase 
in AQP2 abundance after dDAVP stimulation, but the long-term regulation of AQP2 by 
dDAVP occurs independently of PKA and CREB.
Regulation of AQP2 by Epac
Our results in chapter 5 further indicate that long-term regulation of AQP2 by dDAVP may 
involve the exchange protein directly activated by cAMP (Epac). In agreement with in vivo 
studies, where both Epacl and Epac2 proteins were found in the collecting duct, mpkCCD 
cells endogenously express Epacl and Epac2 proteins. Epacl is mainly expressed in 
intercalated cells, although it is also found in principal cells in the outer medulla. Epac2 is 
highly expressed in all principal cells all along the collecting duct (84).
In mpkCCD cells, Epacl abundance was stimulated by dDAVP, while Epac2 abundance was 
reduced, suggesting that AVP regulates Epac protein expression. Epac activation alone, 
without dDAVP preincubation, did not increase the expression of AQP2. However, 
stimulation of Epac activity after sustained dDAVP stimulation increased both AQP2 
transcription and AQP2 protein abundance, although AQP2 abundance was not maintained 
to the same level with the Epac activator as with dDAVP. As after prolonged dDAVP 
incubation, cAMP levels are still increased compared to control cells, Epac activation by the 
increased cAMP levels may form part of the PKA independent pathway to maintain high 
AQP2 abundance levels at long-term dDAVP incubation. The reduced level of maintaining 
AQP2 levels may be due to instability of the Epac stimulator over the 24-hour period used, or 
may indicate that Epac is not the only factor involved in stimulating long-term AQP2 
expression. It remains to be established whether Epac has a similar role in vivo.
In conclusion, our study shows that long-term regulation of AQP2 may involve the activation 
of Epac. Besides an effect on AQP2 transcription, Epac activation also leads to Ca2+ 
mobilization, increasing AVP-stimulated translocation of AQP2 to the apical membrane, what 
suggests that both PKA and Epac are part of the signaling events in AVP-stimulated AQP2 
trafficking (85). The distinct localization of Epacl and Epac2 in the collecting duct would 
imply that Epac2 rather than Epacl mediates the stimulatory effects on AQP2.
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The pathway by which Epac activation increases AQP2 expression is not known. Epac 
selectively activates the Ras-like small GTPase Rap1 and Rap2. Epac has been shown to be 
involved in the effect of calcitonin on the H,K-ATPase in collecting duct intercalated cells by a 
cAMP/Epac/Rap-1/Raf-B/ERK cascade (86) and ERK-inhibition has been shown to prevent 
the insulin-mediated increase of AQP2 expression in mpkCCD cells, suggesting a role of 
ERK in AQP2 regulation (87). Epac has also been shown to stimulate integrin-mediated cell 
adhesion by influencing focal adhesions (88; 89), either by Rap1-mediated activation of 
integrins, or by increasing phosphorylated paxillin, involved in integrin-regulation (90). 
Recently, integrins have been suggested to influence AQP2 expression (91). Whether 
integrins or ERK are indeed involved in Epac-mediated AQP2 expression remains to be 
established.
Transcriptional control of AQP2
It is well known that AVP, on the short term, increases AQP2 transcription via an increase in 
cAMP, leading to phosphorylation of the cAMP responsive element binding protein (CREB), 
which stimulates transcription from the AQP2 promoter (71-73). We showed that Epac 
activation increases transcription as well (chapter 5), however, the pathway is not known. 
Besides AVP, we found many other factors to affect AQP2 transcription. Dopamine and ATP 
decreased cAMP levels (chapter 2), suggesting a reduction of AQP2 transcription would be 
by a decrease in PKA-mediated CREB phosphorylation or the pathway activated by Epac, 
counteracting directly the pathway activated by AVP. Demeclocycline decreases adenylate 
cyclase abundance and thereby cAMP generation (chapter 6), and the demeclocycline- 
mediated decrease of AQP2 transcription will therefore also likely be a direct effect on the 
pathway activated by AVP. Tonicity did not affect cAMP levels, and the tonicity-responsive 
elements were pin-pointed to nucleotides -283 to -252 and -157 to -126 bp of the AQP2 
promoter (chapter 4). In these segments, binding sites for nuclear factor kappa B (NF- 
kappaB), SP1 and GATA were found. Like tonicity, lithium also decreases AQP2 
independently of cAMP (75). We show in chapter 7 that the effect of lithium on AQP2 
transcription involves the most proximal 200 bp of the AQP2 promoter. The exact 
transcription factor involved needs however to be identified.
Pharmacological regulation of AQP2
Regulation of AQP2 by demeclocycline
Demeclocycline is a bacteriostatic antibiotic of the tetracycline group, which has been shown 
to cause water diuresis and NDI (92; 93). Because of the effect on water diuresis,
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demeclocycline is currently used to treat sustained hyponatremia in patients with SIADH 
(94). Demeclocycline has been shown to restore the sodium plasma concentration in SIADH 
patients to normal levels, permitting unrestricted water intake in these patients (95).
Wilson et al. showed that the demeclocycline-induced diuresis is exerted by selective 
inhibition of the water reabsorption in the distal part of the nephron (96). Others have shown 
that demeclocycine inhibits the AVP-induced osmotic water flow in the toad urinary bladder 
(92; 97; 98), a model system of the mammalian collecting duct. Just like demeclocycline, the 
tetracycline antibiotics minocycline, doxycycline and tetracycline have been shown to reduce 
the water flow in the toad bladder (97), and tetracycline has been reported to decrease 
urinary concentrating ability in men (96), suggesting that other tetracycline antibiotics affect 
collecting duct function and urinary concentrating ability as well.
In chapter 6, we showed that demeclocycline and minocycline down-regulated AQP2 
abundance in the mpkCCD cell line in a time- and concentration-dependent manner. 
Demeclocycline down-regulates AQP2 at concentrations that are equivalent to those 
measured in urine from patients (99), illustrating that the effects observed are at 
pharmacologically-relevant doses and that the demeclocycline-mediated diuresis in patients 
is caused by a decrease in AQP2 abundance.
The protein synthesis inhibitor cycloheximide abolishes the effect of demeclocycline on 
AQP2, suggesting that a decrease in AQP2 production explains the decrease in AQP2 
abundance. Using an AQP2 promoter-luciferase reporter construct, we showed that 
demeclocycline decreases AQP2 transcription. In regard to the intracellular cell signaling, we 
found a blunting of dDAVP-induced cAMP production, which is in line with findings of Dousa 
and Wilson showing a decreased basal and AVP-induced cAMP generation in renal medulla 
tissue (100). Our results also show a decreased abundance of both adenylate cyclase 3 and 
6 after demeclocycline incubation, which explains the lower cAMP generation.
In conclusion, our data show that the diuretic effect of tetracycline antibiotics such as 
demeclocycline and minocycline is mediated via down-regulation of the water channel AQP2. 
Demeclocycline decreases AQP2 gene transcription by decreasing adenylate cyclase 
abundance and cAMP generation. Its effect on AQP2 transcription will therefore likely be by 
reducing AVP-mediated PKA or Epac activation. If demeclocycline has a similar effect in vivo 
needs further investigation.
Regulation of AQP2 in lithium-induced NDI
Lithium is regularly used to treat psychiatric diseases, such as bipolar disorders, 
schizoaffective disorders and depression. Unfortunately, approximately 20% of patients 
undergoing lithium treatment develop NDI (101-103). In fact, lithium-induced NDI is the most 
common form of NDI.
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Studies in rats have shown that lithium-induced NDI occurs in conjunction with AQP2 down- 
regulation (104; 105) and in agreement with this, lithium treatment reduces urinary AQP2 
excretion in humans, indicating a decreased renal AQP2 expression (103). Chronic lithium 
treatment also leads to a severe decrease in the fraction of principal cells in rats. This is 
‘compensated’ by an increase in the fraction of intercalated cells, which are involved in 
acid/base balance regulation (106; 107).
Furthermore, lithium leads to inactivation of glycogen synthase kinase (Gsk) 3p and this is 
temporally related to an increased renal COX-2 abundance and increased urinary PGE2 
excretion (49; 108). As PGE2 reduces AVP-stimulated water reabsorption, as discussed in 
chapter 3, this suggests an important role for PGE2 in lithium-induced NDI development.
In chapter 7, we investigated the potential role of prostaglandins in lithium-induced down- 
regulation of AQP2 in mpkCCD cells. As in vivo, the reduced AQP2 abundance after lithium 
incubation coincided with Gsk3p inactivation and increased COX-2 abundance. The lithium- 
induced increase in COX-2 abundance did however not result in elevated prostaglandin 
levels in media of mpkCCD cells. This might be explained by the fact that the availability of 
free arachidonic acid, the substrate for production of prostaglandins, and not COX, is the 
rate-limiting step in in prostaglandin production in most tissues and cells (109).
Similarly to the increase in AQP2 abundance after treatment with the COX-blocker 
indomethacin (chapter 3), dexamethasone-induced down-regulation of COX-2 coincided with 
increased AQP2 abundance. However, dexamethasone did not affect the lithium-induced 
upregulation of COX-2 nor down-regulation of AQP2.
Indomethacin significantly reduced PGE2 and PGF2a levels in lithium-treated cells, 
suggesting that a reduction of PGE2 and/or PGF2a is involved in the attenuating effect of 
indomethacin on the lithium-induced AQP2 down-regulation. In line with this, addition of 
PGE2 or PGF2a to dDAVP-treated mpkCCD cells resulted in reduced AQP2 levels as 
discussed in chapter 3.
However, as no effect of lithium on prostaglandin production was found in mpkCCD cells, this 
suggests that the lithium-induced AQP2 down-regulation in these cells occurs independently 
of prostaglandins. This is also suggested by the observation that in the presence of 
indomethacin, lithium still decreased AQP2 abundance compared to cells incubated with 
indomethacin alone.
Addition of PGE2 or PGF2a, reducing AQP2 protein abundance, did not decrease AQP2 
transcription or mRNA levels. In line with this, indomethacin, blocking prostaglandin 
production, increased dDAVP-stimulated AQP2 protein abundance, but did not increase 
AQP2 transcription or mRNA levels. Prostaglandin-induced AQP2 down-regulation could be 
prevented by co-incubation with the lysosome inhibitor chloroquine, showing that the effect of
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prostaglandins on AQP2 abundance in mkpCCD cells is mediated by increasing AQP2 
degradation.
Lithium, however, did not affect AQP2 degradation, in agreement with previous results (75), 
but decreased AQP2 mRNA by decreasing AQP2 gene transcription. Our results show that 
the lithium-sensitive AQP2 promoter segment is within the most proximal 200 bp. As lithium 
decreases AQP2 transcription in contrast to prostaglandins, these data indicate that the 
effect of lithium on AQP2 transcription is independent of prostaglandin production.
In vivo data show that blocking prostaglandin production by indomethacin reduces urine 
volume and increases AQP2 abundance of lithium-treated rats (110) and reduces the urine 
volume of lithium-induced NDI patients as well (111; 112). Extrapolated to this in vivo data 
and our data showing that addition of PGE2 to mpkCCD cells, simulating the increase in 
PGE2 found in vivo, leads to AQP2 down-regulation in mpkCCD cells, this indicates that the 
increased prostaglandin levels in the kidney in lithium-NDI might contribute to the reduced 
AQP2 abundance observed. However, this does not contribute to the effect of lithium on 
AQP2 gene transcription.
A limitation of our cell model is the absence of the EP3 receptor, which is found in vivo in the 
collecting duct. EP3 activation inhibits cAMP generation via Gi (51), and might therefore 
inhibit AVP-stimulated AQP2 transcription by decreasing CRE-mediated transcription. 
Although this might contribute to the AQP2 down-regulation induced by PGE2, earlier studies 
show no decrease in cAMP after lithium treatment in vivo (75), suggesting that an in vivo 
effect of lithium on AQP2 transcription is EP3-independent. Conclusive evidence for the roles 
of particular prostaglandin receptors in mediating a prostaglandin-induced down-regulation of 
AQP2 in lithium-induced NDI awaits studies using collecting duct specific knockout of these 
receptors.
In conclusion, our data reveal that in mpkCCD cells lithium decreases AQP2 protein 
abundance as well as AQP2 gene transcription. Lithium decreases AQP2 transcription 
independently of the endogenous prostaglandin production in mpkCCD cells. Our data 
furthermore show that in mpkCCD cells, released prostaglandins decrease AQP2 protein 
stability by increasing its lysosomal degradation, Based on these observations, in vivo 
paracrine produced prostaglandins might have an additional role in lithium-induced NDI by 
decreasing AQP2 protein stability, without affecting AQP2 transcription.
Protection of AQP2 down-regulation in lithium-induced NDI
To further investigate the mechanism of lithium-induced NDI and to investigate if lithium- 
induced NDI can be attenuated, we investigated in chapter 8 the effect of amiloride, blocking 




In the mouse collecting duct cell lines mCCDc11 and mpkCCD, the AVP-induced AQP2 
abundance was time- and dose-dependently reduced by clinically-relevant lithium 
concentrations, which could be prevented by co-incubation with the ENaC blockers amiloride 
or benzamil. Consistently, amiloride reduced transcellular lithium transport, the intracellular 
lithium concentration and lithium-induced inactivation of Gsk3p. Overall, our study shows that 
ENaC is the major cellular entry pathway for lithium and that blocking ENaC reduces lithium- 
induced Gsk3p inactivation and prevents AQP2 down-regulation.
In vivo, simultaneous treatment of rats with amiloride attenuated the AQP2 down-regulation, 
and completely prevented the reduction of principal/intercalated cell ratio. Amiloride 
treatment furthermore decreased urine volume and increased urine osmolality, although 
values were still different from those of control rats. Taken together, our data indicate that 
blocking ENaC with amiloride has a protective effect on lithium-induced NDI development by 
preventing the lithium-induced change in cellular composition and partial protection of AQP2 
down-regulation, leading to a preserved concentrating ability of the collecting duct. As such, 
our data provide a rationale for the use of amiloride as a treatment for lithium-induced NDI. 
The complete prevention of the change in cell ratio and the partial protection of AQP2 down- 
regulation by amiloride suggests that AQP2 expression is more sensitive to lithium than the 
integrity of the principal cells, which is in agreement with the fact that AQP2 down-regulation 
precedes the fractional decrease in principal cells in lithium-induced NDI development (104; 
107). It furthermore suggests that the used amiloride concentration did not completely 
prevent the deleterious effect of lithium, as also seen in the mCCD cells. This could be due to 
an incomplete block of ENaC by amiloride, although the amiloride dose given to the rats and 
cell lines is expected to block ENaC completely, or this could be due to cellular lithium influx 
via other transporters or channels.
A recent paper showed that collecting duct specific aENaC knockout mice did not 
demonstrate the polyuria and reduction in urine osmolality induced by lithium treatment, and 
lithium treatment reduced AQP2 protein levels only in the inner medulla in these mice, not in 
the cortex or outer medulla (113). The protection from lithium-induced NDI by the absence of 
functional ENaC in the collecting duct supports our conclusion that ENaC is the main entry 
pathway into the principal cells. The remaining decrease of AQP2 in the inner medulla 
suggests an additional mechanism of AQP2 down-regulation, either another entry pathway 
into the principal cells, or increased prostaglandin release from interstitial cells. The absence 
of an NDI phenotype in the aENaC knockout mice suggests that the role of this additional 
mechanism is small. However, as the serum concentration of lithium in knockout mice given 
lithium was lower than the concentration in control mice administered lithium, and also below 
the clinically used concentrations, it cannot be excluded that a clinically relevant lithium dose
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would induce a more severe AQP2 down-regulation and the development of an NDI 
phenotype in the aENaC knockout mice.
Based on our own studies and earlier data, we propose the following model for the 
mechanism of lithium-induced NDI (Fig. 4): lithium enters the principal cells predominantly 
through the epithelial sodium channel ENaC (chapter 8), leading to AQP2 down-regulation, 
and, on the long term, to an increase in apoptosis as well as proliferation, resulting in a 
decreased fraction of principal cells (106; 107; 114). Lithium entry in the principal cell leads 
to inactivation of Gsk3p (chapter 8, (49)). In line with an important role of Gsk3p in AQP2 
expression, also other Gsk3p inhibitors lead to a down-regulation of AQP2 expression in 
mpkCCD cells, as shown in chaper 8. Inactivation of Gsk3p leads to an increased 
abundance of COX-2 (49; 115), resulting in increased production of PGE2 (49; 108) by renal 
medullary interstitial cells and, possibly, renal principal cells, leading to an increase in AQP2 
protein degradation.
Besides a change in COX-2 abundance, a change in the purinergic system could also be 
involved in the increased PGE2 production seen with lithium treatment. Recently, lithium has 
been shown to cause a change in relative purinergic receptor expression, and a P2Y2 
knockout mouse shows a reduced sensitivity to develop lithium-induced NDI (116; 117),
Figure 4. Model of the lithium-induced inhibition of AQP2-mediated water reabsorption. Lithium 
enters the principal cells through the epithelial sodium channel ENaC, leading to inactivation of Gsk3p, 
thereby reducing AQP2 transcription. Inactivation of Gsk3 in interstitial cells, and possibly principal 
cells, leads to an increased expression of COX-2, resulting in increased production of PGE2. Binding of 
PGE2 to the EP1 receptor leads to an increase in AQP2 protein degradation. Lithium might also effect 
purinergic receptor expression or activation, leading to increased arachidonic acid availability, further 
stimulating PGE2 release. Indicated are adenylate cyclase (AC), aquaporin-2 (AQP2), vasopressin 
(AVP), cyclic adenosine monophosphate (cAMP), cyclooxygenase-2 (COX-2), Diacylglycerol (DAG), 
lithium (Li), purinergic receptor (P2), protein kinase A (PKA), protein kinase C (PKC), phospholipase C 
(PLC) and vasopressin V2 receptor (V2R).
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suggesting a role of purinergic receptor activation in lithium-induced NDI.
Besides the effect on protein degradation, lithium also decreases AQP2 expression by 
reducing AQP2 gene transcription, which is prostaglandin independent (chapter 7), and is 
likely a consequence of inhibition of one of the other pleiotropic pathways steered by Gsk3p, 
like the pathways involving the transcription factors Nuclear factor of activated T-cells 
(NFAT), p-catenin, or hypoxia-inducible factor (HIF).
The two different pathways leading to a decrease in AQP2 abundance might also have 
consequences for the clinical treatment of lithium-induced NDI. Both COX inhibitors and 
the ENaC blocker amiloride have been shown to individually reduce the NDI phenotype (111; 
112; 118-120). However, as the effect of lithium on prostaglandin production could be 
blocked by COX inhibitors, and the entry of lithium into the principal cells leading to a 
decrease in AQP2 transcription could be blocked by amiloride treatment, this suggest a 
benicifial effect of combining these two therapies for the treatment of lithium-induced NDI.
Concluding remarks
In this thesis, we unraveled a small part of the complex regulation of AQP2 trafficking and 
expression. Besides AVP, hormones as dopamine and ATP are tightly involved in AQP2 
regulation, as they induce ubiquitination, internalization and degradation of AQP2, thereby 
inhibiting AVP-induced water permeability. One of the challenges of the future is to further 
identify the receptors and signaling pathways involved in these effects. Similarly, 
prostaglandins PGE2 and PGF2a decrease AVP-induced AQP2 abundance by increasing 
AQP2 degradation, leading to decreased water permeability. In the absence of AVP, PGE2 
stimulates AQP2 abundance, thereby increasing water permeability. This difference in PGE2 
effects might be explained by an AVP-induced change in relative receptor expression, 
increasing inhibitory pathways and decreasing stimulatory pathways. Tonicity also stimulates 
AQP2 expression, however, this is independent of AVP, and in contrast to the prostaglandin 
effects, this affects AQP2 transcription. Tonicity-responsive regions in the AQP2 promoter 
were identified. It remains to be established which transcription factors and their promoter 
elements are responsible for the tonicity effect on AQP2 transcription.
The regulation of AQP2 by AVP was further elucidated by showing that the PKA-CRE 
pathway is involved in the initial increase in AQP2 abundance after AVP stimulation, but not 
in the long-term effect of AVP. Instead, long-term regulation of AQP2 may involve the 
activation of Epac. Further studies are necessary to determine the role of Epac in vivo, and 
the signaling pathway activated by Epac.
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The tetracycline antibiotic demeclocycline was shown to cause diuresis via down-regulation 
of AQP2. Demeclocycline decreases AQP2 protein abundance and gene transcription by 
decreasing adenylate cyclase abundance and cAMP generation. Further studies are 
necessary to confirm that demeclocycline has a similar effect in vivo.
Lithium was shown to mainly enter the principal cell by the epithelial sodium channel ENaC, 
leading to a decreased AQP2 gene transcription, which is prostaglandin independent. The in 
vivo observed increased PGE2 levels in lithium-induced NDI might decrease AQP2 protein 
stability by increasing its lysosomal degradation. Blocking lithium entry with amiloride 
attenuates lithium-NDI by preventing AQP2 down-regulation and the change in 
principal/intercalated cell ratio. As such, our data provide a rationale for the use of amiloride 
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Behoud van de waterbalans door het reguleren van zowel de osmolaliteit als het 
bloedvolume is essentieel voor de meeste fysiologische processen in het menselijk lichaam. 
De waterbalans in het lichaam wordt nauw gereguleerd via de waterinname en de 
waterexcretie in de urine. Verhoging van de natriumconcentratie in het bloed zorgt voor een 
activatie van specifieke osmoreceptoren in de hypothalamus, wat resulteert in een 
dorstprikkel en de daaropvolgende inname van water. Tegelijkertijd wordt het hormoon 
arginine vasopressine (AVP) uitgescheiden door de hypofyse en komt in de bloedbaan 
terecht. Behalve door de natriumconcentratie, wordt AVP-uitscheiding ook beïnvloed door 
het bloedvolume en veranderingen van de bloeddruk, gedetecteerd door baroreceptoren. Het 
vrijgekomen AVP regelt de hoeveelheid water in het lichaam, doordat het zorgt dat de nieren 
water uit de voorurine reabsorberen en daardoor het urinevolume verminderen.
Zoals uiteengezet in dit proefschrift, speelt het aquaporine-2 (AQP2) waterkanaal een 
sleutelrol in de regulatie van de renale waterexcretie en is cruciaal voor de osmoregulatie en 
de waterbalans in het lichaam. De binding van AVP aan zijn type-2 receptor, aanwezig op 
het basolaterale membraan van de hoofdcellen in de verzamelbuis en de verbindingsbuis 
van de nier, induceert een signaalcascade, resulterend in de verplaatsing van AQP2 
waterkanalen van intracellulaire blaasjes naar het apicale membraan. Water komt vervolgens 
via de AQP2 waterkanalen de cel binnen en stroomt vervolgens via de AQP3 en AQP4 
waterkanalen in het basolaterale membraan richting het bloed, hetgeen leidt tot een 
concentrering van de urine. Naast het effect op AQP2-lokalisatie, verhoogt AVP ook AQP2- 
transcriptie. Zodra de waterbalans hersteld is, daalt de AVP-uitscheiding en wordt AQP2 
geïnternaliseerd, waardoor het apicale membraan opnieuw water-ondoorlaatbaar wordt.
Door zijn belangrijke rol in de waterhomeostase, is het niet verwonderlijk dat AQP2 is 
betrokken bij verschillende ziekten die samenhangen met een verstoorde waterhomeostase, 
waaronder het syndroom van inadequate secretie van antidiuretisch hormoon (SIADH) en 
nefrogene diabetes insipidus (NDI). AQP2 wordt nauw gereguleerd, niet alleen door AVP, 
maar ook door andere hormonen, moleculen en medicijnen. Echter, de exacte moleculaire 
mechanismen die AQP2 in deze verschillende omstandigheden reguleren zijn nog niet 
bekend. Het doel van dit proefschrift was het verkrijgen van meer inzicht in de fysiologische 
en farmacologische regulatie van de renale waterreabsorptie en AQP2.
Naast AVP reguleren diverse andere hormonen de waterhuishouding door middel van 
inhibitie van AVP-geïnduceerd watertransport. Voorbeelden zijn extracellulaire purines, 
dopamine, endotheline, epidermale groeifactor en prostaglandine. Het werkingsmechanisme
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van deze hormonen is onbekend. Het doel van hoofdstuk 2 was meer inzicht te krijgen in het 
mechanisme waarmee hormonen het effect van AVP op AQP2 tegengaan, door in detail de 
werking van ATP en dopamine op de AVP-geïnduceerde AQP2 expressie te analyseren, 
zowel in een celmodel van de verzamelbuis (mpkCCD-cellen) als in de nier.
Toevoeging van deze hormonen aan mpkCCD-cellen verlaagde zowel de totale hoeveelheid 
AVP-geïnduceerd AQP2 als de hoeveelheid op het plasmamembraan, onder meer door een 
verhoogde internalisatie in blaasjes. De vermindering van de AQP2-expressie werd 
geblokkeerd door co-incubatie met chloroquine, een remmer van lysosomale degradatie, wat 
aangeeft dat deze hormonen lysosomale afbraak van AQP2 veroorzaken. Eerder is 
aangetoond dat AQP2-internalisatie en degradatie veroorzaakt door AVP-verwijdering of 
door proteïne kinase C activatie wordt voorafgegaan door ubiquitinering van AQP2 op 
Lys270. Ook ATP en dopamine verhogen de ubiquitinering van AQP2. De AQP-internalisatie 
was ubiquitine-afhankelijk, aangezien de plasmamembraan-lokalisatie van AQP2-K270R, die 
niet kan worden geübiquitineerd, niet beïnvloed werd door deze hormonen. Eenzelfde proces 
vindt plaats in vivo, waar incubatie van dDAVP-behandelde nierplakjes met beide hormonen 
ook resulteerde in AQP2-internalisatie. Beide hormonen zorgden ook voor verlaagde cAMP 
en AQP2 mRNA niveaus, hetgeen wijst op een bijkomend effect op de AQP2-transcriptie. 
Hieruit concludeerden we dat ATP en dopamine de AVP-geïnduceerde waterpermeabiliteit 
tegengaan door het verhogen van AQP2-degradatie in lysosomen, voorafgegaan door 
ubiquitine-afhankelijke internalisatie, en daarnaast door het verlagen van AQP2-transcriptie 
door het verminderen van de AVP-geïnduceerde cAMP hoeveelheid.
Onlangs is aangetoond dat, naast de fosforylering van Ser256, waarvan bekend is dat deze 
belangrijk is voor de AVP-geïnduceerde translocatie naar het apicale membraan, AQP2 ook 
kan worden gefosforyleerd op Ser261, Ser264 en Ser269. Interessant is dat zowel dopamine 
als ATP AQP2-fosforylering op Ser261 verhogen, zowel in mpkCCD cellen als in de nier. De 
exacte functie van deze fosforylering dient nog verder onderzocht te worden.
Zoals hierboven vermeld, zijn ook prostaglandines betrokken bij de regulatie van de 
waterbalans. Met name van prostaglandine E2 (PGE2) is aangetoond dat het de 
waterdoorlaatbaarheid van verzamelbuisjes vergroot in de afwezigheid van de AVP. In 
tegenstelling hiermee vermindert PGE2 de waterreabsorptie in de aanwezigheid van AVP. 
Het mechanisme is echter nog onduidelijk. In hoofdstuk 3 gebruiken we daarom mpkCCD 
cellen als modelsysteem voor de renale hoofdcellen om te onderzoeken hoe prostaglandines 
deze uiteenlopende effecten op het waterreabsorptie in de aanwezigheid of afwezigheid van 
AVP uit kunnen oefenen.
In afwezigheid van AVP werd AQP2-expressie verhoogd door PGE2, in overeenstemming 
met het hierboven vermelde effect van PGE2 op de waterreabsorptie. In aanwezigheid van
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de AVP-analoog dDAVP zorgde PGE2 voor een verlaging van de AQP2-expressie. Naast 
PGE2 zorgde ook PGF2a-toevoeging voor een verlaging van de AQP2-expressie, in 
overeenstemming met eerdere bevindingen dat PGF2a AVP-gestimuleerde 
waterpermeabiliteiit in de verzamelbuis remt. Het blokkeren van de prostaglandine-productie 
door indomethacine in dDAVP-gestimuleerde mpkCCD cellen verhoogde de AQP2- 
expressie, waaruit blijkt dat onder fysiologische condities, dDAVP-gestimuleerde AQP2- 
expressie verminderd wordt door de werking van endogeen geproduceerde prostaglandines. 
MpkCCD cellen produceerden vooral PGE2 en PGF2a. dDAVP-toevoeging zorgde voor een 
toename van de PGE2 en PGD2-productie, terwijl PGF2a-productie afnam. De prostaglandine- 
receptoren EP1, EP4, FP en TP werden gedetecteerd via RT-PCR. dDAVP-toevoeging 
verhoogde de expressie van de EP1 en FP-receptoren, terwijl EP4-expressie afnam. 
Samenvattend blijkt uit ons onderzoek dat in dDAVP-gestimuleerde mpkCCD cellen zowel 
PGE2 als PGF2a de AQP2-expressie verlagen, terwijl in de afwezigheid van dDAVP, PGE2 de 
AQP2-expressie verhoogt. dDAVP zorgt voor een toename in de productie van PGD2 en 
PGE2, en afname van PGF2a. Aangezien het remmende effect van PGE2 op de AVP- 
geïnduceerde waterreabsorptie zeer waarschijnlijk ontstaat door activatie van EP1 en / of 
EP3 receptoren, terwijl het stimulerende effect van PGE2 op het basale watertransport kan 
worden gemedieerd via de EP4 receptor, suggereert dit dat de verschillen in het PGE2- 
gemedieerde effect op de waterpermeabiliteit hoogstwaarschijnlijk wordt veroorzaakt door de 
verschillende relatieve expressie van de prostaglandine-receptor subtypes.
Osmolaliteit beïnvloedt niet alleen de AVP-afgifte, maar lijkt ook een direct effect te hebben 
op AQP2-expressie en het urine-concentrerend vermogen. SIADH, bijvoorbeeld, gaat 
gepaard met te veel waterreabsorptie en verlaagde toniciteit in het bloed. De mate van 
hypotoniciteit is echter veel minder dan men zou verwachten naar aanleiding van de AVP- 
concentratie in het bloed. Dit wordt toegeschreven aan een afweermechanisme, de 
vasopressine-escape, wat gepaard gaat met een AQP2-afname. Het onderliggende 
mechanisme is echter onduidelijk. Om dit te onderzoeken, gebruikten we de mpkCCD cellijn. 
In hoofdstuk 4 vonden we dat in mpkCCD cellen, getransfecteerd met een AQP2-promotor 
luciferase construct, de AQP2 eiwit-hoeveelheid en transcriptie werden verlaagd en 
verhoogd na een kweek in hypotoon en hypertoon medium, respectievelijk. Dit hing af van 
toniciteit in plaats van de osmolaliteit, en was onafhankelijk van de AVP-analoog dDAVP, 
intracellulaire cAMP-niveaus of proteïne kinase A (PKA)-activiteit. Hoewel prostaglandines 
en stikstofmonoxide de AQP2-eiwit hoeveelheid verlagen, had remming van hun synthese 
geen invloed op de toniciteit-geïnduceerde AQP2 transcriptie. Ook cellen waarin het cAMP of 
toniciteit responsieve element (CRE / TonE) in de AQP2-promotor werden gemuteerd 
reageerden op een vergelijkbare wijze op hypotoniciteit. In plaats daarvan werden toniciteit-
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responsieve elementen gelokaliseerd in de nucleotiden -283 tot -252 en -157 tot -126 bp van 
de AQP2-promoter.
Concluderend blijkt uit onze gegevens dat hypotoniciteit de AQP2-eiwit expressie en 
transcriptie verlaagd, en dat dit effect onafhankelijk is van vasopressine, cAMP, en de 
bekende TonE en CRE in de AQP2-promoter. Verhoogde prostaglandine en 
stikstofmonoxide-concentraties, zoals gevonden in vivo, kunnen bijdragen aan een 
vermindering van AQP2 in vasopressine-escape, maar zijn niet betrokken bij het effect van 
hypotoniciteit op AQP2-transcriptie. Onze gegevens suggereren dat twee nieuwe segmenten 
(-283 tot -252 en -157 tot -126 bp) in de AQP2-promoter betrokken zijn bij de hypotoniciteit 
geïnduceerde AQP2-afname tijdens vasopressine-escape.
Zoals hierboven beschreven leidt AVP-stimulatie tot fosforylering van AQP2 op Ser256 en 
een daaropvolgende herverdeling van AQP2-waterkanalen van intracellulaire blaasjes naar 
het apicale membraan. Daarnaast verhoogt AVP de transcriptie van AQP2 en dus de AQP2 
eiwit-hoeveelheid. Veranderingen in de AQP2-expressie zijn toegeschreven aan PKA- 
geïnduceerde fosforylering van het cAMP-responsieve element bindend eiwit (CREB), die de 
AQP2 transcriptie stimuleert via de CRE in de AQP2 promoter. Aangezien cAMP-niveaus 
afnemen kort na AVP-toevoeging, terwijl de AQP2-hoeveelheid nog steeds toeneemt en 
hoogt blijft, onderzochten we in hoofdstuk 5 het mechanisme verantwoordelijk voor de 
AQP2-verhoging na een lange termijn dDAVP-toevoeging met behulp van mpkCCD cellen. 
Terwijl een korte termijn (30 minuten) dDAVP-stimulatie zorgde voor een sterke toename van 
de cAMP-hoeveelheid, was cAMP sterk verminderd met lange termijn (4 dagen) dDAVP, 
hoewel cAMP nog steeds significant meer was dan in ongestimuleerde controle cellen. Eén 
dag dDAVP-stimulatie zorgde voor een stijging van de AQP2-promoter afhankelijke 
transcriptie, wat kon worden geblokkeerd door H89, een specifieke remmer van PKA. 
Bovendien werd fosforylering van CREB en CRE-afhankelijke transcriptie waargenomen na 
korte termijn dDAVP-toevoeging. Met 4 dagen dDAVP-stimulatie bleef de AQP2-transcriptie 
verhoogd, maar deze stijging kon niet meer worden geblokkeerd door H89. Bovendien was 
de CRE-afhankelijke transcriptie en CREB-fosforylering niet toegenomen na 4 dagen 
dDAVP-stimulatie ten opzichte van ongestimuleerde controle cellen, wat aangeeft dat de 
lange termijn regulatie van AQP2 door dDAVP onafhankelijk is van PKA en CREB.
Onze resultaten in hoofdstuk 5 laten verder zien dat de lange termijn regulatie van AQP2 
door dDAVP mogelijk deels wordt gemedieerd door het eiwit Epac. In overeenstemming met 
in vivo studies, waar zowel Epac1 en Epac2-eiwitten werden gevonden in de verzamelbuis, 
brengen mpkCCD cellen endogeen Epac1 en Epac2 tot expressie. Epac1-expressie werd 
gestimuleerd door dDAVP, terwijl Epac2 werd verminderd. Epac-activatie alleen, zonder 
dDAVP-voorincubatie, zorgde niet voor een toename van de AQP2-expressie. Echter,
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stimulatie van de Epac-activiteit na een voorbehandeling met dDAVP zorgde voor een 
toename in zowel AQP2-transcriptie als AQP2-eiwit, suggererend dat Epac deel uitmaakt 
van de PKA-onafhankelijke signaalcascade zorgend voor een handhaving van een hoge 
AQP2-expressie tijdens een lange termijn dDAVP-incubatie.
Concluderend is de PKA-CRE signaleringscascade betrokken bij de initiële stijging van de 
AQP2-expressie na AVP-stimulatie, maar niet bij het lange termijn effect van AVP. In plaats 
daarvan wordt AQP2 op de lange termijn mogelijk gereguleerd door activatie van Epac.
Demeclocycline en minocycline zijn antibiotica van de tetracycline-groep, die een diuretisch 
effect hebben. Vanwege dit effect wordt demeclocycline momenteel gebruikt om langdurige 
hyponatriëmie te behandelen bij patiënten met SIADH. Hoewel van deze medicijnen wordt 
gedacht dat ze werken op het distale deel van het nefron is hun precieze 
werkingsmechanisme nog niet beschreven. In hoofdstuk 6 laten we zien dat demeclocycline 
en minocycline het eiwit-niveau van AQP2 in de mpkCCD-cellijn verlagen op een tijds- en 
concentratie-afhankelijke wijze. De eiwitsynthese remmer cycloheximide blokkeert het effect 
van demeclocycline op AQP2, wat impliceert dat een daling van de AQP2-productie de 
afname van de AQP2-expressie verklaart. Met behulp van een AQP2-promoter luciferase 
construct toonden we aan dat demeclocycline zorgt voor een afname van de AQP2- 
transcriptie. Ook vonden we een afname van de dDAVP-geïnduceerde cAMP-productie en 
een verlaagde expressie van zowel adenylaatcyclase 3 als 6, wat de afgenomen cAMP- 
productie verklaart.
Concluderend blijkt uit onze gegevens dat het diuretische effect van tetracycline antibiotica, 
zoals van demeclocycline en minocycline, wordt gemedieerd door het verlagen van 
adenylaatcyclase-expressie en cAMP-generatie, met als gevolg een verminderde AQP2- 
gentranscriptie en eiwit-expressie.
Lithium wordt regelmatig gebruikt voor de behandeling van psychiatrische ziektebeelden, 
zoals een bipolaire stoornis, schizoaffectieve stoornis en depressie. Helaas ontwikkelt 
ongeveer 20% van de lithium-behandelde patiënten NDI, een aandoening waarbij de nieren 
niet in staat zijn om de urine te concentreren. Lithium-geïnduceerde NDI gaat gepaard met 
een verminderde AQP2-expressie. Chronische lithium behandeling in ratten leidt ook tot een 
afname van de fractie van de hoofdcellen, wat wordt 'gecompenseerd' door een toename 
van de fractie van intercalaire cellen, die betrokken zijn bij de regulatie van het zuur / base- 
evenwicht. Bovendien leidt lithium in vivo tot een inactivatie van glycogeen synthase kinase 
(Gsk) 3p. Dit gaat gepaard met een verhoogde renale cyclooxygenase 2 (COX-2)-expressie, 
betrokken bij prostaglandine productie, en verhoogde PGE2 uitscheiding in de urine. PGE2
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vermindert de AVP-gestimuleerde water reabsorptie en kan dus een belangrijke rol spelen in 
de ontwikkeling van lithium-geïnduceerde NDI.
In hoofdstuk 7 onderzochten we de mogelijke rol van prostaglandines in de lithium- 
geïnduceerde AQP2 afname, met behulp van mpkCCD cellen. In deze cellen ging de AQP2- 
afname na lithium-incubatie samen met Gsk3ß-inactivatie en verhoogde COX-2-expressie. 
Remming van COX door indomethacine of dexamethason-geïnduceerde afname van COX- 
2-expressie verhoogden beide de AQP2-expressie. Echter, beide behandelingen 
voorkwamen niet de lithium-geïnduceerde AQP2-afname. Lithium heeft geen invloed op de 
prostaglandine-hoeveelheid geproduceerd door mpkCCD cellen. Lithium-toevoeging 
verlaagde de AQP2-eiwit expressie, mRNA niveaus en transcriptie. Prostaglandines 
verlaagden de AQP2-expressie door het verhogen van de eiwit-afbraak, maar hadden geen 
invloed op AQP2-gentranscriptie.
Concluderend blijkt uit onze gegevens dat in mpkCCD cellen, prostaglandines zorgen voor 
een afname van de AQP2-eiwitstabiliteit door verhoging van de lysosomale degradatie, 
hetgeen aangeeft dat in vivo paracrien geproduceerde prostaglandines mogelijk een rol 
spelen in lithium-geïnduceerde NDI. Echter, lithium heeft ook invloed op AQP2 
gentranscriptie, en dit effect is prostaglandine-onafhankelijk. Onze resultaten tonen aan dat 
het lithium-gevoelige AQP2-promotor segment zich bevindt in de meest proximale 200 bp.
Om het mechanisme van lithium-geïnduceerde NDI verder te onderzoeken en om te 
onderzoeken of lithium-geïnduceerde NDI kan worden behandeld, onderzochten we in 
hoofdstuk 8 het effect van amiloride. Van amiloride is in een selecte groep patiënten 
aangetoond dat het lithium-geïnduceerde NDI vermindert, maar het mechanisme is nog 
onduidelijk. Aangezien amiloride het epitheliale natrium-kanaal (ENaC) in het apicale 
membraan van de hoofdcellen blokkeert, hadden we de hypothese dat ENaC de 
toegangspoort is voor lithium in de cel en dat amiloride daarom nuttig kan zijn door de 
toegang van lithium in de cel te blokkeren.
Inderdaad vonden we in de muis-verzamelbuis cellijnen mCCD en mpkCCD dat de AVP- 
geïnduceerde AQP2-expressie tijds- en dosisafhankelijk werd verminderd door klinisch 
relevante lithium-concentraties, wat kon worden voorkomen door co-incubatie met de ENaC- 
blokkers amiloride en benzamil. Amiloride verlaagde ook het transcellulair lithium-transport, 
de intracellulaire lithium-concentratie en de lithium-geïnduceerde inactivatie van Gsk3ß. 
Samenvattend toont onze studie aan dat ENaC de belangrijkste cellulaire toegang voor 
lithium is en dat het blokkeren van ENaC AQP2-afname voorkomt.
In vivo zorgde gelijktijdige behandeling van ratten met amiloride voor een vermindering van 
de lithium-geïnduceerde AQP2-afname, en amiloride voorkwam volledig de vermindering van
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de verhouding in hoofdcellen / intercalaire cellen. Amiloride-behandeling zorgde verder voor 
een afname van het urinevolume en een verhoogde urine-osmolaliteit. Concluderend blijkt uit 
onze gegevens dat het blokkeren van ENaC met amiloride een beschermend effect heeft op 
de ontwikkeling van lithium-geïnduceerde NDI door de lithium-geïnduceerde veranderingen 
in cellulaire samenstelling te voorkomen en de AQP2-expressie gedeeltelijk te beschermen, 
wat leidt tot een bewaard gebleven concentrerend vermogen van de verzamelbuis. Als 
zodanig verstrekken onze gegevens een onderbouwing voor het gebruik van amiloride als 
een behandeling voor lithium-geïnduceerde NDI.
In dit proefschrift hebben we een klein deel van de complexe regulatie van AQP2 ontrafeld. 
Naast AVP zijn dopamine en ATP betrokken bij de AQP2-regulatie, via ubiquitinering, 
internalisatie en degradatie van AQP2, zo de AVP-geïnduceerde waterpermeabiliteit 
verminderend. Ook prostaglandines PGE2 en PGF2a verlagen AVP-geïnduceerde AQP2- 
expressie door het verhogen van AQP2-degradatie, leidend tot een verminderde 
waterpermeabiliteit. In afwezigheid van AVP stimuleert PGE2 de AQP2-expressie en 
waterpermeabiliteit. Dit verschil in PGE2-effect kan worden verklaard door een AVP- 
geïnduceerde verandering in de relatieve prostaglandine-receptor expressie, leidend tot een 
verhoging van remmende signaleringscascades en een afname van stimulerende cascades. 
Toniciteit stimuleert ook de AQP2-expressie, maar dit is onafhankelijk van AVP, en in 
tegenstelling tot prostaglandines heeft toniciteit effect op AQP2-transcriptie. De regulatie van 
AQP2 door AVP werd verder opgehelderd door aan te tonen dat de PKA-CRE cascade 
betrokken is bij de initiële stijging van AQP2-expressie na AVP-stimulatie, maar dat het lange 
termijn effect van AVP PKA-CRE-onafhankelijk is, en mogelijk gaat via Epac-activatie. We 
toonden aan dat demeclocycline diurese veroorzaakt door middel van een afname in AQP2- 
eiwit, via een verminderde AQP2-transcriptie veroorzaakt door een verlaging van 
adenylaatcyclase-expressie en cAMP-productie. Verder toonden we aan dat lithium de 
hoofdcel voornamelijk binnengaat via het epitheliale natrium-kanaal ENaC, wat leidt tot een 
verminderde AQP2-transcriptie, wat onafhankelijk is van prostaglandines. Het blokkeren van 
lithium door middel van amiloride vermindert lithium-geïnduceerde NDI door AQP2-afname 
en de verandering in hoofdcel / intercalaire cel-verhouding te voorkomen. Als zodanig 
verstrekken onze gegevens een onderbouwing voor het gebruik van amiloride als een 
behandeling voor lithium-geïnduceerde NDI. Zoals beschreven voor lithium-geïnduceerde 
NDI, kan een beter begrip van de fysiologische regulatie van AQP2 bijdragen tot het vinden 
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